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°C	  	   	   Degrees	  Celcius	  
%	   	   Percentage	  
ACE-­‐1	   	   Angiotensin	  Converting	  Enzyme-­‐1	  
ACE-­‐2	  	   	   Angiotensin	  Converting	  Enzyme-­‐2	  
AKT	   	   Protein	  Kinase	  B	  
AngII	   	   Angiotensin	  II	  
Ang-­‐(1-­‐7)	   Angiotensin-­‐(1-­‐7)	  
APS	  	   	   Ammonium	  Persulphate	  
AT1R	   	   Angiotensin	  Type-­‐1	  Receptor	  
AT2R	   	   Angiotensin	  Type-­‐2	  Receptor	  
BCA	  	   	   Bicinchoninic	  acid	  
BSA	  	   	   Bovine	  Serum	  Albumin	  
CAMKII	   Calcium	  Calmodulin	  Kinase	  II	  
CDDP	   	   Cisplatin,	  cis-­‐diamminedichloridoplatinum	  (II)	  
CDK	   	   Cyclin-­‐dependent	  Kinase	  
CI	   	   Combination	  Index	  
CO2	  	   	   Carbon	  Dioxide	  
C-­‐PARP	   Cleaved	  Poly(ADP-­‐Ribose)	  Polymerase	  
Ctl	   	   Control	  
DMEM	  	   Dulbecco’s	  Modified	  Eagle’s	  Medium	  
dH2O	   	   Distilled	  Hydrogen	  Dioxide	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DIZE	   	   Diminazene	  aceturate	  
DNA	   	   Deoxyribonucleotide	  	  
DOX	   	   Doxorubicin	  
EGF	   	   Epidermal	  Growth	  Factor	  
EGFR	   	   Epidermal	  Growth	  Factor	  Receptor	  
ECL	  	   	   Enhanced	  Chemiluminescence	  
EMT	   	   Epithelial-­‐Mesenchymal	  Transition	  
Fa	   	   Fraction	  affected	  
FCS	  	   	   Fetal	  Calf	  Serum	  
GAPDH	  	   Glyceraldehyde	  3-­‐Phosphate	  Dehydrogenase	  
HPV	   	   Human	  Papillomavirus	  
Hr	   	   Hour	  
HRP	  	   	   Horse	  Radish	  Peroxidase	  
IC50	   	   Half	  maximal	  inhibitory	  concentration	  
kDa	   	   Kilodaltons	  
Log	   	   Logarithm	  
Luc	   	   Luciferase	  
MasR	   	   MAS1	  receptor	  	  
Mcl-­‐1	   	   Myeloid	  Cell	  Leukemia	  1	  
MTT	   	   3’-­‐(4’,5’-­‐Dimethylthiazol-­‐2’-­‐yl)-­‐2’,5’-­‐diphenyltetrazolium	  bromide	  
Na3VO4	   Sodium	  orthovanadate	  
NaCl	   	   Sodium	  chloride	  
NF-­‐ΚB	   	   Nuclear	  Factor	  ΚB	  
NSCLC	   	   Non-­‐small	  cell	  lung	  cancer	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PAGE	   	   Polyacrylamide	  Gel	  Electrophoresis	  
PARP	   	   Poly(ADP-­‐Ribose)	  Polymerase	  
PBS	   	   Phosphate	  Buffered	  Saline	  
pCAMKII	   phosphorylated	  calcium	  calmodulin	  kinase	  II	  
PRR	   	   Pro(renin)	  receptor	  
p/s	   	   Penicillin	  and	  Streptomycin	  
Rb	   	   Retinoblastoma	  Protein	  
RIPA	  	   	   Radioimmunoprecipitation	  assay	  	  
RNA	   	   Ribonucleic	  Acid	  
RNAi	   	   RNA	  interference	  
RNase	   	   Ribonuclease	  
RNAsin	  	   Ribonuclease	  inhibitor	  
SD	   	   Standard	  Deviation	  
SDS	   	   Sodium	  Dodecyl	  Sulfate	  
SDS-­‐PAGE	   SDS	  Polyacrylamide	  gel	  electrophoresis	  
SEM	   	   Standard	  Error	  of	  the	  Mean	  
siRNA	   	   Small	  interfering	  RNA	  
SV40	   	   Simian	  Virus	  40	  
TBS	   	   Tris	  Buffered	  Saline	  
TBST	   	   Tris	  Buffered	  Saline	  Tween	  
V	   	   Volts	  
H2AX	   	   139-­‐serine	  phosphorylated	  histone	  H2A.X	  
	   	  




M	   	   Molar	  
min	   	   Minutes	  
μM	   	   Micromolar	   	  
nM	   	   Nanomolar	  
	  
G	   	   Gram	  
kg	   	   Kilogram	  
mg	   	   Milligram	  
μg	   	   Microgram	  
ng	   	   Nanogram	  
	  
L	   	   Litre	  
mL	   	   Millilitre	  
μL	   	   Microlitre	  
	  
μm	   	   Micrometre	  
nm	   	   Nanometre	  
N	   	   Normality	  
	  
	   	  




It	  has	  recently	  been	  discovered	  that	  cancer	  shares	  a	  link	  with	  metabolic	  diseases,	  including	  
that	   of	   cardiovascular	   disease,	   diabetes,	   amongst	   others,	   where	   common	   sets	   of	   genes	  
show	   similar	   gene	   expression.	   	   There	   is	   thus	   interest	   to	   investigate	   current	   therapies	   for	  
metabolic	   diseases	   as	   possible	   anti-­‐cancer	   agents.	   The	   renin-­‐angiotensin	   system	   (RAS)	  
regulates	   blood	   pressure	   and	   cardiovascular	   homeostasis	   through	  Angiotensin	   Converting	  
Enzyme-­‐1	  (ACE-­‐1)	  and	  its	  homolog	  ACE-­‐2.	  RAS	  has	  also	  been	  implicated	  in	  the	  progression	  of	  
various	   cancers	   due	   to	   the	   increased	   action	   of	   the	   vasoconstrictor,	   angiotensin	   II,	   which	  
requires	  ACE-­‐1	  and	  specifically	   the	  Angiotensin	  Type	  1	  Receptor	   (AT1R)	   for	   its	   function.	   In	  
this	   study,	  we	   investigated	   the	   potential	   association	   of	   the	   endogenous	  ACE-­‐1	   and	  ACE-­‐2	  
enzymes	  in	  cervical	  cancer.	  Our	  results	  showed	  that	  ACE-­‐1	  and	  AT1R	  protein	  expression	  was	  
elevated	  in	  cervical	  cancer	  cell	  lines	  compared	  to	  normal	  cells	  and	  that	  this	  correlated	  with	  
elevated	   ACE-­‐1	   enzyme	   activity	   in	   cancer	   cells.	   Treatment	   with	   the	   ACE-­‐1	   inhibitors,	  
Captopril	   and	   Lisinopril,	   reduced	   this	   activity.	   We	   showed	   that	   ACE-­‐1	   axis	   stimulation	   in	  
cancer	   cells	   results	   in	   increased	   calcium	   signaling	   preferentially	   via	   the	   AT1R	   and	   this	  
associates	  with	  cancer	  cell	  proliferation.	  Candesartan,	  an	  AT1R	  blocker	  significantly	  reduced	  
these	  effects.	  ACE-­‐2	  expression	  and	  activity	  were	  decreased	  in	  cancer	  compared	  to	  normal	  
cells.	  Our	  data	   shows	   that	  ACE2	  activators,	   the	  natural	  peptide	  angiotensin	  1-­‐7	  and	   small	  
molecule	  Diminazene	  aceturate	   (DIZE)	  have	  anticancer	  effects	  with	  DIZE	   inducing	  a	  G2/M	  
arrest	  in	  cancer	  cells.	  	  
We	   also	   investigated	   associations	   between	   drugs	   targeting	   RAS	   and	   current	  
chemotherapeutic	   agents,	   Cisplatin	   (CDDP)	   and	   Doxorubicin	   (DOX).	   Our	   data	   shows	   that	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ACE-­‐1	  axis	   inhibitors	  have	  an	  antagonistic	   effect	  on	  CDDP,	  while	   the	  ACE-­‐2	  activator	  DIZE	  
associates	  synergistically	  with	  DOX.	  Taken	  together,	  these	  results	  suggest	  that	  elevated	  ACE-­‐
1	   expression	   associates	   with	   cervical	   cancer	   and	   that	   the	   inhibitors	   of	   ACE-­‐1	   function	   or	  
activators	   of	   ACE-­‐2	   function	   have	   potential	   as	   anticancer	   therapies	   as	   single	   agents	   or	   in	  
combination	  treatments	  with	  current	  chemotherapeutics.	  	  
	  	   	  







Cancer	  describes	   a	   large	  number	  of	  diseases	   characterised	  by	   the	  uncontrolled	  growth	  of	  
abnormal	  cells	  with	  the	  ability	  to	  affect	  any	  part	  of	  the	  human	  body	  as	  they	  spread.	  Cancer	  
is	   an	   enormous	   burden	   on	   society	   and	   a	   leading	   cause	   of	   death	  worldwide	   (Torre	   et	   al.,	  
2015).	   Cancer	   is	   caused	   by	   a	   number	   of	   external	   factors,	   which	   include	   tobacco,	   an	  
unhealthy	  diet,	  infectious	  agents	  as	  well	  as	  inherited	  genetic	  mutations	  (Torre	  et	  al.,	  2015).	  
In	  2012	  GLOBOCAN	  estimated	  the	  number	  of	  cancer	  cases	  globally	  to	  be	  approximately	  14.1	  
million	  with	  8.2	  million	  cancer	  deaths	  recorded	  (Torre	  et	  al.,	  2015).	  In	  developing	  countries	  
cancer	   is	   responsible	   for	   542	   000	   deaths	   with	   approximately	   715	   000	   new	   cancer	   cases	  
recorded	  in	  2008.	  Cervical	  and	  breast	  cancers	  were	  diagnosed	  more	  frequently	  than	  other	  
forms	   of	   cancer	   in	   women	   while	   cancers	   of	   the	   lung,	   bronchus	   and	   trachea,	   liver	   and	  














Figure	   1.1:	   Estimated	   new	   cancer	   cases	   and	   deaths	   in	   2012.	   From	   GLOBOCAN	   2012	  
worldwide	   new	   cases	   of	   breast	   and	   cervical	   cancer	   are	   amongst	   the	   most	   frequently	  
diagnosed	   and	   are	   two	   of	   the	   leading	   causes	   of	   cancer-­‐related	   deaths	   globally	   and	   in	  
developing	  countries.	  (Torre	  et	  al.,	  2015)	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1.2	  New	  and	  alternative	  cancer	  targets	  
Cancer	   has	   predominantly	   been	   known	   as	   a	   disease	   driven	   by	   rapid	   and	   uncontrolled	  
proliferation.	  However,	  emerging	  evidence	  has	  shown	  that	  cancer	  can	  also	  be	  considered	  a	  
metabolic	   disease,	   with	   associated	   metabolic	   reprogramming,	   disturbances	   in	   energy	  
production	  and	  the	  disruption	  of	  normal	  cell	  signaling	  networks	  (Coller,	  2014;	  Seyfried	  and	  
Shelton,	  2010;	  Seyfried	  et	  al.,	  2014).	  
	  
1.2.1	  Links	  between	  metabolism	  and	  cancer	  
Cancer	   cells	   re-­‐engineer	   their	   metabolic	   pathways	   to	   drive	   proliferation	   and	   growth	   of	  
tumours	   with	   emerging	   evidence	   indicating	   that	   oncogenic	   molecules	   such	   as	   c-­‐MYC,	  
hypoxia-­‐inducible	   factor-­‐1	   (HIF-­‐1)	   and	   AKT	   and	   tumour	   suppressors	   such	   as	   p53	   enforce	  
these	  metabolic	  shifts	  (Coller,	  2014).	  In	  addition	  to	  reports	  that	  c-­‐MYC	  has	  well	  defined	  roles	  
in	   regulating	   proliferation,	   differentiation	   and	   apoptosis	   it	   has	   also	   been	   found	   to	   induce	  
glucose	   consumption,	   lactate	   production	   which	   assist	   growing	   tumours	   in	   anaerobic	  
microenvironments.	   Similarly,	   HIF-­‐1	   has	   also	   been	   found	   to	   facilitate	   the	   activation	   of	  
oxygen	   independent	  modes	   of	   energy	   and	   is	   well	   documented	   as	   being	   stabilized	   during	  
hypoxia	  leading	  to	  the	  transcription	  of	  target	  genes	  involved	  in	  angiogenesis.	  Under	  normal	  
conditions	   the	   phosphatidyl	   inositol-­‐3-­‐kinase	   (PI3K)	   pathway	   is	   activated	   through	   growth	  
signals.	  	  In	  many	  cancers,	  it	  is	  observed	  that	  this	  pathway	  is	  constitutively	  activated	  resulting	  
in	   the	  activation	  of	  AKT	  kinase	  and	   the	  powerful	  activation	  of	  growth	  promoting	  program	  
(Coller,	   2014).	   In	   summary,	   these	   oncogenes	   contribute	   strongly	   to	   the	   metabolic	  
reprogramming	  which	  takes	  place	  during	  carcinogenesis	  (Coller,	  2014).	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In	   response	   to	  DNA	  damage	  p53	   is	   responsible	   for	   the	   regulation	   of	  many	   important	   cell	  
processes	  such	  as	  cell	  cycle	  arrest	  and	  cell	  death	  but	  has	  also	  recently	  been	  investigated	  in	  
the	  modulation	  of	  cellular	  metabolism	  (Coller,	  2014).	  	  	  
	  
Although	  metabolic	   changes	   in	   tumours	  have	  been	  documented	   in	   the	  past	   this	   shift	  was	  
observed	  only	  as	  a	  secondary	  effect	  with	  uncontrolled	  proliferation	  being	  the	  major	  cause	  
of	  cancer.	  Growing	  evidence	  suggests	   that	  metabolic	  changes	  are	  more	   fundamental	   than	  
what	  was	  once	  thought.	  As	  a	   result	  of	   this	  shift	  metabolic	  diseases	  such	  as	  cardiovascular	  
disease	   and	   diabetes	   have	   been	   linked	   to	   cancer	   (Hirsch	   et	   al.,	   2010;	   Reznik	   and	   Sander,	  
2015).	   By	   performing	   transcriptional	   profiling	   in	   two	   isogenic	   models	   of	   cellular	  
transformation,	   Hirsch	   et	   al.	   (2010)	   identified	   a	   cancer	   gene	   signature	   associating	   with	  
inflammatory	   and	  other	  metabolic	   diseases.	   Three	   groups	  of	   genes	  were	   identified	  which	  
associate	  with	   cancer.	   These	   include	   genes	   associating	  with	   cancer	   cell	   functions	   such	   as	  
enhanced	   proliferation,	   cell	   cycle	   control	   and	   cell	   death;	   genes	   associated	   with	  
inflammation	   and	   immune	   system	   function	   as	   well	   as	   genes	   responsible	   for	   lipid	  
metabolism,	  gastrointestinal	  disease,	  metabolic	  disease	  and	  cardiovascular	  disease.	  	  	  
	  
Moreover,	   the	   study	   also	   found	   that	   the	   cancer	   gene	   signature	   was	   comprised	   of	   genes	  
which	  were	  previously	  not	  associated	  with	  cancer,	  such	  as	  the	  lipid	  metabolism	  genes	  OLR1	  
(oxidized	   LDL	   receptor	   1),	   SREBP-­‐1	   (sterol	   element-­‐binding	   protein	   1),	   SNAP23	   (SNARE	  
protein	   synaptosomal-­‐associated	   protein	   of	   23	   kDa)	   and	   VAMP4	   (Vesicle	   associated	  
membrane	  protein-­‐4).	  siRNA	  knockdown	  of	  the	  associated	  lipid	  metabolism	  proteins	  proved	  
their	  importance	  in	  cellular	  transformation	  and	  growth	  of	  cancer	  cells.	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As	   a	   result	   of	   emerging	   evidence	   there	   have	   been	   reports	   supporting	   findings	   that	   drugs	  
used	   to	   treat	   metabolic	   diseases	   have	   anti-­‐cancer	   properties	   (Figure	   1.2	   A).	   	   The	   anti-­‐
diabetic	   drug	   Metformin;	   anti-­‐inflammatory	   drugs,	   including	   Celecoxib,	   Piroxicam	   and	  
Sulindac;	   and	   lipid	   lowering	   drugs	   such	   as	   Simvastatin,	   Cerulenin	   and	   Mevastatin	   all	  
successfully	  reduced	  or	  prevented	  cellular	  transformation	  (Figure	  1.2	  B).	  The	  ability	  of	  single	  
cancer	  cells	  to	  form	  clonogenic	  colonies	  was	  also	  reduced	  after	  treatment	  with	  these	  drugs.	  
In	   addition,	   Metformin,	   Cerulenin,	   Simvastatin	   and	   Sulindac	   were	   effective	   at	   reducing	  
tumour	  growth	  in	  nude	  mice	  (Figure	  1.2	  C).	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Figure	  1.2:	  Many	  non-­‐cancer	  drugs	  have	  anti-­‐cancer	  effects.	  (A)	  Percentage	  of	  transformed	  
cells	   (morphology	   assay)	   observed	   by	   treating	   TAM-­‐induced	  MCF10	   ER-­‐Src	   cells	   with	   the	  
indicated	   drugs.	   (B)	   Soft	   agar	   colony	   assay	   of	   the	   effect	   of	   the	   indicated	   drugs	   on	  
transformation.	  (C)	  Tumour	  growth	  (mean	  ±	  SD)	  of	  MCF10	  ER-­‐Src	  cells	  after	  4	  cycles	  of	   i.p	  
treatments	  with	  the	  indicated	  drugs	  (Hirsch	  et	  al.,	  2010).	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Emerging	  evidence	  describes	  the	  multifaceted	  association	  between	  metabolism	  and	  cancer.	  
(Reznik	  and	  Sander,	  2015)	  examined	  the	  altered	  metabolism	  of	  breast	  and	  clear-­‐cell	  kidney	  
cancer,	  thereby	  discovering	  the	  altered	  co-­‐expression	  patterns	  of	  four	  clusters	  of	  metabolic	  
genes.	   As	   a	   result	   of	   this,	   mitochondrial	   dysfunction	   is	   exhibited	   in	   these	   cancer	   types	  
promoting	  disease	  progression.	  	  Moreover,	  there	  is	  an	  association	  between	  atherosclerosis	  
and	   cancer	   development	   through	   lectin-­‐like	   oxidized	   low-­‐density	   lipoprotein	   receptor-­‐1	  
(LOX-­‐1)	   (Jiang	  et	  al.,	  2011).	  LOX-­‐1	   is	  mainly	  expressed	   in	  endothelial	  cells	  and	  thus	  plays	  a	  
role	   in	  angiogenesis,	   the	  creation	  of	  new	  blood	  vessels	   in	  healthy	  development	  but	  also	  a	  
source	  of	  nutrition	  for	  a	  growing	  tumour.	  Jiang	  et	  al.,	  (2011)	  found	  that	  LOX-­‐1	  is	  important	  
for	  maintaining	  the	  transformed	  state	  of	  cells	  driving	  carcinogenesis	  and	  is	  associated	  with	  
the	  risk	  factors	  for	  atherosclerosis,	  such	  as	  hypertension,	  hyperlipidemia	  and	  diabetes.	  	  
	  
These	   studies	   suggest	   that	   metabolic	   reprogramming	   is	   associated	   with	   cancer.	  
Consequently,	  genes	  associated	  with	  metabolic	  diseases	  provide	  attractive	  new	  targets	  for	  
cancer	   therapies.	   Current	   drugs,	   in	   addition	   to	   their	   primary	   function	   of	   treating	   specific	  
metabolic	   diseases,	   may	   be	   able	   to	   exert	   secondary	   functions	   with	   potent	   anti-­‐cancer	  
effects	  and	  thus	  provide	  a	  novel	  and	  alternative	  means	  of	  treating	  cancer.	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1.3	  The	  RAS	  as	  a	  potential	  cancer	  target	  
The	   renin-­‐angiotensin	   system	   (RAS)	   was	   discovered	   in	   1898	   by	   the	   Finnish	   physiologist	  
Robert	  Tigerstedt	  and	  his	  student	  Bergman	  through	  their	  investigations	  into	  pressor	  effects	  
exerted	  by	  crude	  saline	  extract	  of	   rabbit	  kidney	   in	   rabbits	   (Kunikullaya	  et	  al.,	  2012;	  Marks	  
and	  Maxwell,	  1979;	  Phillips	  and	  Schmidt-­‐Ott,	  1999).	  	  
	  
Today	  the	  RAS	  exists	  as	  a	  complex	  system	  responsible	  for	  regulation	  of	  arterial	  pressure	  and	  
tissue	  perfusion.	  Fundamental	  to	  the	  pathway	  or	  cascade	  is	  angiotensin-­‐converting	  enzyme-­‐
1	   (ACE-­‐1),	   which	   converts	   the	   peptide	   hormone	   angiotensin	   I	   to	   angiotensin	   II	   (Ang-­‐II)	  
(Deshayes	  and	  Nahmias,	  2005;	  Peach,	  1977).	  Ang-­‐II	  mediates	   its	  biological	  effects	   through	  
binding	   to	   two	   receptors	   which	   belong	   to	   the	   G-­‐protein	   coupled	   receptor	   family,	   the	  
angiotensin	  type	  I	  and	  type	  II	  receptors	  (AT1R	  and	  AT2R)	  (Figure	  1.3).	  While	  both	  receptors	  
are	  responsible	  for	  signal	  transduction,	  they	  result	  in	  opposing	  effects,	  with	  AT1R	  activation	  
leading	  to	  vasoconstriction	  of	  blood	  vessels	  as	  well	  as	  increased	  cell	  proliferation,	  and	  AT2R	  
activation	   resulting	   in	  vasodilation	  and	   reports	  of	  decreased	  cell	  proliferation	   (Ager	  et	  al.,	  
2008).	  	  
	  
As	  a	  result	  of	  the	  far	  reaching	  effects	  of	  ACE-­‐1	  and	  the	  RAS	  as	  a	  whole,	  numerous	  studies	  
have	   shown	   the	   association	   between	   ACE-­‐1	   function	   and	   metabolic	   diseases	   such	   as	  
diabetes	  as	  well	  as	  various	  cancer	  such	  as	  pancreatic	  and	  breast	  cancer	  (Anandanadesan	  et	  
al.,	  2008;	  Du	  et	  al.,	  2012;	  Hsueh	  and	  Wyne,	  2011).	  Thus,	  drugs	  used	  to	  target	  RAS	  might	  also	  
prove	   effective	   against	   cancer.	  While	   some	   studies	   have	   	   shown	   an	   association	   between	  
ACE-­‐1	  or	  AT1R	  hyperactivation	  with	  cancer	  (Escobar	  et	  al.,	  2004;	  Greco	  et	  al.,	  2002b;	  Vinson	  
et	  al.,	  2012),	  others	  have	  been	  inconclusive	  (Cheng	  et	  al.,	  2015).	  Cohort	  studies,	  such	  as	  that	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of	  (van	  der	  Knaap	  et	  al.,	  2008),	  assessed	  the	  effects	  of	  RAS	  inhibitors	  and	  ACE-­‐1	  insertion	  or	  
deletion	   (I/D)	   polymorphism	   on	   risk	   of	   cancer.	   The	   data	   showed	   that	   persons	  with	   a	   DD	  
genotype	  associate	  with	  high	  levels	  of	  ACE-­‐1,	  and	  that	  RAS	  inhibitors	  protect	  against	  cancers	  
in	   such	   individuals.	   Furthermore,	   a	   meta-­‐analysis	   of	   the	   association	   of	   the	   ACE-­‐1	   gene	  
polymorphism	  with	   cancer	   risk	   	   showed	   that	   the	   ACE-­‐1	   (I/D)	   polymorphism	   is	   associated	  
with	  cancer	  in	  Caucasians	  (Zhang	  et	  al.,	  2014).	  	  
	  
	   	  







Figure	   1.3:	   The	   extended	   renin	   angiotensin	   system.	   Angiotensin	   converting	   enzyme	   -­‐1	  
(ACE-­‐1)	  is	  responsible	  for	  cleavage	  of	  the	  inactive	  peptide	  angiotensin	  I,	  yielding	  angiotensin	  
II	  which	   is	   the	  main	  effector	  peptide	  of	   the	  renin	  angiotensin	  system	  (RAS).	  Angiotensin-­‐II	  
causes	  a	  wide	  range	  of	  outcomes	  depending	  on	  the	  activation	  of	  either	  the	  angiotensin	  type	  
I	   receptor	   (AT1R),	   or	   angiotensin	   type	   II	   receptor	   (AT2R).	   	   Apart	   from	   vasodilation,	   AT1R	  
activation	   results	   in	   increased	   proliferation	   and	   angiogenesis	   in	   different	   cell	   types.	  	  
Activation	  of	   the	  AT2R	  or	   the	  mas	  Receptor	   (masR)	   serves	   to	   counter	   such	   effects.	  MasR	  
activation	   occurs	   through	   the	   binding	   of	   angiotensin-­‐	   (1-­‐7)	   as	   a	   result	   of	   cleavage	   of	  
angiotensin-­‐I	  by	  angiotensin	  converting	  enzyme-­‐2	  (ACE-­‐2)	  and	  angiotensin-­‐	  (1-­‐9)	  by	  ACE-­‐1.	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1.3.1.	  Components	  of	  the	  RAS	  as	  potential	  anticancer	  targets	  
Cancer	  shares	  a	  link	  with	  various	  inflammatory	  and	  metabolic	  diseases,	  where	  common	  sets	  
of	  genes	  show	  similar	  gene	  expression(Hirsch	  et	  al.,	  2010).	  As	  previously	  mentioned,	  it	  was	  
shown	  that	  genes	  associating	  with	  cell	  cycle	  control,	  inflammation	  and	  lipid	  metabolism	  are	  
also	  important	  for	  cancer	  function,	  thus	  showing	  increased	  expression	  in	  cancer	  tissues.	  The	  
RAS	  has	  classically	  been	  known	  for	   its	   regulation	  of	  cardiovascular	  homeostasis	  and	  blood	  
pressure	   control	   (Peach,	   1977).	   However,	   there	   is	   increasing	   evidence	   that	   the	   major	  
effector	   peptide	   of	   the	   RAS,	   Ang-­‐II,	   as	   well	   as	   other	   components,	   are	   role	   players	   in	  
pathophysiological	  conditions	  including	  the	  progression	  of	  many	  cancers	  (Ager	  et	  al.,	  2008;	  
Atlas,	  2007;	  Deshayes	  and	  Nahmias,	  2005;	  Neo	  et	  al.,	  2010).	  
	  
Apart	   from	   causing	   vasoconstriction,	   AT1R	   activation	   through	   binding	   of	   Ang-­‐II	   has	   been	  
observed	   to	   result	   in	   tissue	   remodelling	   and	   some	   of	   the	   hallmarks	   of	   cancer;	   cellular	  
proliferation,	   angiogenesis,	   migration	   and	   invasion	   (Ager	   et	   al.,	   2008)	   (Figure	   1.3).	   Ang-­‐II	  
exerts	  many	  of	  its	  effects	  through	  binding	  to	  the	  AT1R	  and	  interestingly	  it	  has	  been	  shown	  
that	  in	  cancer	  the	  AT1R	  specifically	  is	  responsible	  for	  pathophysiological	  outcomes,	  i.e.	  pro-­‐
proliferative	  effects,	  whereas	  AT2R	  activation	  results	  in	  anti-­‐proliferative	  effects	  (De	  Paepe	  
et	  al.,	  2001	  and	  Stoll	  et	  al.,	  1995).	  	  	  
	  
Angiotensin-­‐converting	  enzyme-­‐2	   (ACE-­‐2)	   regulates	   the	  effects	  of	  ACE-­‐1,	   through	  cleavage	  
of	   both	   Ang-­‐I	   and	   Ang-­‐II	   to	   form	  Angiotensin	   1-­‐7	   (Ang-­‐(1-­‐7)).	   Initial	   studies	   into	   the	  Mas	  
oncogene,	  considered	  it	  an	  “orphan”	  G-­‐protein	  receptor,	  without	  known	  functions	  	  (Santos	  
et	   al.,	   2003).	   Studies	   by	   groups	   such	   as	   (Kostenis	   et	   al.,	   2005;	   Santos	   et	   al.,	   2007),	   later	  
described	   the	  association	  between	  between	  AT1	  Receptors,	  Mas	   and	  Ang-­‐17.	   Since	   these	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studies	   it	   is	   now	   well	   reported	   that	   binding	   of	   Ang-­‐(1-­‐7)	   to	   its	   specific	   receptor,	   the	  
Mitochondrial	   Assembly	   Receptor	   (MasR),	   results	   in	   vasodilation	   and	   a	   reduction	   in	  
proliferation	  and	  other	  pathophysiological	  actions	  of	  ACE-­‐1	  and	  the	  AT1R	  (Ager	  et	  al.,	  2008).	  
	  
With	   growing	   evidence	   that	   Ang-­‐II	   is	   synthesized	   not	   only	   systemically	   in	   circulation,	   but	  
also	   at	   tissue	   sites	   and	   components	   of	   the	   RAS	   are	   expressed	   in	   tissues,	   the	   classic	   RAS	  
paradigm	  has	  included	  the	  growing	  concept	  of	  tissue	  RAS.	  	  
	  
The	  complexity	  of	  the	  RAS	  is	  a	  result	  of	  the	  wide	  spectrum	  of	  downstream	  effects	  induced	  
through	  Ang-­‐II	  activation	  of	  the	  AT1R.	  For	  this	  reason,	  crosstalk	  between	  signaling	  pathways	  
exists	   facilitating	   an	   environment	   for	   carcinogenesis.	   For	   example,	   as	   well	   as	   being	  
responsible	   for	   the	   proliferation	   of	   breast	   cells,	   Ang-­‐II	   also	   stimulates	   the	   proliferation	   of	  
endometrial,	  anterior	  pituitary	  and	  adrenocortical	  cells	  (Wegman-­‐Ostrosky	  et	  al.,	  2013)	  
	  
In	   the	   cancer	   setting	   Ang-­‐II	   activation	   of	   the	   AT1R	   has	   been	   reported	   to	   stimulate	   the	  
proliferation	  of	  breast,	  colorectal	  and	  prostate	  cancer	  cells	  (Ager	  et	  al.,	  2008;	  Lewandowska	  
et	  al.,	  2011;	  Rodrigues-­‐Ferreira	  et	  al.,	  2012).	  Since	  the	  discovery	  of	  the	  tissue	  RAS	  there	  has	  
been	   much	   research	   targeting	   RAS	   components	   in	   various	   cancers	   (Table	   1)	   (Neo	   et	   al.,	  
2010;	  Wegman-­‐Ostrosky	  et	  al.,	  2013).	  ACE-­‐1	  inhibitors	  such	  as	  Captopril	  have	  been	  shown	  
to	   reduce	   growth	   and	   metastases	   in	   vivo	   of	   lewis	   lung	   carcinoma,	   renal	   carcinoma,	  
colorectal,	   	   gastric	   cancer,	   and	   	   fibrosarcoma	   (Hii	   et	   al.,	   1998;	  Huang,	  2007;	  Kosugi	   et	   al.,	  
2006;	  Kowalski	  and	  Herman,	  1996;	  Miyajima	  et	  al.,	  2002;	  Miyajima	  et	  al.,	  2015;	  Neo	  et	  al.,	  
2007;	  Neo	  et	  al.,	  2010;	  Prontera	  et	  al.,	  1999;	  Suganuma	  et	  al.,	  2005;	  Volpert	  et	  al.,	  1996;	  
Yoshiji	  et	  al.,	  2002).	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AT1R	  inactivation	  with	  antagonists	  has	  also	  been	  seen	  to	  successfully	  reduce	  tumour	  growth	  
of	   cancers	   including	   prostate,	   gastric,	   colorectal,	   breast,	   non-­‐small	   cell	   lung	   and	   renal	  	  
cancers	   (Alhusban	   et	   al.,	   2014;	   Araujo	   et	   al.,	   2015;	   Du	   et	   al.,	   2012;	   Kosaka	   et	   al.,	   2007;	  
Kowalski	   and	   Herman,	   1996;	   Nakagawa	   et	   al.,	   1995;	   Namazi	   et	   al.,	   2014;	   Okazaki	   et	   al.,	  
2014).	   Studies	  have	   shown	   the	  blockade	  of	   the	  ACE-­‐1	   axis	  with	  ACE-­‐1	   inhbitors	   results	   in	  
increased	  levels	  of	  Ang-­‐I,	  due	  to	  a	  lack	  of	  feedback	  inhibition	  of	  renin	  secretion.	  Subsequent	  
cleavage	  of	  Ang-­‐I	  results	  in	  increased	  levels	  of	  Ang-­‐(1-­‐7),	  which	  is	  known	  to	  exert	  anti-­‐cancer	  
activity	   (Ritter,	   2011;	   Santos	   et	   al.,	   2013).	   Any	   disruption	   within	   the	   complex	   cacades	  
constituting	   the	   RAS	   has	   the	   potential	   to	   either	   promote,	   or	   reduce,	   the	   development	   of	  
cancers,	  such	  as	  those	  mentioned	  above.	  	  
	  
ACE-­‐1	   inhibitors	  or	  AT1R	  blockers	  could	  potentially	  be	  used	  as	  anticancer	  agents	  either	  as	  
single	   treatments	   or	   in	   combination	   therapy	   as	   they	   are	   already	   being	   used	   in	   patients	  
without	   any	   serious	   side	   effects,	   and	   as	   mentioned	   above,	   show	   signs	   of	   anticancer	  
potential.	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Table	  1:	  RAS	  blockade	  in	  murine	  malignancy	  models.	  Adapted	  from	  (Ager	  et	  al.,	  2008)	  
	  
N/A,	   not	   assessed.	   Several	   cancer	   cell	   lines	   have	   been	   used	   in	   xenograft	   or	   allograft	   animal	   models	   of	   metastases.	   These	   experiments	   have	   shown	  
decreased	  tumour	  volume	  and	  when	  assessed	  decreased	  metastasis	  
Cell$line/model$ Agent$ Tumour$volume$ Metastases$ Reference$
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1.3.1.1	  Inhibitors	  of	  the	  ACE-­‐1	  axis	  
Captopril,	   was	   the	   first	   synthetic	   ACE-­‐1	   inhibitor	   to	   be	   used	   in	   the	   treatment	   of	  
hypertension	  and	   is	  a	  sulfydryl-­‐containing	  alanine-­‐proline	  analog	  (Figure	  1.4).	  A	  short	  half-­‐
life	  and	  adverse	   side	  effects	   such	  as	  a	  metallic	   taste	   in	   the	  mouth,	  a	   rash,	  or	  a	  persistent	  
cough,	  attributed	  to	  the	  sulfhydryl	  group	  unique	  to	  the	  compound,	  led	  to	  the	  development	  
of	  improved	  ACE-­‐1	  inhibitors	  with	  carboxylate	  zinc	  binding	  groups,	  such	  as	  Lisinopril	  (Hanif	  
et	  al.,	  2010).	  
	  
The	   chemical	   structures	   of	   the	   ACE-­‐1	   inhibitors	   are	   diverse	   leading	   to	   varying	   degrees	   of	  
potency,	  bioavailability,	  plasma	  half-­‐life,	  respective	  affinity	  for	  tissue	  bound	  ACE-­‐1	  and	  route	  
of	  elimination	  from	  the	  body.	  In	  addition	  to	  this	  they	  also	  differ	  in	  terms	  of	  whether	  or	  not	  
they	  are	  administered	  as	  prodrugs	  requiring	  subsequent	  activation	  (Table	  2).	  	  	  
	  
AT1R	  blockers	  were	  developed	  in	  an	  endeavour	  to	  improve	  the	  efficacy	  of	  the	  RAS	  blockade	  
and	  improve	  the	  side	  effect	  profile	  of	  existing	  drugs.	  In	  1971	  Saralasin	  was	  introduced	  as	  the	  
first	   AT1R	   blocker	   (Pals,	   D.	   T.,	  Masucci,	   F.	   D.,	   Denning,	  G.S.Jr.,	   Sipos,	   F.	   and	   Fessler,	   D.C.,	  
1971).	   Further	   research	  efforts	  were	   conducted	   to	   improve	   characteristics	  of	   this	   class	   as	  
saralisin	  together	  with	  other	  antagonists	  such	  as	  sarmesin	  and	  sarilesin	  demonstrated	  poor	  
bioavailabilty	  and	  short	  duration	  of	  action	  (Chung	  et	  al.,	  1999).	  	  	  
	  
Current	   AT1R	   blockers	   have	   been	   further	   developed	   resulting	   in	   improved	   bioavailability	  
compared	   to	   the	   first	   antagonists	   (Table	   3).	   Similar	   to	   the	   ACE-­‐1	   inhibitors	   the	   chemical	  
structures	  and	  pharmacological	  characteristics	  of	  AT1R	  blockers	  are	  variable	  although	  they	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all	   show	  selective	  blockade	  of	   the	  AT1R	  while	   showing	  no	  off-­‐target	  effects	   (Chung	  et	  al.,	  
1999).	  	  
	  
Candesartan	   is	   a	   benzimidazole-­‐derived	   compound	   developed	   to	   further	   reduce	   ACE-­‐1	  
inhibitor	   side	   effects,	   and	   block	   the	   activation	   of	   the	   AT1R	   preventing	   any	   downstream	  
signaling	   (McClellan	   and	   Goa,	   1998).	  






Figure	  1.4:	  Chemical	  structures	  of	  ACE-­‐1	  axis	  inhibitors.	  Captopril	  and	  Lisinopril	  target	  the	  inhibition	  of	  ACE-­‐1	  activity	  while	  Candesartan	  is	  an	  
antagonist	   of	   the	   AT1R,	   activation	   through	   which	   results	   in	   a	   wide	   range	   of	   effects.	  
Captopril) Lisinopril) Candesartan)
	   33	  
Table	  2:	  Pharmacology	  of	  ACE-­‐1	  Inhibitors	  including	  Captopril	  and	  Lisinopril	  (Arora,	  2013;	  Brown	  and	  Vaughan,	  1998;	  Macdonald	  et	  al.,	  1993;	  
Zaman	  et	  al.,	  2002)	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Table	  3:	  Pharmacology	  of	  clinically	  used	  AT1R	  antagonists	  
	  
	  
Candesartan) Losartan) Olmesartan) Eprosartan) Irbesartan) Telmisartan) Valsartan)
Binding)
Aﬃnity)(Kd))
9.5$%$9.7$ 7.4$–$8.7$ 8.1$ 8.4$–$8.8$ 8.7$–$8.8$ 8.4$ 8.6$
Bioavailability) 40%$ 33%$ 26%$ 13%$ 60%80%$ 67%$ 25%$
Route)of)
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1.3.1.2	  Activating	  the	  ACE-­‐2	  axis	  of	  RAS	  
	  
1.3.1.2.1	  Activation	  of	  the	  ACE-­‐2	  axis	  using	  Ang-­‐(1-­‐7)	  	  
	  In	  addition	   to	   targeting	   the	  ACE-­‐1	  axis,	   there	  has	  also	  been	  an	   increase	   in	   the	  number	  of	  
studies	  investigating	  the	  potential	  role	  that	  the	  ACE-­‐2	  axis	  may	  play	  as	  it	  is	  well	  documented	  
as	  being	   the	  protective	  arm	  of	   the	  RAS	   (Ager	  et	  al.,	   2008;	  Ferrario,	  1990b;	  Fleming	  et	  al.,	  
2006;	  Wegman-­‐Ostrosky	  et	  al.,	  2013).	  Activation	  of	  the	  ACE-­‐2	  axis	  using	  Ang-­‐(1-­‐7)	  in	  cancer	  
studies	   has	   shown	   to	   have	   promising	   anti-­‐cancer	   effects	   with	   disruption	   of	   growth-­‐
promoting	  signals	  as	  well	  as	  decreased	  angiogenesis,	  inflammation	  and	  metastasis	  of	  cancer	  
cells	  (Feng	  et	  al.,	  2010a;	  Gallagher	  et	  al.,	  2014;	  Ni	  et	  al.,	  2012;	  Passos-­‐Silva	  et	  al.,	  2015).	  
	  
Furthermore,	   the	  overexpression	  of	  ACE-­‐2	  has	  been	  shown	  to	  produce	  anti-­‐cancer	  effects	  
through	   inhibition	   of	   angiogenesis	   and	   tumour	   cell	   invasion	   of	   non-­‐small	   cell	   lung	   cancer	  
cells	  (Feng	  et	  al.,	  2011a)	  as	  well	  as	  assisting	  with	  inhibiting	  acquired	  resistance	  to	  platinum-­‐
based	  chemotherapy	  in	  this	  cancer	  (Cheng	  et	  al.,	  2016).	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1.3.1.2.2	  Activation	  of	  the	  ACE-­‐2	  axis	  	  	  	  
Supplementing	  the	  fight	  against	  harmful	  effects	  of	  the	  ACE-­‐1	  axis	  are	  small	  molecule	  such	  as	  
Diminazene	  aceturate	  (DIZE),	  a	  currently	  used	  ACE-­‐2	  enzyme	  activator	  (da	  Silva	  Oliveira	  and	  
de	   Freitas,	   2015;	   de	   Macedo	   et	   al.,	   2015;	   Kuriakose	   and	   Uzonna,	   2014;	   Qi	   et	   al.,	   2013;	  
Velkoska	  et	  al.,	  2015).	  Since	   its	  discovery,	   it	  has	  been	  utilised	  to	   increase	  ACE-­‐2	  activity	   in	  
environments	  where	  ACE-­‐2	  activity	  was	  poor	  thus	  enabling	  the	  protective	  effects	  of	  ACE-­‐2.	  	  
DIZE	  has	  been	  used	  since	  1955	  to	  treat	  animal	  trypanosomiasis,	  also	  referred	  to	  as	  sleeping	  
sickness.	   It	   has	   been	   reported	   to	   possess	   trypanolytic	   properties,	  with	   the	  mechanism	   of	  
action	   including	   the	   downregulation	   of	   phosphorylated	  mitogen	   activated	  protein	   kinases	  
(MAPKs,	  including	  p38,	  ERK	  and	  JNK)(Peregrine	  and	  Mamman,	  1993)Side	  effects	  associated	  
with	  DIZE	  treatment	  in	  animals	  include	  tremors,	  sweating,	  convulsions	  and	  itching	  and	  thus	  
has	   not	   yet	   been	   reported	   to	   be	   safe	   for	   testing	   in	   humans(Kuriakose	   et	   al.,	  
2012)Considerations	  for	  future	  use	  in	  humans	  could	  involve	  structural	  modifications	  to	  the	  
compound	   in	  order	  to	  maintain	  a	  high	  degree	  of	  potency	  with	  a	  reduction	  of	  side	  effects.	  
Alternatively,	  studies	  could	  investigate	  the	  lowest	  possible	  dose	  for	  efficacy	  in	  animals	  and	  
humans,	  as	  a	  single	  or	  combined	  treatment.	  
	  
1.4	  Signalling	  pathways	  associated	  with	  the	  tissue	  RAS	  and	  disease	  	  
	  
1.4.1	  Calcium	  Signalling	  
With	   the	   discovery	   of	   the	   local	   RAS	   in	   various	   tissues	   there	   is	   increasing	   interest	   to	  
investigate	  how	  the	  system	  gets	  initiated,	  i.e	  the	  generation	  of	  angiotensin	  I.	  (Pro)	  renin	  is	  
the	  inactive	  form	  of	  Renin	  and	  can	  be	  activated	  both	  proteolytically	  and	  non-­‐proteolytically	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(Sihn	  et	  al.,	  2010a).	  Very	  little	  is	  known	  regarding	  (pro)	  renin	  as	  well	  as	  the	  role	  of	  the	  (pro)	  
renin	   receptor	   in	   cancer.	   It	   has	   been	   assumed	   that	   (pro)	   renin	   was	   recruited	   and	   locally	  
activated	  within	  the	  tissue	  to	  aid	  in	  the	  generation	  of	  angiotensin	  II	  (Nguyen	  and	  Contrepas,	  
2008).	  	  
	  
Binding	   of	   (pro)	   renin	   to	   the	   (pro)	   renin	   receptor	   has	   been	   shown	   to	   activate	   (pro)	   renin	  
non-­‐proteolytically	   with	   the	   result	   of	   local	   Angiotensin	   I	   generation	   (Sihn	   et	   al.,	   2010b).	  
Studies	   using	   RAS	   inhibitors	   have	   shown	   that	   the	   activation	   of	   (pro)	   renin	   receptor	   can	  
trigger	  intracellular	  signalling	  that	  is	  independent	  of	  Ang-­‐II	  such	  as	  MAPK	  signalling	  (ERK	  1/2)	  
(Sihn	  et	  al.,	  2010a).	  Blockade	  of	  the	  AT1R	  can	  still	  result	  in	  signalling	  as	  activated	  (pro)	  renin	  
can	  signal	  independently	  of	  AT1R	  activation.	  
	  
Studies	   by	   (Cruciat	   et	   al.,	   2010)	   have	   identified	   an	   additional	   function	   of	   the	   (pro)	   renin	  
receptor	  (PRR),	  acting	  as	  a	  V-­‐ATPase	  which	  is	  an	  essential	  component	  of	  the	  Calcium-­‐related	  
Wnt	   signalling	  pathway	   (Figure	  1.5).	   Through	   the	  phosphorylation	  of	   the	  Wnt	  co-­‐receptor	  
LRP6,	  they	  showed	  activated	  intracellular	  Wnt	  signalling	  was	  dependent	  on	  V-­‐ATPase	  action.	  
The	   (pro)	   renin	   receptor	   has	   been	   seen	   to	   trigger	   pro-­‐proliferative	   and	   survival	   effects	  
independent	  of	  Ang-­‐II	  and	  the	  AT1R.	  	  
	  
Cross	   talk	   between	   G	   protein-­‐coupled	   receptors	   (like	   AT1R)	   and	   growth	   factor	   receptors	  
(such	  as	  EGFR)	  can	  lead	  to	  the	  amplification	  of	  commonly	  used	  signalling	  pathways.	  This	  also	  
encourages	  the	  overlap	  of	  other	  signalling	  mechanisms	  such	  as	  non-­‐canonical	  Wnt/	  Calcium	  
signalling	   (Katoh,	   2005).	   The	   Wnt/	   Calcium	   pathway	   has	   been	   observed	   to	   activate	  
Calmodulin-­‐Dependent	   Kinase	   II	   (CAMKII)	   and	   protein	   kinase	   C	   (PKC)	   resulting	   in	   survival	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and	  proliferation	  of	  cancer	  cells	  (Katoh,	  2005).	  In	  addition	  to	  this,	  there	  have	  been	  reports	  
that	  Ang-­‐II	   via	  AT1R	  activation	   increases	   intracellular	  calcium	   in	  normal	  and	  breast	  cancer	  
cells	  (Greco	  et	  al.,	  2002a).	  
	  
Ang-­‐II	  has	  been	  reported	  as	  being	  a	  mitogen	  promoting	  the	  growth	  of	  a	  variety	  of	  cell	  types	  
through	   activation	   of	   protein	   tyrosine	   kinases.	   Activation	   of	   receptors	   to	   which	   tyrosine	  
kinases	  are	  attached	   leads	   to	  growth	  stimulation.	  Further	  growth	  promoting	  effects	  occur	  
via	  Ang-­‐II	   stimulation	  of	  phosphatidylinositol	   (IP3)	  and	  diacylglycerol	   (DAG)	   resulting	   in	  an	  
increase	  of	  cytosolic	  calcium	  and	  thus	  is	  not	  only	  responsible	  for	  proliferation	  of	  normal	  cells	  
where	   it	   is	   synthesized	   but	   also	   neoplastic	   cells	   (Lewandowska	   et	   al.,	   2011;	   Wegman-­‐
Ostrosky	  et	  al.,	   2013).	   In	  a	   study	  by	  Greco	  et	  al	   (2002),	  phospholipase	  C	  was	   found	   to	  be	  
activated	   triggering	   IP3	   DAG.	   This	   then	   lead	   to	   the	   activation	   of	   PKC	   and	   calcium	  
mobilization	  from	  the	  intracellular	  stores	  (Figure	  1.5).	  
	  
Calcium	  has	  been	  reported	  to	  be	  an	  important	  mediator	  of	  Ang-­‐II	  effects	  and	  the	  expression	  
of	  early	  cancer	  progression	  genes	  such	  as	  c-­‐fos,	  c-­‐	  jun	  and	  c-­‐myc	  which	  are	  involved	  in	  the	  
regulation	  of	  a	  number	  of	  target	  genes	  (Greco	  et	  al.,	  2003).	  
	  
The	  nuclear	   factor	  of	   activated	  T	   cells	   (NFAT)	  protein	   family	   are	   transcription	   factors	   that	  
have	  been	   implicated	   in	  cancer	  progression	   (Mancini	  and	  Toker,	  2009).	  Overexpression	  of	  
NFAT	   results	   in	   tumourigenic	   characteristics	   such	   as	   the	   promoted	   growth,	   migration,	  
invasion,	  differentiation	  and	  survival	  of	  cells.	  NFAT	  is	  activated	  by	  the	  release	  of	  intracellular	  
calcium	  stores	  as	  well	  as	  the	  addition	  of	  extracellular	  calcium	  to	  a	  cell.	  Since	  Ang-­‐II	  has	  been	  
well	  reported	  in	  the	  activation	  of	  calcium	  signalling	  in	  various	  cardiovascular	  diseases	  as	  well	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as	  cancer	  (Kim	  and	  Iwao,	  2000;	  Muscella	  et	  al.,	  2003a),	  we	  hypothesized	  that	  this	  signalling	  
pathway	  might	  be	  altered	  in	  cervical	  cancer	  cells.	  	  
	   	  









Figure	  1.5:	  Tissue	  RAS	  signaling	  pathways.	  Via	  possible	  crosstalk	  between	  activated	  GPCRS,	  
AT1R	  and	  EGFR	  or	  via	  Wnt	  signaling	  pathways,	  Intracellular	  calcium	  signaling	  is	  disrupted	  in	  
cancer	   cells	   leading	   to	   increased	   cytosolic	   calcium	   activating	   downstream	   proliferation	  
signals.	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1.5	  Drug	  repurposing	  as	  anticancer	  treatments	  
As	   traditional	   anticancer	   drug	   discoveries	   and	   research	   takes	   years	   and	   a	   large	   budget	  
before	   a	   new	   drug	   can	   reach	   patients	   an	   alternative	   approach	   is	   much	   needed.	   “Drug	  
repurposing”,	   also	   known	   as	   “drug	   repositioning”,	   provides	   the	   opportunity	   for	   the	  
identification	  of	  alternative	  therapeutic	  indications	  for	  existing	  approved	  drugs	  (Oprea	  and	  
Mestres,	   2012).	   This	   nonconventional	   approach	   to	   traditional	   drug	   discovery	   methods	   is	  
useful	   in	   that	   existing	   drugs	   have	   already	   undergone	   extensive	   screening	   and	   received	  
approval	   for	  safety	   in	  patients.	  Thus,	  discovery	  of	  suitable	  anticancer	  drug	  candidates	  and	  
subsequent	   research	  on	   them	  could	   result	   in	   the	  drug	  reaching	   the	  cancer	  patient	  sooner	  
than	  new,	  or	  traditionally	  discovered	  drugs	  (Jin	  et	  al.,	  2012).	  	  	  	  	  	  
	  
As	  drug	   repurposing	   is	  becoming	   increasingly	  attractive	  due	   to	   the	  many	  benefits,	   several	  
strategies	  to	  effectively	  identify	  and	  analyzing	  potential	  cancer	  targets	  and	  thus	  anticancer	  
drugs	  are	  being	  utilised.	  One	   such	   strategy	   is	  based	  on	   the	   fact	   that	  many	  currently	  used	  
drugs	  possess,	  in	  addition	  to	  their	  primary	  targets,	  some	  form	  of	  secondary	  activity.	  Another	  
strategy	  derived	  from	  numerous	  studies,	  such	  as	  those	  previously	  discussed,	  makes	  use	  of	  
the	   fact	   that	   different	   diseases	   share	   common	   molecular	   pathways	   resulting	   in	   a	   drug	  
exerting	  therapeutic	  effects	  in	  diseases	  that	  share	  core	  pathways	  (Gupta	  et	  al.,	  2013;	  Hirsch	  
et	  al.,	  2010).	  
	  
Over	   the	   years	   non-­‐cancer	   drugs	   have	   been	   selected	   for	   study	   for	   potential	   anticancer	  
activity	   as	   their	   biological	   activity	   has	  been	  well	   described.	   Examples	  of	   a	   few	   such	  drugs	  
include	  Aspirin,	  Metformin,	  Thalidomide,	  Methotrexate	  and	  Noscapin	  (Table	  4),	  which	  had	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initial	   therapeutic	   indications	   toward	   pain	   relief,	   nausea,	   immunosuppressant	   therapy	   or	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The	  abandoned	  antihypertensive	  agent,	  Mibefradil,	   is	   another	  example	  of	   successful	  drug	  
repurposing.	   	  Short	  administration	  of	  the	  drug	  followed	  by	  conventional	  anticancer	  agents	  
has	   been	   proven	   to	   enhance	   the	   therapeutic	   potential	   of	   the	   conventional	   anticancer	  
regimen	  (Krouse	  et	  al.,	  2015).	  While	  Mibefradil	  was	  removed	  from	  the	  market	  due	  to	  drug-­‐
drug	   interactions,	   it	   could	   be	   rescued	   as	   the	   short	   administration	   of	   the	   drug	   prior	   to	  
chemotherapy	   remedied	   this	   effect	   and	   improved	   the	   therapeutic	   potential	   of	  
chemotherapy.	  Evolving	  cancer	  chemotherapy	  regimens	  to	  include	  a	  repurposed	  drug	  may	  
have	   the	   potential	   to	   reduce	   the	   dosage,	   as	  well	   as	   potential	   side	   effects,	   of	  well	   known	  
chemotherapeutic	  agents,	  such	  as	  Cisplatin	  (CDDP)	  or	  Doxorubicin	  (DOX).	  	  
	  
1.6	  Explorations	  in	  combination	  treatment	  	  
	  
1.6.1	  Current	  anticancer	  treatments	  
The	  chemotherapy	   landscape	  has	  changed	  and	   improved	  over	  the	  years.	  Chemotherapy	   is	  
aggressive	   on	   the	   body	   as	   surrounding	   healthy	   cells	   are	   often	   sacrificed	   in	   order	   to	   kill	  
nearby	   cancer	   cells.	   Good	   patient	   management	   includes	   analyzing	   the	   best	   choice	   of	  
treatment	  methods	  and	  frequent	  monitoring	  of	  toxic	  side	  effects.	  Changes	  in	  practice	  have	  
seen	  improvement	  in	  the	  tolerability	  of	  many	  drugs	  including	  CDDP	  (Fennell	  et	  al.,	  2016).	  
	  
CDDP	  and	  DOX	  are	   two	  of	   the	  most	  widely	  used	  chemotherapeutic	  agents	  on	   the	  market	  
today	   for	  many	   cancers	   some	   of	  which	   include	   lung,	   neck,	   bladder,	   cervical,	   ovarian	   and	  
testicular	   (Figure	   1.6).	   CDDP	   is	   a	   platinum	  based	   compound	   effective	   against	   carcinomas,	  
germ	  cell	  tumours,	  sarcomas	  and	  lymphomas	  (Dasari	  and	  Tchounwou,	  2014).	  Furthermore,	  
it	  is	  an	  alkylating	  agent	  specifically	  intercalating	  with	  DNA	  destabilizing	  the	  double	  helix	  into	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adducts	   in	  the	  cis	  configuration.	  This	  DNA	  damage	  and	  subsequent	   interference	  with	  DNA	  
repair	   mechanisms	   induces	   apoptosis	   in	   cancer	   cells	   (Dasari	   and	   Tchounwou,	   2014).	   In	  
cervical	  cancer	  CDDP	  is	  one	  of	  the	  most	  effective	  frontline	  chemotherapeutic	  drugs	  (Fennell	  
et	  al.,	  2016;	  Long,	  2007;	  Thigpen	  et	  al.,	  1981)	  
	  
DOX	  is	  an	  anthracycline	  antibiotic	  used	  most	  importantly	  for	  the	  treatment	  of	  solid	  tumours	  
(Hortobagyi,	  1997;	  Lenglet	  and	  David-­‐Cordonnier,	  2010).	  DOX	   is	  highly	   toxic	   inducing	  DNA	  
damage	   via	   inhibition	   of	   topoisomerase	   II	   as	   well	   as	   free	   radical	   formation	   leading	   to	  
apoptosis	  of	  cancer	  cells	   (Patel	  and	  Kaufmann,	  2012).	  While	  DOX	   is	  extremely	  effective	   in	  
killing	   cancer	   cells,	   one	   of	   the	   dominant	   side	   effects	   of	   this	   harsh	   treatment	   is	  




Figure	  1.6:	  Chemical	  structures	  of	  Doxorubicin	  and	  Cisplatin.	  Adapted	  from	  (Lenglet	  and	  
David-­‐Cordonnier,	  2010).	  
	   	  
Doxorubicin* Cispla0n*
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1.6.2	  Combination	  treatments	  in	  cancer	  
	  
Combination	  treatments	  in	  cancer	  have	  become	  standard	  practice	  in	  order	  to	  increase	  drug	  
response	   and	   improve	   tolerability.	   In	   an	   effort	   to	   combat	   chemoresistance,	   research	  
investigating	  effective	  combination	  treatments	  has	  been	  conducted	  with	  promising	  results	  
(Jia	  et	  al.,	  2009;	  Pritchard	  et	  al.,	  2012;	  Pritchard	  et	  al.,	  2013;	  Ricevuto	  et	  al.,	  2010).	  Some	  of	  
the	  potential	  benefits	  of	  using	  combination	  treatments	  include	  the	  possible	  amplification	  of	  
the	  effective	  agent	  when	  treating	  cancer	  cells.	  Combination	  therapies	  are	  tested	  in	  the	  hope	  
that	  effects	  of	  the	  combined	  usage	  may	  be	  greater	  than	  either	  of	  the	  individual	  treatments.	  
The	   ultimate	   aim	   of	   combination	   treatments	   is	   it	   maximize	   efficacy	   of	   treatment	   while	  
minimizing	  toxicity.	  	  	  
	  
In	   cervical	   cancer,	   a	   number	   of	   effective	   alternative	   therapies	   to	   CDDP	   have	   been	  
investigated	   some	   of	   which	   include	   paclitaxel,	   topotecan,	   ifosfamide,	   gemcitabine,	  
irinotecan	   (Coleman	  et	   al.,	   1986;	   Fushiki	   et	   al.,	   1997;	   Kim	  et	   al.,	   1999;	   Kumar	   and	  Gupta,	  
2016;	  Li	  et	  al.,	  2015;	  Muderspach	  et	  al.,	  2001;	  Urruticoechea	  et	  al.,	  2010;	  Valle	  et	  al.,	  2010;	  
Verschraegen	   et	   al.,	   1997).	   CDDP	   combination	   treatments	   in	   cervical	   as	   well	   as	   other	  
cancers	  using	  drugs	  such	  as	  paclitaxel	  have	  also	  been	  investigated	  with	  great	  success	  (Crino	  
et	  al.,	  1997;	  Esteban	  et	  al.,	  2006;	  Koizumi	  et	  al.,	  2008;	  Larasati	  et	  al.,	  2014;	  Minami	  et	  al.,	  
2013;	   Takahashi	   et	   al.,	   2012).	   It	   was	   shown	   by	   (Larasati	   et	   al.,	   2014)	   that	   the	   combined	  
treatment	   of	   cinnamon	   essential	   oil	   with	   CDDP	   induces	   HeLa	   cell	   cycle	   arrest	   thereby	  
inhibiting	  proliferation.	  Furthermore,	   in	  PC-­‐9	  and	  H1650	  non-­‐small	  cell	   lung	  cancer	  cells	  as	  
well	  as	  in	  xenograft	  models,	  (Minami	  et	  al.,	  2013)	  showed	  that	  the	  combined	  treatment	  of	  
the	  PARP	  inhibitor,	  olaparib,	  with	  CDDP	  was	  more	  effective	  at	  killing	  cancer	  cells	  than	  each	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drug	  individually.	  CDDP	  combination	  therapy	  has	  proven	  effective	  in	  improving	  prognosis	  of	  
patients	  in	  phase	  I	  to	  phase	  III	  studies.	  The	  prognosis	  of	  gastric	  cancer	  patients	  in	  a	  phase	  I	  
study	   was	   improved	   after	   triple	   combination	   treatments	   of	   paclitaxel,	   CDDP	   and	   S-­‐1	  
(Takahashi	  et	  al.,	  2012).	   In	  a	  phase	   II	   study	   investigating	   the	  effects	  of	  CDDP	  combination	  
treatment	   with	   the	   EGFR	   inhibitor,	   erlotinib,	   it	   was	   found	   that	   combination	   treatment	  
exerted	  significant	  antitumour	  activity	  in	  cervical	  cancer	  patients	  (Nogueira-­‐Rodrigues	  et	  al.,	  
2014).	  A	  phase	  III	  study	  by	  (Goto	  et	  al.,	  2016)	  showed	  that	  a	  second-­‐line	  chemotherapy	  of	  
CDDP,	  etoposide	  and	  irinotecan	  improved	  overall	  survival	  of	  small-­‐cell	  lung	  cancer	  patients	  
when	  compared	  to	  topotecan	  monotherapy.	  
	  
DOX	  combination	  treatments	  have	  also	  seen	  much	  success	  in	  cancer.	  The	  use	  of	  docetaxel	  
(DOC)	   with	   DOX	   in	   PC3	   and	   DU145	   prostate	   cancer	   cells	   resulted	   in	   a	   synergistic	   effect	  
(Tsakalozou	  et	  al.,	  2012).	  Similarly	  to	  CDDP,	  in	  addition	  to	  in	  vivo	  studies,	  the	  use	  of	  DOX	  in	  
combination	   treatments	   has	   proven	   successful	   in	   phases	   I	   to	   III	   trials.	   A	   phase	   I	   trial	   by	  
(Thomas	   et	   al.,	   2014)	   showed	   that	   the	   combined	   treatment	   of	   DOX	   with	   a	   histone	  
deactylase	   inhibitor,	   belinostat,	   together	  with	   CDDP	   and	   cyclophosphamide	  was	   effective	  
against	   thymic	   epithelial	   tumours	   with	   improved	   progression-­‐free	   survival.	   The	   phase	   II	  
study	  by	   (Pautier	  et	  al.,	  2015)	   showed	   that	   in	   combination	  with	  Trabectedin,	  DOX	  was	  an	  
effective	   first-­‐line	   treatment	   of	  metastatic	   leiomyosarcomas,	  which	   typically	   show	   limited	  
sensitivity	  to	  chemotherapy.	  Furthermore,	  a	  phase	  III	  study	  by	  (Judson	  et	  al.,	  2014a)	  showed	  
that	  the	  combined	  treatment	  of	  DOX	  with	   ifosfamide	  for	  first-­‐line	  treatment	  of	  metastatic	  
soft	   tissue	   sarcoma	   was	   effective	   in	   the	   shrinkage	   of	   tumours.	   These	   studies	   provide	  
evidence	  that	  combination	  treatments,	  with	  the	  use	  of	  DOX	  and	  CDDP	  in	  such	  treatments,	  
lay	  the	  foundation	  for	  effective	  chemotherapy	  strategies.	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Drug	  interaction	  effects	  in	  combination	  therapy	  
Drug	   combinations	   can	   result	   in	   one	   of	   three	   outcomes	  with	   regard	   to	   their	   interaction:	  
synergism,	   antagonism	  or	   additive	   effects	   (Chou	   and	   Talalay,	   1984).	   Such	   evaluations	   are	  
best	  determined	  using	  mathematical	  software,	  which	  carefully	  interrogates	  the	  combination	  
of	   two	  or	  more	  drugs.	  Chou	  and	  Talalay	  are	  considered	  the	  drug	  combination	  pioneers	  as	  
their	  combined	  input	  to	  understand	  combination	  therapies	  has	  assisted	  studies	  worldwide	  
to	   accurately	   define	   the	   effects	   resulting	   from	   multiple	   drug	   interactions.	   “Synergism,	  
antagonism	   and	   additivity	   can	   be	   defined	   as	   the	   interaction	   between	   two	   or	   more	  
components	  such	  that	  the	  combined	  effect	  is	  superior,	  inferior	  or	  equal,	  respectively,	  to	  the	  
expected	   sum	  of	   the	   individual	   drug	   effects”(Chou	   and	   Talalay,	   1984;	   Chou,	   2006;	  Mayer	  
and	   Janoff,	   2007;	  Merlin,	  1994).	   The	  benefit	  of	   combination	   treatment	   to	   cancer	  patients	  
has	   been	   promising	   with	   researchers	   showing	   synergistic	   drug	   combination	   treatments	  
improve	  patient	  outcomes	  compared	  to	  single	  treatments.	  In	  a	  phase	  II	  trial	  by	  (Finn	  et	  al.,	  
2015),	   it	   was	   shown	   that	   a	   small	   molecule	   inhibitor	   of	   cyclin	   dependent	   kinases	   4/6,	  
palbociclib,	  maintained	   its	  synergism	  with	  the	  anti-­‐oestrogen	  treatment,	   letrozole.	   In	  both	  
cohorts	   studied	   it	   was	   found	   that	   median	   progression-­‐free	   survival	   of	   patients	   was	  
significantly	  greater	  in	  the	  group	  receiving	  the	  combination	  treatment.	  As	  a	  result	  a	  phase	  III	  
trial	  is	  being	  pursued.	  Furthermore,	  a	  review	  of	  some	  notable	  combined	  immunotherapy	  to	  
cancer	   patients	   by	   (Melero	   et	   al.,	   2015)	   highlights	   the	   benefits	   of	   effective	   combination	  
treatments.	   	   One	   such	   study	   conducted	   by	   (Reck	   et	   al.,	   2013)	   was	   a	   phase	   II	   trial	  
investigating	  first-­‐line	  therapies	  in	  extensive	  disease-­‐small-­‐cell	  lung	  cancer.	  It	  was	  observed	  
that	   the	   sequential	   administration	   of	   an	   anti-­‐CTLA4	   monoclonal	   antibody,	   ipilimumab,	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together	   with	   carboplatin	   and	   paclitaxel,	   improved	   immune	   related	   progression-­‐free	  
survival	  of	  patients	  when	  compared	  to	  control	  groups.	  	  
	  
The	  use	  of	  Chou	  and	  Talalay’s	  method	  of	  fixed	  ratio	  treatments	  has	  advanced	  the	  systematic	  
screening	  of	  multiple	  drug	  combinations.	  This	  form	  of	  analysis	  was	  previously	  unrecognized	  
and	  much	  research	  has	  provided	  insight	  as	  to	  how	  dependent	  synergistic	  effects	  can	  be	  on	  
drug	  ratios	  (Chou,	  2006;	  Mayer	  and	  Janoff,	  2007).	  
	  
1.6.2.1	  RAS	  inhibitors	  as	  combination	  treatments	  
As	  RAS	  inhibitors	  are	  already	  approved	  for	  clinical	  use	  and	  have	  shown	  to	  have	  anticancer	  
effects	   (see	   section	   1.3.1),	   it	   would	   be	   greatly	   beneficial	   to	  make	   use	   of	   their	   anticancer	  
function	  to	  augment	  current	  anticancer	  regimens.	  While	  the	  use	  of	  antihypertensive	  agents	  
has	   been	   shown	   to	   provide	   protection	   against	   harmful	   side	   effects	   of	   DOX	   or	   CDDP	  
treatment	   such	   as	   cardio	   or	   nephrotoxicity	   (Akolkar	   et	   al.,	   2015;	   Saleh	   et	   al.,	   2009),	  
repurposing	   the	   RAS	   inhibitors	   to	   target	   cancer	   in	   combination	   treatments	   has	   not	   been	  
widely	  explored.	  The	  in	  vivo	  study	  by	  (Akolkar	  et	  al.,	  2015)showed	  that	  the	  use	  of	  the	  ACE-­‐1	  
inhibitor,	  perindopril,	  and	  the	  AT1R	  antagonist,	  valsartan,	  had	  a	  prophylactic	  effect	  against	  
cardiotoxicity	   induced	   through	   the	   treatment	   of	   DOX	   and	   trastuzumab,	   the	   monoclonal	  
antibody	  used	  to	  treat	  HER2	  positive	  breast	  cancer.	  It	  was	  shown	  that	  RAS	  inhibition	  in	  the	  
combination	  treatment	  improved	  the	  survival	  of	  mice	  compared	  to	  the	  control	  group.	  (Saleh	  
et	   al.,	   2009)	   also	   showed	   the	   therapeutic	   benefit	   of	   RAS	   inhibition	   on	   CDDP-­‐induced	  
nephrotoxicity,	   where	   the	   ATR	   antagonist,	   Losartan,	   showed	   protective	   effects	   against	  
kidney	  injury	  in	  rats.	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1.7	  Project	  Aims	  
This	  study	  was	  based	  on	  the	  hypothesis	  that	  altered	  expression	  and	  activity	  of	  the	  RAS	  may	  
contribute	  to	  cancer	  development.	  Thus,	   the	  aim	  was	  to	  determine	  the	  role	  of	   the	  RAS	   in	  
different	  cancer	  cell	  lines.	  The	  objectives	  were:	  
	  
1. To	  investigate	  the	  effects	  of	  ACE-­‐1	  axis	  of	  the	  RAS,	   i.e.	  Ang-­‐II,	  ACE-­‐1	  and	  the	  AT1R,	  
expression	  and	  ACE-­‐1	  activity	  in	  cancer	  cells,	  with	  respect	  activation	  of	  intracellular	  
signalling	  
2. To	  investigate	  the	  effect	  of	  ACE-­‐2	  axis	  activation	  on	  cancer	  cell	  biology	  using	  Ang-­‐(1-­‐
7),	  and	  the	  small	  molecule	  ACE-­‐2	  activator	  DIZE	  
3. To	   investigate	   the	   effects	   of	   combined	   treatment	   with	   RAS	   inhibitors/antagonists	  
and	  chemotherapeutic	  agents	  on	  cancer	  cell	  biology	  
	  	   	  










Since	   the	   discovery	   that	   cancer	   shares	   a	   link	  with	  metabolic	   diseases,	  more	   reports	   have	  
been	   recorded	   implicating	   the	   Renin	   Angiotensin	   System	   (RAS)	   in	   the	   development	   of	  
various	   cancers(Carl-­‐McGrath	   et	   al.,	   2007;	   Dinh	   et	   al.,	   2001;	   Ino	   et	   al.,	   2011;	   Wegman-­‐
Ostrosky	   et	   al.,	   2015).	   The	  direct	   and	   indirect	   effects	   of	   RAS	   signaling	  on	   cancer	   cells	   are	  
increasingly	   being	   documented.	   Potential	   therapeutic	   strategies	   such	   as	   AT1	   receptor	  
(AT1R)	   blockers	   (ARBs)	   have	   demonstrated	   anticancer	   effects	   and	   are	   thus	   being	   further	  
researched.	  Literature	  studies	  have	  reported	  the	  up-­‐regulation	  of	  AT1R	  protein	  expression	  
within	  breast	  cancer	  tissue	  and	  the	  blockade	  of	  AT1R	  signaling	  via	  ARB’s	  such	  as	  Irbesartan,	  
reduced	  cancer	  cell	  proliferation(Anandanadesan	  et	  al.,	  2008;	  Du	  et	  al.,	  2012;	  Escobar	  et	  al.,	  
2004;	  Hunyady	  and	  Catt,	  2006;	  Muscella	  et	  al.,	  2003b;	  Puddefoot	  et	  al.,	  2006;	  Vinson	  et	  al.,	  
2012;	  Wegman-­‐Ostrosky	  et	  al.,	  2013;	  Zhao	  et	  al.,	  2010a).	  Cancer	  cells	  within	  the	  developing	  
tumour	   can	  be	  directly	   affected	   via	  RAS	   signals,	  whereas	   the	  growth	  of	   vascular	   cells	   can	  
promote	   angiogenesis	   and	   thus	   indirectly	   influence	   tumour	   growth	   and	   metastasis.	   RAS	  
signaling	   stimulates	   hematopoiesis	   (Park	   and	   Zambidis,	   2009)	   and	   the	   proliferation	   of	  
various	   cell	   types	   including	   endothelial	   cells,	   squamous	   cells	   lining	   either	   blood	   or	   lymph	  
vessels	  (Wegman-­‐Ostrosky	  et	  al.,	  2013),	  vascular	  smooth	  muscle	  cells,	  glomerular	  mesangial	  
cells,	   and	   hepatic	   stellate	   cells,	   (Bataller	   et	   al.,	   2000;	   Griendling	   et	   al.,	   1997;	   Ray	   et	   al.,	  
1991).	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It	   has	   been	   reported	   that	   the	   RAS	   plays	   numerous	   roles	   in	   cancer	   progression,	   such	   as	  
proliferation,	  angiogenesis,	  migration	  and	  invasion	  (Dorsam	  and	  Gutkind,	  2007;	  Escobar	  et	  
al.,	   2004;	  Greco	  et	   al.,	   2002b;	  Hunyady	  and	  Catt,	   2006;	  Puddefoot	  et	   al.,	   2006;	  Wegman-­‐
Ostrosky	   et	   al.,	   2013).	   ACE-­‐1	   axis	   signalling,	   meaning	   the	   activation	   of	   the	   AT1R	   by	  
Angiotensin	   II	   (Ang-­‐II),	   has	   been	   shown	   to	   control	   the	   proliferation	   of	   endometrial,	  
colorectal,	   breast,	   anterior	   pituitary	   and	   adrenocortical	   cells	   (Ager	   et	   al.,	   2008;	   Ino	   et	   al.,	  
2011;	  Kuniyasu,	  2012;	  McEwan	  et	  al.,	  1996;	  Muscella	  et	  al.,	  2002;	  Pawlikowski	  et	  al.,	  1999).	  
While	  there	  is	  literature	  on	  RAS	  downstream	  signalling	  in	  endothelial	  cells,	  calcium	  signalling	  
in	  particular,	   little	  is	  known	  regarding	  signalling	  surrounding	  ACE-­‐1	  axis	  signalling	  in	  cancer	  
cells,	  particularly	  cervical	  cancer.	  	  
	  
In	  this	  chapter	  we	  investigated	  the	  expression	  and	  activity	  of	  ACE-­‐1	  axis	  components	  of	  the	  
RAS.	  The	  potential	  cell	  killing	  effect	  of	  the	  ACE-­‐1	  inhibitors,	  Captopril,	  Lisinopril	  and	  the	  AT1	  
receptor	  antagonist,	  Candesartan,	  was	  explored.	  We	  also	   investigated	   the	  ability	  of	  ACE-­‐1	  
axis	  inhibition	  to	  disrupt	  the	  cell	  cycle	  and	  associated	  cell	  killing	  events.	  
	  
	   	  




2.2.1.	   Expression	   and	   activity	   of	   ACE-­‐1	   axis	   components,	   ACE-­‐1	   and	   AT1	   Receptor	   in	  
transformed,	  cancer	  and	  non-­‐cancer	  cell	  lines	  
	  
Using	   western	   blot	   analysis	   protein	   expression	   levels	   of	   components	   of	   the	   ACE-­‐1	   axis,	  
namely	  the	  ACE-­‐1	  enzyme	  and	  the	  AT1	  Receptor,	  were	  investigated	  in	  a	  panel	  of	  cancer	  and	  
transformed	   cell	   lines	   of	   different	   tissue	   origin,	   including	   breast	   cancer	   (MDA-­‐MB-­‐231),	  
cervical	   cancer	   (HeLa	  and	  SiHa)	  and	  hepatocellular	   carcinoma	   (HepG2)	  and	  a	   transformed	  
cell	   line,	   SVWI38.	   Expression	   levels	  were	   compared	   to	   that	   observed	   in	   non-­‐cancer	  WI38	  
cells.	   Results	   showed	   elevated	   ACE-­‐1	   expression	   in	   the	   cancer	   and	   transformed	   cells	  
compared	   to	   the	  non-­‐cancer	  WI38	   cells	   (Figure	  2.1A).	  Using	  a	   selected	   cell	   lines,	  we	  next	  
investigated	   whether	   elevated	   ACE-­‐1	   expression	   correlated	   with	   ACE-­‐1	   activity.	   ACE-­‐1	  
protein	   expression	   had	   good	   correlation	  with	   ACE-­‐1	   enzyme	   activity,	   as	  measured	  with	   a	  
fluorimetric	  assay	  using	  the	  ACE-­‐1	  specific	  substrate,	  benzyloxycarbonyl-­‐Phe-­‐His-­‐Leu	  (ZFHL),	  
with	  the	  cancer	  cell	  lines	  showing	  elevated	  activity	  (Figure	  2.1B).	  	  
	  
After	  establishing	  that	  ACE-­‐1	  protein	  expression	  was	  elevated	  in	  cancer	  cells	  and	  that	  there	  
was	   an	   increase	   ACE-­‐1	   enzyme	   activity	   in	   cancer	   cells	   compared	   to	   control,	   we	   next	  
investigated	  protein	  expression	  of	  the	  AT1R	  (Figure	  2.2	  A),	  as	  there	   is	  evidence	  linking	  the	  
activation	  of	  the	  AT1R	  with	  the	  pathophysiological	  effects	  of	  Ang-­‐II	  (Abd	  El-­‐All	  et	  al.,	  2015;	  
Blaszczak-­‐Swiatkiewicz	   and	  Mikiciuk-­‐Olasik,	   2015;	  Chu	  et	   al.,	   2015;	   El	  Rashedy	  and	  Aboul-­‐
Enein,	  2013;	  Koronkiewicz	  et	  al.,	  2015;	  Yadav	  et	  al.,	  2015;	  Yurttas	  et	  al.,	  2015).	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Our	  results	  suggest	  elevated	  AT1R	  expression	  in	  the	  majority	  of	  cancer	  cell	  lines	  investigated	  
compared	  to	  that	  in	  the	  non-­‐cancer	  WI38	  cell	  line.	  Together	  these	  results	  show	  that	  two	  key	  
components	  of	  the	  RAS,	  ACE-­‐1	  and	  AT1R,	  have	  elevated	  expression	  in	  cancer	  cells.	  
	  
	   	  





Figure	  2.1:	  Endogenous	  ACE-­‐1	  expression	  and	  activity	  is	  elevated	  in	  cancer	  cells	  compared	  
to	   normal	   cells.	   A:	   Western	   blot	   analysis	   showing	   ACE-­‐1	   expression	   in	   WI38	   (normal	  
fibroblasts),	   SVWI38	   (transformed	   fibroblasts)	   and	   breast	   cancer,	   MDA-­‐MB-­‐231,	   cervical	  
cancer,	  HeLa	  and	  SiHa,	  and	  hepatocellular	  carcinoma,	  HepG2,	  cell	  lines.	  GAPDH	  was	  used	  as	  
a	   control	   for	  protein	   loading.	  B:	  ACE-­‐1	  activity	  measured	   in	  normal	  and	  cancer	   cells	  using	  
the	   ACE-­‐1	   enzyme	   assay	   showing	   cleavage	   of	   the	   ZFHL	   substrate.	   Results	   shown	   are	   the	  
mean	   +/-­‐	   SEM	   of	   experiments	   performed	   in	   triplicate	   and	   repeated	   at	   least	   two	  
independent	  times.	  *p-­‐value	  <0.05.	   	  










Figure	  2.2:	  Endogenous	  AT1R	  protein	  expression	  is	  elevated	  in	  cancer	  compared	  to	  normal	  
cells.	   A:	   Western	   blot	   analysis	   showing	   AT1R	   expression	   in	   normal	   fibroblasts,	   WI38,	  
transformed,	  SVWI38,	  breast	   cancer,	  MDA-­‐MB-­‐231,	   cervical	   cancer	  C33A,	  CaSki,	  HeLa	  and	  
SiHa,	  and	  hepatocellular	   carcinoma,	  HepG2,	   cell	   lines.	  β-­‐tubulin	  was	  used	  as	  a	   control	   for	  
protein	   loading.	   B:	   Quantification	   of	   band	   intensity	   relative	   to	   β-­‐tubulin	   showing	   AT1R	  
expression	   in	   cancer	   cells.	   Results	   shown	   represent	   experiments	   performed	   two	  
independent	  times.	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2.2.2	  ACE-­‐1	  axis	  inhibition	  reduces	  proliferation	  of	  cancer	  cells	  
	  
Having	   shown	   that	   ACE-­‐1	   and	   AT1R	   expression	   was	   elevated	   in	   cancer	   cells	   we	   next	  
explored	   the	   functional	   relevance	   of	   this	   by	   inhibiting	   their	   activities.	   ACE-­‐1	   inhibitors,	  
Captopril	  and	  Lisinopril,	  and	  the	  AT1R	  antagonist,	  Candesartan,	  were	  tested	  for	  effects	  in	  a	  
panel	  of	  cancer	  cell	  lines.	  The	  cervical	  cancer	  cell	  lines	  tested	  included	  HeLa,	  CaSki	  and	  SiHa.	  
The	  MDA-­‐MB-­‐231	  breast	  cancer	  cell	  line	  was	  also	  included.	  	  
	  
The	   50%	   inhibitory	   concentrations	   (IC50)	   for	   Captopril,	   Lisinopril	   and	   Candesartan	   were	  
determined	  in	  non-­‐cancer	  (WI38	  and	  FG0)	  and	  cancer	  cell	  lines	  (HeLa,	  CaSki,	  SiHa,	  MDA-­‐MB-­‐
231	   and	  HepG2).	  Non-­‐cancer	   cell	   lines,	  WI38	   and	   FG0,	   appeared	   insensitive	   to	   treatment	  
with	  the	  ACE-­‐1	  inhibitors	  and	  AT1R	  antagonist	  and	  thus	  an	  IC50	  concentration	  could	  not	  be	  
determined.	   The	   cancer	   cell	   lines	   (HeLa,	   CaSki,	   SiHa	   and	   HepG2)	   all	   on	   the	   other	   hand	  
showed	  IC50	  concentrations	  for	  Captopril,	  Lisinopril	  and	  Candesartan	  of	  310	  to	  367	  μM,	  400	  
to	  478	  μM,	  150	  to	  182	  μM	  respectively.	  
	  
The	  results	  showed	  that	  a	  lower	  dose	  of	  the	  AT1R	  antagonist,	  Candesartan,	  was	  required	  to	  
give	  50%	  maximal	  inhibition	  compared	  to	  the	  ACE-­‐1	  inhibitors,	  Captopril	  and	  Lisinopril.	  	   	  




Table	   1:	   IC50	   values	   of	   ACE-­‐1	   inhibitors,	   Captopril	   and	   Lisinopril	   and	   AT1R	   antagonist,	  
Candesartan	   in	  normal	  and	  cancer	   cells.	   IC50	  values	  were	  generated	   for	  non-­‐cancer	   cells	  
(WI38	   and	   FG0)	   and	   cancer	   cell	   lines	   (HeLa,	   CaSki,	   SiHa	   and	  MDA-­‐MB-­‐231).	   Experiments	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Since	   ACE-­‐1	   and	   AT1R	   expression	   were	   elevated	   in	   cancer	   cells,	   their	   requirements	   for	  
cancer	  cell	  proliferation	  were	  investigated	  by	  inhibiting	  their	  activity	  using	  two	  approaches,	  
an	  ACE-­‐1-­‐specific	  siRNA,	  and	  with	  the	  ACE-­‐1	  inhibitors,	  Captopril	  and	  Lisinopril.	  The	  effect	  of	  
inhibiting	  activation	  of	  the	  AT1R	  on	  cell	  proliferation	  was	  also	  monitored	  (Figure	  2.3).	  
	  
The	  proliferation	   assays	   showed	  a	   significant	   reduction	   in	  HeLa	   cell	   proliferation	  with	   the	  
ACE-­‐1	   inhibitor,	   Lisinopril,	   and	   the	   AT1R	   antagonist,	   Candesartan	   (Figure	   2.3	   A).	   For	  
Captopril,	  a	  small	  but	  non-­‐significant,	  decrease	  in	  cell	  proliferation	  was	  only	  observed	  after	  
3	  days	  treatment.	  All	  3	  agents	  had	  a	  significant	  inhibitory	  effect	  on	  the	  proliferation	  of	  CaSki	  
cells	  (Figure	  2.3	  B).	  The	  requirement	  of	  ACE-­‐1	  activity	  was	  further	  investigated	  by	  silencing	  
of	   ACE-­‐1	   using	   siRNA,	   which	   resulted	   in	   a	   significant	   reduction	   in	   HeLa	   cell	   proliferation	  
(Figure	   2.3	   C)	   similar	   to	   that	   seen	   for	   Lisinopril.	   Western	   blot	   results	   showing	   ACE-­‐1	  
knockdown	  can	  be	  found	  in	  Appendix	  	  	  
	  
These	   results	   show	   that	   inhibiting	  ACE-­‐1	  expression	  with	   siRNA	  and	   its	   activity	  with	   small	  
molecules	  interferes	  with	  the	  proliferation	  of	  cancer	  cells.	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Figure	  2.3:	  Effect	  of	  ACE-­‐1	  axis	   treatments	  on	  HeLa	  and	  CaSki	   cell	  proliferation.	  A:	  HeLa	  
and	   B:	   CaSki	   cells	   were	   treated	   with	   Captopril,	   Lisinopril	   and	   Candesartan	   at	   IC50	  
concentration	   and	   the	   effect	   on	   cell	   proliferation	   monitored	   using	   the	   MTT	   assay.	   C:	  
Transient	  knockdown	  of	  ACE-­‐1	  using	  siRNA	  in	  HeLa	  cells	  significantly	  reduces	  proliferation	  of	  
HeLa	  cells.	  Control	  siRNA	  was	  used	  to	  control	  for	  the	  effect	  of	  DNA	  transfection	  Results	  are	  
the	  mean	   +/-­‐	   SEM	   of	   experiments	   performed	   in	   triplicate	   and	   repeated	   three	   times.	   *p-­‐
value	  <0.05.	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To	  investigate	  whether	  inhibition	  of	  ACE-­‐1	  axis	  proteins	  associates	  with	  cell	  death,	  we	  used	  
the	  Annexin	  V	  assay	  to	  determine	  the	  percentage	  of	  live,	  early	  and	  late	  apoptotic	  as	  well	  as	  
necrotic	  cells	  after	  treatment	  with	  Captopril,	  Lisinopril	  or	  Candesartan.	  	  
	  
Our	   results	   show	   that	   Captopril	   had	   a	   small	   but	   significant	   inhibitory	   effect	   on	   the	  
percentage	  of	   live	  cells	  on	  all	  three	  cell	   lines	  tested,	  HeLa,	  CaSki	  and	  MDA-­‐MB-­‐231	  (Figure	  
2.4).	  Accompanying	  this	  was	  a	  small	  but	  significant	  increase	  in	  cells	  in	  early,	  late	  apoptosis	  
and	   necrosis.	   Lisinopril	   treatment	   similarly	   resulted	   in	   an	   increase	   in	   cells	   undergoing	  
apoptosis	  and	  necrosis	  (Figure	  2.5).	  Candesartan	  treatment	  resulted	  in	  a	  significant	  increase	  
in	   necrosis	   in	   HeLa	   and	   CaSki	   cells	   and	   an	   increase	   in	   both	   apoptosis	   and	   necrosis	   in	  
MDAMB-­‐231	  cells	  (Figure	  2.6).	  	  
	  
This	  data	  suggests	  that	  inhibitors	  of	  ACE-­‐1	  axis	  proteins	  influence	  cell	  death	  having	  signs	  of	  
both	  apoptosis	  and	  necrosis.	  
	  
	  
	   	  












Figure	   2.4:	   Captopril	   induces	   apoptosis	   and	   necrosis	   in	   cancer	   cells.	   Annexin	   V	   profiles	  
indicate	  that	  a	  48	  hr	  treatment	  with	  the	  IC50	  concentration	  of	  Captopril	  reduces	  the	  number	  
of	  live	  cells	  via	  apoptosis	  in	  A:	  HeLa,	  B:	  CaSki	  and	  C:	  MDA-­‐MB-­‐231	  cells.	  Annexin	  V	  profiles	  
for	   one	   representing	   experiment	   is	   shown	   for	   each	   cell	   line	   and	  bar	   chart	   results	   are	   the	  
mean	  +/-­‐	  SEM	  of	  experiments	  performed	  in	  triplicate	  and	  repeated	  two	  independent	  times	  
(*p-­‐value<0.05).	   	  















Figure	   2.5:	   Lisinopril	   induces	   apoptosis	   and	   necrosis	   in	   cancer	   cells.	   Annexin	   V	   profiles	  
show	  that	  a	  48	  hr	  treatment	  with	  the	  IC50	  concentration	  of	  Lisinopril	  reduces	  the	  number	  of	  
live	  cells	  via	  apoptosis	  and	  necrosis	  in	  A:	  HeLa,	  B:	  CaSki	  and	  C:	  MDA-­‐MB-­‐231	  cells.	  Annexin	  V	  
profiles	  for	  one	  representing	  experiment	  is	  shown	  for	  each	  cell	  line	  and	  bar	  chart	  results	  are	  
the	  mean	  +/-­‐	   SEM	  of	   experiments	   performed	   in	   triplicate	   and	   repeated	   two	   independent	  
times	  (*p-­‐value<0.05).	   	  
















Figure	   2.6:	   Candesartan	   reduces	   live	   cells	   via	   necrosis	   in	   cancer	   cells.	  Annexin	  V	  profiles	  
show	  that	  a	  48	  hr	  treatment	  with	  the	  IC50	  concentration	  of	  Candesartan	  reduces	  the	  number	  
of	   live	   cells	   via	   necrosis	   in	  A:	   HeLa,	  B:	   CaSki	   and	   late	   apoptosis	   in	  C:	  MDA-­‐MB-­‐231	   cells.	  
Annexin	  V	  profiles	  for	  one	  representing	  experiment	  is	  shown	  for	  each	  cell	  line	  and	  bar	  chart	  
results	   are	   the	  mean	   +/-­‐	   SEM	  of	   experiments	   performed	   in	   triplicate	   and	   repeated	   three	  
independent	  times	  (*p-­‐value<0.05).	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2.2.3	  Ang-­‐II	  stimulates	  cancer	  cell	  growth	  
	  
As	  we	  observed	   that	  ACE-­‐1	  and	  AT1R	  protein	  expression	  was	  elevated	   in	  cancer	  cells	  and	  
that	   ACE-­‐1	   enzyme	   activity	   was	   also	   increased	   in	   cancer	   cells	   we	   investigated	   whether	  
cancer	   cells	   would	   respond	   to	   Ang-­‐II	   treatment.	   Ang-­‐II	   signaling	   is	   predominantly	   via	   the	  
AT1R(Ager	   et	   al.,	   2008)	   thus	   the	   following	   investigations	   would	   confirm	   our	   earlier	  
observations	   that	   the	   ACE-­‐1	   axis	   is	   present	   and	   active	   in	   cancer	   cells.	   HeLa	   and	   SiHa	   cell	  
proliferation	  was	  monitored	  over	  48	  hours	   in	  the	  presence	  of	   increasing	  concentrations	  of	  
Ang-­‐II.	  Our	   results	   show	  a	  dose	  dependent	   increase	   in	   the	  proliferation	  of	  both	  HeLa	  and	  
SiHa	  cells	  with	  increasing	  Ang-­‐II,	  with	  400	  nM	  showing	  an	  approximate	  two-­‐fold	  increase	  in	  
cell	  proliferation	  (Figure	  2.7	  A	  and	  B).	  	  
	  
To	  confirm	  that	  Ang-­‐II	  increase	  in	  proliferation	  was	  as	  a	  result	  of	  activation	  of	  the	  AT1R,	  we	  
inhibited	   its	   activity	   using	   Candesartan.	   The	   antagonist	   for	   the	   AT2R,	   a	   synthetic	   small	  
molecule	  called	  PD123319	  was	  used	  to	  monitor	  possible	  effects	  via	  the	  AT2R.	  We	  found	  in	  
both	   HeLa	   and	   SiHa	   cells,	   that	   the	   stimulatory	   effect	   of	   Ang-­‐II	   on	   their	   proliferation	  was	  
significantly	  inhibited	  by	  Candesartan	  (Figure	  2.8	  A	  and	  C).	  The	  AT2R	  antagonist	  PD123319	  
had	  no	  effect	  (Figure	  2.8	  B	  and	  D).	  	  
	  
These	   results	   suggest	   that	   Ang-­‐II	   stimulation	   of	   HeLa	   and	   SiHa	   cancer	   cell	   proliferation	  
occurs	  preferentially	  via	  the	  AT1R	  rather	  than	  the	  AT2R.	  
	   	  










Figure	   2.7:	   Effect	   of	   Ang-­‐II	   on	   cancer	   cell	   proliferation.	   Ang-­‐II	   treatment	   significantly	  
increases	   HeLa	   (A)	   and	   SiHa	   (B)	   cell	   proliferation	   in	   a	   dose	   dependent	   manner.	   Results	  
shown	  are	  the	  mean	  +/-­‐	  SEM	  of	  experiments	  performed	  in	  triplicate	  and	  repeated	  at	  least	  
two	  independent	  times.	  *p-­‐value<0.05.	   	  










Figure	  2.8:	  AT1R	  inhibition	  reduces	  cancer	  cell	  proliferation.	  	  
A	  and	  B:	  Stimulated	  proliferation	  of	  HeLa	  cells	  with	  Ang-­‐II	   is	  reduced	  after	  treatment	  with	  
Candesartan	   and	   not	   PD123319.	   C.	   and	   D:	   Similar	   results	   are	   observed	   with	   SiHa	   cells.	  
Results	  shown	  are	  the	  mean	  +/-­‐	  SEM	  of	  experiments	  performed	  in	  triplicate	  and	  repeated	  
two	  independent	  times.	  *p-­‐value<0.05.	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2.2.4	  Ang-­‐II	  treatment	  associates	  with	  the	  release	  of	  intracellular	  calcium	  stores	  
	  
Ang-­‐II	  alters	  calcium	  signalling	   in	  a	  variety	  of	  cells	  types	   including	  endothelial	  and	  vascular	  
smooth	  muscle	   cells	   (Haller	  et	  al.,	   1999;	  Helou	  and	  Marchetti,	  1997;	  Montiel	  et	  al.,	   2003;	  
Nitschke	  et	  al.,	  2000;	  Pueyo	  et	  al.,	  1998;	  Touyz	  and	  Schiffrin,	  1997;	  Tran	  et	  al.,	  2000).	  We	  
were	  therefore	  interested	  in	  determining	  whether	  Ang-­‐II	  had	  effects	  on	  calcium	  signaling	  in	  
cancer	  cells.	  
	  
We	  first	  investigated	  the	  effect	  of	  Ang-­‐II	  on	  calcium	  release	  from	  intracellular	  calcium	  stores	  
in	  cancer	  cells.	  Calcium	  release	  was	  measured	  using	  a	  calcium	  fluorescent	  indicator,	  Fluo-­‐4	  
AM.	  After	  incubation	  with	  0.75mM	  Fluo-­‐4	  AM	  for	  30	  minutes,	  the	  release	  of	  calcium	  stores	  
within	   the	   live	   cancer	   cells	   was	  monitored	   using	   the	   BD	   Accuri	   flow	   cytometer.	   Baseline	  
calcium	  levels	  were	  monitored	  for	  two	  minutes	  to	  ensure	  there	  were	  no	  fluctuations	  before	  
Ang-­‐II	  treatment.	  	  
	  
Our	  results	  show	  that	  Ang-­‐II	  treatment	  releases	  intracellular	  calcium	  stores	  in	  HeLa	  and	  SiHa	  
cells	   as	   observed	   by	   a	   significant	   increase	   in	   calcium	   fluorescence	   in	   both	   the	   cancer	   cell	  
lines	   used	   (Figure	   2.9	   A	   and	   C).	   Pre-­‐treatment	   with	   the	   AT1R	   inhibitor,	   Candesartan,	  
significantly	  decreased	  the	  Ang-­‐II	   induced-­‐	  release	  of	  intracellular	  calcium	  in	  both	  cell	   lines	  
(Figure	   2.9	   B	   and	   D).	   It	   was	   observed	   that	   Candesartan	   treatment	   had	   no	   effect	   on	   the	  
release	  of	  calcium	  in	  HeLa	  or	  SiHa	  cells	  (Figure	  2.9	  E	  and	  F).	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Figure	  2.9:	  Effect	  of	  stimulation	  and	  inhibition	  of	  the	  ACE-­‐1	  axis	  on	  release	  of	  intracellular	  
calcium	   in	   cancer	   cells.	   A.	   and	  C:	  One	  representative	  Calcium	  release	  profile	  of	  HeLa	  and	  
SiHa	   cells	   after	   treatment	  with	   400	   nM	  Ang-­‐II	   using	   flow	   cytometry.	  B.	   and	   D:	   Bar	   chart	  
quantification	  showing	  that	  Ang-­‐II	  significantly	  stimulates	  the	  release	  of	  intracellular	  calcium	  
in	   cancer	   cells	   which	   Candesartan	   pretreatment	   can	   prevent.	   E	   and	   F:	   Representative	  
calcium	  release	  profile	  of	  HeLa	  and	  SiHa	  cells	  after	  treatment	  with	  IC50	  Candesartan.	  Results	  
shown	   are	   the	  mean	   +/-­‐	   SEM	  of	   experiments	   performed	   in	   triplicate	   and	   repeated	   three	  
independent	  times,	  *p-­‐value<0.05.	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Having	  observed	  the	  release	  of	   intracellular	  calcium	  we	  next	   investigated	  the	  activation	  of	  
calcium/calmodulin-­‐dependent	   kinase	   II	   (CAMKII),	   a	   key	   enzyme	   associated	   with	   calcium	  
signalling.	  
	  
Ang-­‐II	   treatment	  resulted	   in	  a	  substantial	   increase	   in	  phosphorylated	  CAMKII	   in	  HeLa	  cells	  
within	   1	   minute	   of	   treatment	   that	   tapered	   off	   with	   increasing	   time	   (Figure	   2.10	   A).	  
Phosphorylated	   CAMKII	   was	   observed	   after	   5	   minutes	   of	   Ang-­‐II	   treatment	   in	   CaSki	   cells	  
(Figure	   2.10	   B).	   Pre-­‐treatment	   of	   both	   HeLa	   and	   CaSki	   cells	   for	   24	   h	   with	   Candesartan	  
prevented	   the	   phosphorylation	   of	   CAMKII	   (Figure	   2.10	   C	   and	   D).	   Densitometric	  
quantification	  of	   the	  protein	  bands,	   indicating	   relative	  pCAMKII	  expression	   in	   the	   two	  cell	  
lines	  can	  be	  found	  in	  Appendix	  I	  (Figure	  A.1).	  
	  	  
These	   results	   suggest	   that	   calcium	   signalling	   pathways	   are	   activated	   in	   cancer	   cells	   in	  
response	  to	  Ang-­‐II	  via	  the	  AT1	  receptor	  resulting	  in	  activation	  of	  calcium	  responsive	  kinases	  
such	  as	  CAMKII.	  	  
	  
Having	  shown	  that	  upstream	  signaling	  pathways	  are	  activated	  by	  Ang-­‐II	   in	  cancer	  cells	  we	  
next	   investigated	   whether	   this	   had	   an	   effect	   on	   transcription	   factors	   known	   to	   be	  
responsive	  to	  calcium	  signaling.	  NFAT,	  is	  a	  transcription	  factor	  that	  is	  known	  to	  translocate	  
to	   the	  nucleus	   after	   the	   release	  of	   calcium	   stores	  where	   it	   activates	   its	   target	   genes.	  We	  
used	  the	  NFAT	   luciferase	  assay	   to	  monitor	  effects	  of	  Ang-­‐II	  and	   its	   inhibitor,	  Candesartan.	  
Our	   results	   show	   that	   Ang-­‐II	   treatment	   had	   a	   dramatic	   stimulatory	   effect	   on	   NFAT	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transcriptional	   activity	   and	   that	   this	   was	   inhibited	   by	   the	   AT1R	   antagonist,	   Candesartan	  
(Figure	  2.11).	  
	  
Together,	  our	  results	  presented	  in	  this	  chapter	  provides	  evidence	  that	  ACE-­‐1	  and	  the	  AT1R	  
associates	  with	  the	  proliferation	  of	  cancer	  cells.	  Ang-­‐II	  stimulates	  cancer	  cells	  via	  activation	  
of	   the	   AT1R,	  which	   results	   in	   the	   release	   of	   intracellular	   calcium	   stores	   and	   activation	   of	  
CAMKII	  and	  transcription	  factors	  such	  as	  NFAT.	  	  
	   	  










Figure	  2.10:	  Effect	  of	  Ang-­‐II	  treatment	  on	  CAMKII	  phosphorylation	  in	  HeLa	  and	  CaSki	  cells.	  
A	  &	  B:	  Phosphorylation	  of	  CAMKII	  can	  be	  seen	  after	  minutes	  of	  exposure	  of	  400	  nM	  Ang-­‐II	  in	  
HeLa	  and	  Caski	  cells	  C:	  HeLa	  and	  CaSki	  (D)	  cells	  were	  pre-­‐treated	  with	  Candesartan	  for	  24	  h	  
before	  being	  subjected	  to	  Ang-­‐II	  treatment	  for	  the	  indicated	  amounts	  of	  time.	  Candesartan	  
prevented	   the	   Ang-­‐II-­‐induced	   phosphorylation	   of	   pCAMKII.	   Positive	   controls	   (PC),	   where	  
HeLa	  and	  CaSki	  cells	  showed	  pCAMKII	  expression	  (after	  AngII	  treatment	  for	  1	  and	  5	  minutes	  
respectively)	   were	   included	   to	   highlight	   this.	   Results	   shown	   are	   representative	   of	   two	  
independent	  experiments.	  	  
	    






























Figure	  2.11:	  Candesartan	  prevents	  Ang-­‐II	  stimulated	  NFAT	  transcriptional	  activity.	  	  
Ang-­‐II	   treatment	  significantly	  stimulates	  NFAT	  activity	   in	  HeLa	  cells,	  which	  can	  be	  reduced	  
with	   Candesartan.	   Results	   shown	   are	   the	   mean	   +/-­‐	   SEM	   of	   experiments	   performed	   in	  
triplicate	  and	  repeated	  three	  independent	  times,	  *p-­‐value<0.05.	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2.3	  DISCUSSION	  
	  
There	   is	   growing	   evidence	   that	   chronic	   conditions	   such	   as	   diabetes	   and	   cardiovascular	  
disease	   share	   common	   differential	   gene	   expression	   patterns	   with	   cancer	   incidence	  
(Chochieva	  et	  al.,	  2008;	  Hirsch	  et	  al.,	  2010;	  Reddy	  et	  al.,	  1995;	  Small	  et	  al.,	  1997;	  Suganuma	  
et	   al.,	   2005;	   Yoshiji	   et	   al.,	   2002).	   The	   aim	   of	   this	   study	   was	   to	   investigate	   whether	  
components	  of	   the	  Renin	  Angiotensin	  System,	   in	  particular	  ACE-­‐1	  and	  the	  AT1R,	  associate	  
with	  the	  cancer	  phenotype	  using	  a	  panel	  of	  cancer	  cells	  of	  different	  tissue	  origin.	  We	  report	  
that	  our	  results	  suggest	  elevated	  ACE-­‐1	  expression	  and	  activity	  in	  cancer	  cell	  lines	  compared	  
to	   normal	   cells.	   AT1R	   expression	   levels	  were	   similarly	   found	   to	   be	   greater	   in	   cancer	   cells	  
than	  normal	  cells.	  	  
	  
Ang-­‐II	   has	   been	   shown	   to	   associate	  with	   the	  AT1R	  with	   pathophysiological	   consequences	  
(Chochieva	  et	   al.,	   2008;	   Zhao	  et	   al.,	   2010b).	   It	   is	   known	   to	   regulate	   expression	  of	   growth	  
factors	  and	  promote	  the	  proliferation	  of	  various	  cell	  types	  as	  well	  as	  other	  cancer	  hallmarks	  
such	  as	  cell	  migration	  and	  invasion	  (Kikkawa	  et	  al.,	  2004;	  Muscella	  et	  al.,	  2002;	  Rodrigues-­‐
Ferreira	   et	   al.,	   2012;	   Suganuma	  et	   al.,	   2005).	   In	   line	  with	   these	   studies	  we	  observed	   that	  
Ang-­‐II	   stimulates	   cervical	   cancer	   cell	   proliferation.	  Our	  work	   supports	   findings	   associating	  
Ang-­‐II	  primarily	  with	   the	  AT1R	  with	  diseased	   states.	  As	  Ang-­‐II	   can	  bind	  both	  AT1	  and	  AT2	  
receptors,	  thus	  we	  were	  interested	  to	  determine	  whether	  its	  effects	  on	  cervical	  cancer	  cell	  
proliferation	  occurred	  via	  AT1R	  or	  AT2R	  activation.	  We	  found	  that	  blocking	  the	  AT2R	  with	  
PD123319	  had	  no	  effect	  on	  Ang-­‐II	  stimulated	  proliferation	  suggesting	  that	  the	  AT1R	   is	  the	  
preferred	  receptor.	  This	  was	  confirmed	  by	  Candesartan	  treatment,	  which	  prevented	  Ang-­‐II	  
stimulated	  proliferation.	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Inhibition	  of	  ACE-­‐1	  or	  AT1R	  has	  been	  reported	  to	  cause	  varying	  effects	  depending	  on	  the	  cell	  
type.	  A	  study	  by	  Carl-­‐Mcgrath	  et	  al.,	  (2007)	  showed	  that	  inhibition	  of	  ACE-­‐1,	  or	  either	  of	  the	  
receptors,	  AT1	  or	  AT2,	  resulted	  in	  increased	  proliferation	  and	  reduction	  in	  invasive	  ability	  of	  
gastric	   cancer	   cell	   lines.	   In	   pancreatic	   cancer,	   using	   PK9	   and	  HS766T	   cell	   lines,	  ACE-­‐1	   axis	  
inhibition	  using	  Captopril	  or	  Candesartan	  reduced	  cell	  proliferation	   (Arafat	  et	  al.,	  2007)	  as	  
well	   as	   inhibiting	   tumour	   growth	   and	   angiogenesis	   in	   vivo	   (Miyajima	   et	   al.,	   2002).	   In	   our	  
study,	  we	  show	  that	  ACE-­‐1	  inhibition	  using	  siRNA	  or	  the	  inhibitors,	  Captopril	  and	  Lisinopril,	  
as	   well	   as	   the	   AT1R	   antagonist,	   Candesartan,	   reduce	   cervical	   cancer	   cell	   proliferation,	  
suggesting	  that	  cancer	  cells	  are	  dependent	  on	  the	  ACE-­‐1	  axis	  for	  their	  proliferation	  and	  that	  
ACE-­‐1	   and	  AT1R	   inhibitors	   have	   potential	   anti-­‐cancer	   effects.	  We	   also	   showed	   that	   these	  
inhibitors	  did	  not	  adversely	  affect	  the	  non-­‐cancer	  cells	  investigated	  in	  our	  study.	  	  
	  
Out	   of	   the	   three	   antihypertensive	   agents	   used	   in	   our	   study,	   Candesartan,	   the	   AT1R	  
antagonist,	   was	   the	   only	   small	   molecule,	   which	   is	   a	   benzimidazole-­‐derived	   compound.	  
Benzimidazole	  derivatives	  have	  been	   shown	   to	   exert	   diverse	  biological	   activities	   including	  
those	   of	   fungicides,	   bacteriosides	   and	   bacteriostatics.	   More	   recently,	   there	   has	   been	  
growing	  evidence	  suggesting	  benzimidazole	  derivatives	  have	  anticancer	  properties	  (Abd	  El-­‐
All	  et	  al.,	  2015;	  El	  Rashedy	  and	  Aboul-­‐Enein,	  2013;	  Yadav	  et	  al.,	  2015;	  Yurttas	  et	  al.,	  2015).	  In	  
vitro	   studies	   investigating	   the	   anti-­‐tumour	   effect	   of	   benzimidazole	   derivatives	   have	   been	  
carried	  out	  using	  colon,	  liver,	  cervix,	  uterine	  sarcoma,	  osteosarcoma,	  lung	  and	  breast	  cancer	  
cells(Abd	  El-­‐All	  et	  al.,	  2015;	  Blaszczak-­‐Swiatkiewicz	  et	  al.,	  2012;	  El	  Rashedy	  and	  Aboul-­‐Enein,	  
2013;	  Nofal	  et	  al.,	  2011;	  Reddy	  et	  al.,	  2015;	  Yadav	  et	  al.,	  2015;	  Yurttas	  et	  al.,	  2015).	  Results	  
presented	  in	  our	  study	  suggest	  that	  Candesartan	  treatment	  of	  cervical	  cancer	  cells	  results	  in	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cell	  death	  due	  to	  necrosis.	  Breast	  cancer	  cells	  (MDA-­‐MB-­‐231)	  showed	  a	  mix	  of	  apoptosis	  and	  
necrosis.	  These	  data	  support	   findings	   that	   the	  ACE-­‐1	  axis	  of	  RAS	   is	  active	   in	  breast	  cancer	  
cells	  and	  that	  ACE-­‐1	  axis	  inhibitors	  can	  reduce	  Ang-­‐II	  induced	  proliferative	  effects	  (Du	  et	  al.,	  
2012;	  Okazaki	  et	  al.,	  2014;	  Puddefoot	  et	  al.,	  2006;	  Rodrigues-­‐Ferreira	  et	  al.,	  2012).	  	  
	  
There	  is	  evidence	  in	  the	  literature	  that	  Ang-­‐II	  and	  its	  receptor,	  AT1,	  have	  a	  role	  in	  increasing	  
intracellular	   calcium	   levels.	   Intracellular	   calcium	   is	   an	   important	   regulator	   of	   various	  
signalling	  mechanisms	  and	  the	  transcription	  of	  genes	  involved	  in	  cell	  processes	  like	  growth	  
and	  proliferation	  (Monteith	  et	  al,	  2007;	  Parkash	  and	  Asotra,	  2010).	  Release	  of	  calcium	  from	  
mitochondrial	  or	  endoplasmic	  reticulum	  stores	  as	  well	  as	  calcium	  influx	  can	  disrupt	  calcium	  
homeostasis	  and	  potentially	  induce	  a	  variety	  of	  effects,	  one	  of	  which	  being	  cell	  death,	  if	  the	  
threshold	  of	   calcium	  release	  within	  a	   cell	   is	   surpassed	   (Monteith	  et	  al,	  2007;	  Parkash	  and	  
Asotra,	   2010).	  We	   thus	   investigated	   calcium	   signalling	   pathways	   in	   cancer	   cells	  with	   high	  
ACE-­‐1	  expression.	  We	  monitored	  the	  release	  of	  intracellular	  calcium	  in	  live	  cells	  directly	  with	  
a	   flow	   cytometry	   approach	   using	   the	   calcium	   fluorophore	   Fluo-­‐4	   AM.	   This	   is	   a	   novel	  
approach	   that	   uses	   live	   cells	   whilst	   monitoring	   effects	   on	   calcium	   signaling.	   Calcium	  
signalling	  events,	  especially	  those	  involving	  calcium,	  typically	  occur	  within	  a	  very	  short	  space	  
of	  time.	  We	  observed	  that	  Ang-­‐II	  treatment	  resulted	  in	  the	  release	  of	   intracellular	  calcium	  
stores	   in	  HeLa,	  CaSki	  and	  SiHa	  cells	  and	  that	  Candesartan	  prevented	  this.	  We	  hypothesize	  
that	   inhibition	   of	   calcium	   signalling	   pathways	   with	   Candesartan	   may	   interfere	   with	  
downstream	  signalling	  events	  in	  cancer	  cells	  	  
	  
To	   test	   this	   we	   investigated	   the	   expression	   levels	   of	   a	   key	   calcium	   signalling	   protein,	  
calcium/calmodulin-­‐dependent	   kinase	   II	   (CAMKII).	   Ang-­‐II	   treatment	   resulted	   in	   the	   rapid	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phosphorylation	  of	  CAMKII,	  which	  could	  be	  observed	  within	  minutes	  in	  HeLa	  and	  CaSki	  cells.	  	  
Ang-­‐II	  also	  resulted	  in	  the	  activation	  of	  the	  transcription	  factor	  NFAT,	  which	  is	  responsive	  to	  
calcium	  release.	  Phosphorylation	  of	  CAMKII	  and	  NFAT	  activation	  was	  significantly	  inhibited	  
by	   Candesartan	   treatment.	   Muthalif	   et	   al.	   (1998),	   describes	   a	   link	   between	   Ang-­‐II	   and	  
CAMKII	  signalling	  in	  vascular	  smooth	  muscle	  cells.	  However,	  our	  study	  is	  the	  first	  to	  report	  
Ang-­‐II	  activation	  of	  calcium	  signaling	  pathways	  in	  cervical	  cancer	  cells.	  	  	  
	  
In	   conclusion,	  we	  have	  established	   that	   the	  ACE-­‐1	  axis	   (i.e	  ACE-­‐1	  and	  AT1R)	  of	   the	  RAS	   is	  
highly	  expressed	  in	  cervical	  cancer	  compared	  to	  normal	  cells	  and	  promotes	  the	  proliferation	  
of	   cancer	   cells.	   We	   have	   observed	   that	   Ang-­‐II	   can	   act	   as	   a	   growth	   promoter	   and	   the	  
inhibitors	   of	   the	  ACE-­‐1	   axis,	   can	   reduce	  Ang-­‐II-­‐induced	   proliferation.	  Our	   results	   show	   an	  
interesting	  association	  between	  the	  ACE-­‐1	  axis	  in	  cancer	  cells	  and	  calcium	  signalling	  proteins	  
like	  CAMKII.	  We	  propose	  that	  elevated	  ACE-­‐1	  and	  AT1R	  in	  cancer	  cells	  results	   in	   increased	  
signalling	   via	   the	   AT1	   receptor,	   which	   when	   bound	   by	   Ang-­‐II	   results	   in	   the	   release	   of	  
intracellular	  calcium	  stores.	  This	  triggers	  the	  phosphorylation	  of	  calcium	  responsive	  proteins	  
including	   CAMKII	   and	   NFAT	   (Figure	   2.12).	   The	   activation	   of	   the	   signalling	   cascade	   is	  
necessary	   for	   cervical	   cancer	   proliferation	   as	   treatment	   with	   ACE-­‐1	   and	   AT1R	   inhibitors	  
blocks	  the	  release	  of	  calcium	  stores,	  phosphorylation	  of	  CAMKII	  and	  activation	  of	  NFAT.	  	  
	  
	  	   	  
















Figure	  2.12:	   Schematic	   representation	   showing	  ACE-­‐1	  axis	   association	  with	  activation	  of	  
intracellular	   signalling	   in	   cancer	   cells.	  ACE-­‐1	  axis	  proteins,	  ACE-­‐1	  and	  AT1R	  have	  elevated	  
expression	  and	  activity	  in	  cancer	  cells.	  Activation	  of	  the	  AT1	  receptor	  by	  Ang-­‐II	  results	  in	  the	  
release	   of	   intracellular	   calcium	   stores	  which	   triggers	   the	   activation	   of	   signaling	  molecules	  
including	   CAMKII	   and	   NFAT.	   We	   propose	   that	   the	   events	   are	   in	   part	   required	   for	   the	  
proliferation	  of	  cervical	  cancer	  cells.	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CHAPTER	  3	  




The	  ACE-­‐2	   enzyme	  within	   the	  RAS	   serves	   to	   counterbalance	   the	   effects	   of	   the	  ACE-­‐1	   axis	  
(Ager	  et	   al.,	   2008;	  Duenas-­‐Gonzalez	  et	   al.,	   2008a;	  Guang	  et	   al.,	   2012;	  Mizuiri	   and	  Ohashi,	  
2015;	   Verma	   et	   al.,	   2012).	  Many	   studies	   have	   begun	   to	   demonstrate	   that	   these	   enzymes	  
function	   beyond	   that	   of	   blood	   pressure	   regulation	   (Ager	   et	   al.,	   2008;	   Deshayes	   and	  
Nahmias,	  2005;	  Guang	  et	   al.,	   2012;	   Ino	  et	   al.,	   2011;	   Juillerat-­‐Jeanneret,	   2007;	  Mizuiri	   and	  
Ohashi,	   2015).	   As	   ACE-­‐1	   and	   ACE-­‐2	   typically	   exist	   in	   a	   balanced	   environment,	   it	   is	  
conceivable	   that	   dysregulation	   of	   these	   proteins	  may	   be	   associated	   with	   diseased	   states	  
within	  various	   tissues	  and	  organs.	   In	   some	  of	   these	   instances	  where	  ACE-­‐2	   itself	   is	  down-­‐
regulated,	  ACE-­‐1	  effects	  overwhelm	  that	  particular	  environment	  (Mizuiri	  and	  Ohashi,	  2015).	  
In	   the	   study	   carried	   out	   by	   Mizuiri	   and	   Ohashi	   (2015),	   the	   activation	   of	   the	   AT1R	   was	  
associated	  with	  the	  aetiology	  of	  renal	  disease,	  whereas	  activation	  of	  the	  ACE-­‐2	  axis	  via	  Ang-­‐
(1-­‐7),	   resulted	   in	   renoprotective	   effects	   in	   addition	   to	   other	   beneficial	   effects	   such	   as	  
reduced	   vasoconstriction,	   cell	   proliferation	   and	   water	   retention.	   Examples	   where	   the	  
activation	  of	  the	  ACE-­‐2	  axis	  has	  been	  successful	  in	  protecting	  against	  disease	  include	  studies	  
focused	   on	   promoting	   antithrombotic	   activity,	   cardiovascular	   disease	   as	   well	   as	   diabetic	  
retinopathy	  which	  eventually	  leads	  to	  blindness	  (Fraga-­‐Silva	  et	  al.,	  2010).	  
	  
Recent	   research	   has	   begun	   to	   address	   whether	   the	   stimulation	   of	   ACE-­‐2	   function,	   or	  
overexpression	  of	  ACE-­‐2	   in	  diseased	   states	   is	   linked	   to	  positive	  effects(Feng	  et	   al.,	   2010a;	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Feng	  et	  al.,	  2011b;	  Ingelfinger,	  2006;	  Lovren	  et	  al.,	  2008;	  Rentzsch	  et	  al.,	  2008;	  Verma	  et	  al.,	  
2012;	   Zhong	   et	   al.,	   2011).	   To	   this	   end,	   there	   are	   encouraging	   results	   where	   ACE-­‐2	  
overexpression	  has	  resulted	  in	  the	  reduction	  of	  diabetes-­‐induced	  retinopathy	  (Verma	  et	  al.,	  
2012)	   as	  well	   as	   potential	   anti-­‐angiogenic	   effects	   together	  with	   the	   suppression	   of	   ACE-­‐1	  
and	   AT1R	   expression	   in	   vivo	   (Feng	   et	   al.,	   2011b).	   ACE-­‐2	   overexpression	   has	   also	   been	  
reported	  to	  inhibit	  cell	  proliferation	  in	  the	  pancreatic	  cancer	  cell	   lines,	  BxPC3	  and	  SW1990	  
(Zhou	  et	  al.,	  2011)	  and	  reduce	  epithelial-­‐mesenchymal	   transition	   (EMT)	   in	  A549	  non-­‐small	  
cell	  lung	  cancer	  cells	  (Qian	  et	  al.,	  2013).	  	  
	  
Activation	  of	  the	  ACE-­‐2	  axis	  using	  Ang-­‐(1-­‐7)	  in	  cancer	  studies	  has	  shown	  to	  have	  promising	  
anti-­‐cancer	   effects	   with	   disruption	   of	   growth-­‐promoting	   signals	   as	   well	   as	   decreased	  
angiogenesis,	  inflammation	  and	  metastasis	  of	  breast,	  prostate	  and	  hepatocellular	  carcinoma	  
cells(Feng	  et	  al.,	  2010a;	  Gallagher	  et	  al.,	  2014;	  Ni	  et	  al.,	  2012;	  Passos-­‐Silva	  et	  al.,	  2015).	   In	  
2009,	   a	   pharmacokinetic	   and	   Phase	   I	   study	   of	   Ang-­‐(1-­‐7)	   was	   carried	   out	   to	   establish	   the	  
recommended	  phase	  II	  dose	  for	  treating	  patients	  with	  advanced	  cancers	  as	  well	  as	  to	  assess	  
pharmacokinetics	  of	  the	  peptide	  hormone(Petty	  et	  al.,	  2009)	  
	  
In	   addition	   to	   natural	   activators	   of	   the	   ACE-­‐2	   axis,	   synthetic	   small	   molecules	   such	   as	  
Diminazene	  aceturate	  (DIZE)	  have	  been	  shown	  to	  enhance	  ACE-­‐2	  activity	  in	  hypertension(de	  
Macedo	  et	  al.,	  2015;	  Kuriakose	  and	  Uzonna,	  2014;	  Qi	  et	  al.,	  2013;	  Velkoska	  et	  al.,	  2016)Thus	  
far,	  literature	  reports	  of	  the	  ACE-­‐2	  activator	  DIZE,	  also	  referred	  to	  as	  its	  trade	  name	  Berenil,	  
have	  primarily	   involved	  studies	  making	  use	  of	   it	  as	  an	  anti-­‐trypanosomal	  drug	   in	   livestock	  
(Burudi	  et	  al.,	  1994;	  Diack	  et	  al.,	  1997;	  Kaminsky	  et	  al.,	  1993;	  Peregrine	  and	  Mamman,	  1993;	  
Poot	   et	   al.,	   1990).	   However	   DIZE	   has	   also	   been	   used	   for	   assisting	   with	   the	   regulation	   of	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blood	   pressure,	   reducing	   inflammation	   and	   producing	   gastroprotective	   effects	   in	   mice	  
(Souza	   et	   al.,	   2016;	   Tao	   et	   al.,	   2016;	   Velkoska	   et	   al.,	   2016).	   Furthermore,	   it	   has	   been	  
reported	   that	   DIZE	   inhibits	   chromatin	   condensation(Haaf	   and	   Schmid,	   2000;	   Poot	   et	   al.,	  
1990)	  and	  could	  potentially	  be	  utilized	  for	  growth	  inhibition	  purposes	  in	  cancer.	  
	  
In	  this	  chapter	  we	  investigated	  ACE-­‐2	  expression	  and	  activity	  in	  cancer	  cells	  using	  a	  natural	  
or	  synthetic	  small	  molecule.	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3.2	  RESULTS	  
3.2.1	  Endogenous	  expression	  and	  activity	  of	  ACE-­‐2	  is	   lower	  in	  cancer	  cell	   lines	  compared	  
to	  normal	  cells	  
Our	   earlier	   results	   showed	   that	   ACE-­‐1	   expression	   was	   elevated	   in	   cancer	   compared	   to	  
normal	   cell	   lines	   under	   tissue	   culture	   conditions.	   Here	   we	   aimed	   to	   determine	   the	  
expression	  of	  ACE-­‐2	  as	  well	  as	  the	  potential	  role	  the	  ACE-­‐2	  axis	  in	  cancer	  cells.	  	  
	  
Western	   blot	   analysis	   showed	   that,	   in	   contrast	   to	   ACE-­‐1	   expression,	   endogenous	   ACE-­‐2	  
protein	   levels	  were	   reduced	   in	   cancer	   cell	   lines	   compared	   to	   non-­‐cancer	  WI-­‐38	   cells	   and	  
transformed	   SVWI-­‐38	   cells	   (Figure	   3.1).	   To	   determine	   whether	   low	   ACE-­‐2	   expression	  
correlated	  with	  ACE-­‐2	  activity	  levels	   in	  these	  cancer	  cells,	  we	  determined	  ACE-­‐2	  enzymatic	  
activity	   using	   a	   flurogenic	   assay.	   This	   assay	   measures	   the	   cleavage	   of	   an	   ACE-­‐2-­‐specific	  
fluorogenic	   substrate,	   (7-­‐methoxycoumarin-­‐4-­‐yl)	   acetyl-­‐Ala-­‐Pro-­‐Lys-­‐(2,4-­‐dinitrophenyl).	  
Results	  were	   represented	   as	   relative	   fluorescence	   to	  microgram	   (μg)	   protein.	   Our	   results	  
showed	  that	  the	  cancer	  cell	  lines	  HeLa,	  CaSki	  and	  MDA-­‐MB-­‐231,	  showed	  significantly	  lower	  
levels	  of	  ACE-­‐2	  activity	  compared	  to	  a	  non-­‐cancer	  cell	  line,	  FG0	  (Figure	  3.1	  B).	  SVWI38	  cells	  
which	  had	  high	  ACE-­‐2	  expression,	  showed	  surprisingly	  low	  ACE-­‐2	  activity.	  The	  reason	  for	  this	  
is	  not	  clear	  at	  present,	  but	  could	  be	  that	  SVWI38	  cells	  contain	  a	  different	  isozyme	  of	  ACE-­‐2,	  
possibly	   the	   ACE-­‐2	   enzyme	   expressed	   by	   SVWI38	   possesses	   different	   post	   transcriptional	  
modifications,	  or	  perhaps	  while	  ACE-­‐2	  is	  expressed	  in	  SVWI38	  cells,	  the	  enzyme	  may	  require	  
activation	  by	  a	   stimulus	   to	   increase	  activity.	  A	   further	  possibility	   is	   that	   the	  antibody	  may	  
have	  shown	  signs	  of	  non-­‐specificity	  as	  ACE-­‐2	  activity	  in	  SVWI38	  cells	  was	  reduced	  compared	  
to	   ACE-­‐2	   expression	   in	   these	   cells.	   Our	   results	   for	   the	   cancer	   cells	   nonetheless	   show	   a	  
correlation	  of	  decreased	  ACE-­‐2	  expression	  with	  ACE-­‐2	  activity.	  	   	  






Figure	  3.1:	  Endogenous	  ACE-­‐2	  expression	  and	  activity	  is	  lower	  in	  cancer	  cells	  compared	  to	  
normal	   cells.	   (A.)	   Western	   blot	   analysis	   showing	   ACE-­‐2	   expression	   in	   WI38	   (normal	  
fibroblasts),	  SVWI38	  (transformed	  fibroblasts)	  and	  cancer	  cell	  lines.	  	  Β-­‐tubulin	  was	  used	  as	  a	  
control	  for	  protein	  loading.	  (B.)	  ACE-­‐2	  activity	  measured	  in	  normal	  and	  cancer	  cells	  using	  the	  
ACE-­‐2	  enzyme	  assay	  measuring	  cleavage	  of	  the	  fluorogenic	  peptide,	  (7-­‐methoxycoumarin-­‐4-­‐
yl)	  acetyl-­‐Ala-­‐Pro-­‐Lys-­‐(2,4-­‐dinitrophenyl).	  Results	  shown	  are	  the	  mean	  +-­‐	  SE	  of	  experiments	  
performed	  in	  triplicate	  and	  repeated	  at	  least	  two	  independent	  times.	  *p<0.05.	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3.2.2	  Activation	  of	  the	  ACE-­‐2	  axis	  in	  cancer	  cells	  disrupts	  cancer	  cell	  proliferation	  
	  
Endogenous	   Ang-­‐(1-­‐7)	   can	   increase	   the	   beneficial	   effects	   associated	   with	   the	   ACE-­‐2	   axis	  
through	   the	   stimulation	   of	   the	   Mas	   receptor(Ager	   et	   al.,	   2008;	   Chappell	   et	   al.,	   2014;	  
Ferrario,	  2011;	  Santos	  et	  al.,	  2013;	  Simoes	  e	  Silva	  et	  al.,	  2013;	  Xu	  et	  al.,	  2011)	  
	  
Thus,	  we	  investigated	  whether	  the	  ACE-­‐2	  cleavage	  product,	  Ang-­‐(1-­‐7),	  could	  exert	  an	  anti-­‐
proliferative	   effect	   in	   the	   cervical	   cancer	   cell	   lines,	   HeLa	   and	   CaSki,	   as	  well	   as	   the	   breast	  
cancer	   cell	   line	  MDA-­‐MB-­‐231.	   Cells	   treated	  with	   an	   increasing	   concentration	   of	   Ang-­‐(1-­‐7)	  
showed	   a	   significant	   decrease	   in	   proliferation	   compared	   to	   control	   cells	   (Figure	   3.2).	   This	  
suggested	  that	  activation	  of	  ACE-­‐2	  regulated	  pathways	  has	  an	   inhibitory	  effect	  on	  cervical	  
cancer	  cells.	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Figure	  3.2	  Natural	  peptide,	  Ang-­‐(1-­‐7)	  reduces	  cancer	  cell	  proliferation.	  A	  48	  hour	  treatment	  of	  Ang-­‐
(1-­‐7)	  significantly	  reduced	  cell	  proliferation	  of	  HeLa	  and	  CaSki	  cervical	  cancer	  cells	  as	  well	  as	  MDA-­‐
MB-­‐231,	   breast	   cancer	   cells	   (*p<0.05).	   Results	   shown	   represent	   the	   mean	   +/-­‐SD	   of	   experiments	  
performed	  in	  triplicate	  and	  repeated	  at	  least	  two	  independent	  times.	  
	   	  
	   85	  
	  
3.2.3	  The	  small	  molecule,	  DIZE,	  significantly	  increases	  ACE-­‐2	  enzyme	  activity	  in	  normal	  and	  
cancer	  cell	  lines	  
	  
Since	  we	  observed	  that	  the	  Ang-­‐(1-­‐7)	  could	  exert	  anti-­‐proliferative	  effects	  in	  cancer	  cells,	  we	  
were	   interested	   in	   determining	  whether	  DIZE	  would	   behave	   in	   a	   similar	  manner	   as	  more	  
recent	  studies	  have	  suggested	  it	  exerts	  a	  stimulatory	  effect	  on	  the	  ACE-­‐2	  enzyme	  (da	  Silva	  
Oliveira	   and	   de	   Freitas,	   2015;	   Kuriakose	   and	   Uzonna,	   2014;	   Qi	   et	   al.,	   2013;	   Souza	   et	   al.,	  
2016;	  Tao	  et	  al.,	  2016)	  
	  
We	  used	  a	  sensitive	  flurogenic	  assay	  to	  measure	  ACE-­‐2	  activity	  in	  the	  absence	  and	  presence	  
of	  DIZE	  treatment.	  Our	  results	  show	  that	  DIZE	  had	  a	  significant	  stimulatory	  effect	  on	  ACE-­‐2	  
activity	  in	  all	  of	  the	  cell	  lines	  tested	  (Figure	  3.3).	  DIZE-­‐stimulated	  ACE-­‐2	  activity	  in	  the	  cancer	  
cell	  lines	  was	  still	  below	  that	  of	  the	  untreated	  non-­‐cancer	  cell	  line	  FGO.	  	  
	   	  
















Figure	   3.3:	  DIZE	   increases	  ACE-­‐2	   enzyme	  activity	   in	  normal	   and	   cancer	   cell	   lines.	  Cells	  were	  pre-­‐
treated	   with	   1μM	   DIZE	   for	   1	   hour	   prior	   to	   being	   incubated	   with	   the	   fluorogenic	   ACE-­‐2	   specific	  
substrate,	   (7-­‐Methoxycoumarin-­‐4-­‐yl)	   acetyl	   dinitrophenyl	   for	   1	   hour.	   The	   amount	   of	   substrate	  
cleavage	  was	   determined	   for	   each	   sample.	   Fluorescence	   readings	  were	   normalised	   to	   μg	   protein.	  
DIZE	   significantly	   increases	   ACE-­‐2	   enzyme	   activity	   in	   the	   normal	   and	   cancer	   cell	   lines	   (*p<0.05).	  
Results	  shown	  represent	  the	  mean	  +/-­‐	  SEM	  of	  experiments	  performed	  in	  triplicate	  and	  repeated	  at	  
least	  two	  independent	  times.	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3.2.4	  The	  ACE-­‐2	  axis	  activators,	  Ang-­‐(1-­‐7)	  and	  DIZE,	  have	  inhibitory	  effects	  on	  cancer	  cell	  
proliferation	  and	  clonogenic	  potential	  
	  
Having	   observed	   that	   DIZE	   could	   stimulate	   ACE-­‐2	   activity	   in	   cancer	   cells,	   we	   next	  
investigated	  its	  effects	  on	  cancer	  cell	  survival	  by	  measuring	  its	  IC50	  in	  treated	  cells.	  DIZE	  had	  
little	   to	   no	   effect	   on	   the	   non-­‐cancer	   cells,	   WI38	   and	   FG0,	   and	   IC50	   values	   could	   not	   be	  
determined.	  In	  contrast,	  IC50	  concentrations	  of	  3	  μM	  for	  HeLa	  cells,	  and	  10	  μM	  for	  CaSki	  and	  
MDA-­‐MB-­‐231	  were	  calculated	  (Table	  3.1).	  
	  
To	  monitor	  the	  effects	  of	  activating	  the	  ACE-­‐2	  axis	  on	  cancer	  cell	  proliferation,	  MTT	  assays	  
were	  performed	  on	  HeLa	  and	  MDA-­‐MB-­‐231	  cells	  treated	  with	  either	  DIZE	  or	  Ang-­‐(1-­‐7).	  Our	  
results	   show	   that	   from	   day	   two	   onwards,	   treatment	   with	   DIZE	   resulted	   in	   a	   significant	  
reduction	   in	   the	   proliferation	   of	   HeLa	   and	   MDA-­‐MB231	   cells	   at	   IC50	   and	   2	   x	   IC50	  
concentrations	   	   (Figure	  3.4	  A	   and	  B).	   Similarly	   treatment	  with	  either	  1	  or	   2	  μM	  Ang-­‐(1-­‐7)	  
showed	  reduced	  cancer	  cell	  proliferation	  at	  48	  hours	  and	  subsequent	  time	  points	  (Figure	  3.4	  
C	  and	  D).	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Table	   3.1.	   IC50	   values	   of	   DIZE	   in	   non-­‐cancer	   and	   cancer	   cell	   lines.	   MTT	   assays	   were	  
performed	  to	  determine	  DIZE	  IC50	  values	  for	  WI38,	  FG0	  non-­‐cancer	  cell	  lines	  and	  HeLa,	  CaSki	  
and	  MDA-­‐MB-­‐231	  cancer	  cell	  lines.	  Experiments	  were	  performed	  in	  triplicate	  and	  repeated	  






	   	  











Figure	   3.4:	   DIZE	   and	   Ang-­‐(1-­‐7)	   reduce	   cancer	   cell	   proliferation.	  HeLa	   (A.),	   and	  MDA-­‐MB-­‐231	   (B.)	  
cells	  were	   treated	  with	   the	   indicated	  concentrations	  of	  DIZE	  or	  Ang-­‐(1-­‐7)	   (C.	   and	  D.)	  once	  off	  and	  
proliferation	  monitored	   for	  5	  days.	  Results	  shown	  are	  representative	  of	  experiments	  performed	   in	  
triplicate	  and	  repeated	  at	  least	  two	  independent	  times,	  (*p<0.05).	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Having	  observed	  an	  anti-­‐proliferative	  response	  in	  the	  cancer	  cell	  lines	  to	  Ang-­‐(1-­‐7)	  and	  DIZE	  
treatment,	  we	  next	  investigated	  their	  effect	  on	  clonogenic	  colony	  formation.	  Briefly,	  HeLa,	  
CaSki	  and	  MDA-­‐MB-­‐231	  cells	  were	  seeded	  into	  a	  6-­‐well	  tissue	  culture	  plate	  at	  a	  low	  enough	  
number	  so	  that	  single	  cells	  could	  establish	  clonogenic	  colonies.	  The	  treated	  groups	  received	  
either	   1	   μM	   Ang-­‐(1-­‐7),	   half	   IC50	   or	   IC50	   concentrations	   of	   DIZE	   for	   24	   hours	   followed	   y	  
incubation	   for	   10	   days	   upon	   which	   visible	   colonies	   could	   be	   observed	   using	   phase	  
microscopy.	   Colonies	   were	   stained	   with	   crystal	   violet	   and	   colonies	   were	   counted	   using	  
ImageJ.	  Results	  showed	  that	  Ang-­‐(1-­‐7)	  reduced	  colony	  formation	  and	  the	  survival	  fraction	  of	  
clonogenic	   colonies	   for	  HeLa	   (Figure	  3.5	  A),	  CaSki	   (Figure	  3.5	  B)	  and	  MDA-­‐MB-­‐231	   (Figure	  
3.5	   C)	   cells.	   Similarly,	   DIZE	   treatment	   at	   half	   IC50	   and	   IC50	   concentrations	   significantly	  
reduced	  the	  number	  of	  colonies	  in	  all	  of	  the	  cancer	  cell	  lines	  tested	  (Figure	  3.6	  A,	  B	  and	  C).	  
These	   results	   provide	   unequivocal	   evidence	   that	   stimulation	   of	   the	   ACE-­‐2	   axis	   inhibited	  
cancer	  cell	  proliferation.	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Figure	  3.5:	  Ang	  (1-­‐7)	  reduces	  clonogenic	  colony	  formation	  of	  cancer	  cells.	  HeLa	  (A.),	  CaSki	  (B.)	  and	  
MDA-­‐MB-­‐231	  (C.)	  cells	  were	  treated	  with	  1μM	  Ang-­‐(1-­‐7)	  once	  off	  and	  clonogenic	  colony	  formation	  
monitored	  for	  10	  days.	  Colonies	  were	  stained	  with	  crystal	  violet	  and	  allowed	  to	  dry	  before	  colonies	  
were	  counted	  using	  ImageJ.	  For	  each	  cell	   line	  the	  %	  survival	  fraction	   indicates	  Ang-­‐(1-­‐7)	  treatment	  
reduced	   the	   number	   of	   clonogenic	   colonies	   able	   to	   form	   after	   10	   days.	   Results	   shown	   is	  
representative	  of	  experiments	  performed	  in	  triplicate	  and	  repeated	  two	  independent	  times.	  	   	  






Figure	  3.6:	  DIZE	   reduces	   colony	   formation	  of	   cancer	   cells.	  HeLa	  (A.),	  CaSki	   (B.)	  and	  MDA-­‐MB-­‐231	  
(C.)	   cells	  were	   treated	  with	   IC50	   DIZE	   once	   off	   and	   clonogenic	   colony	   formation	  monitored	   for	   10	  
days.	   Colonies	   were	   stained	  with	   crystal	   violet	   and	   allowed	   to	   dry	   before	   colonies	   were	   counted	  
using	  ImageJ.	  DIZE	  treatment	  significantly	  reduced	  the	  number	  of	  clonogenic	  colonies	  able	  to	  form	  
after	  10	  days,	  (*p<0.05).	  Results	  shown	  are	  the	  mean	  +/-­‐	  SEM	  of	  experiments	  performed	  in	  triplicate	  
and	  repeated	  three	  independent	  times.	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3.2.6	  ACE-­‐2	  activation	  by	  DIZE	  results	  in	  altered	  cell	  cycle	  progression	  
	  
Using	  phase	  microscopy	  we	  observed	  that	  DIZE	  treatment	  caused	  a	  substantial	   increase	  in	  
the	  appearance	  of	  rounded	  cells,	  some	  of	  which	  were	  still	  adherent	  on	  the	  cell	  culture	  dish	  
while	   others	  were	   floating	   in	   the	   culture	  medium	   (Figure	   3.7	   A).	  We	   postulated	   that	   the	  
rounded	  cells	  may	  be	  indicative	  of	  cells	  undergoing	  mitotic	  arrest.	  A	  significant	   increase	  in	  
rounded	  cells	  compared	   to	  healthy	  adherent	  cells	  was	  quantified	  using	   ImageJ	   (Figure	  3.7	  
B).	  In	  the	  DIZE	  treated	  samples,	  the	  degree	  to	  which	  healthy	  adherent	  cells	  were	  beginning	  
to	   round	  and	   lift	   from	   the	   culture	  dish	  varied	  between	   the	   replicates,	  however,	   a	  greater	  
number	  of	  rounded	  and	  non-­‐adherent	  cells	  were	  observed	  (Figure	  3.7	  B).	  Cell	  cycle	  analysis	  
was	  performed	  on	  control	  and	  DIZE	  treated	  cells.	  Our	  results	  showed	  a	  clear	  and	  significant	  
increase	  in	  the	  G2/M	  population	  of	  DIZE	  treated	  HeLa,	  CaSki	  and	  MDA-­‐MB-­‐231	  cells	  (Figure	  
3.8	  A,	  B	  and	  C).	  A	  notable	  increase	  of	  cells	  in	  the	  subG1	  population	  was	  observed	  for	  CaSki	  
and	  MDA-­‐MB-­‐231	  cells.	  While	  DIZE	  treatment	  significantly	  increased	  the	  subG1	  population	  
in	  HeLa	  cells,	  the	  increase	  was	  not	  as	  robust	  as	  for	  CaSki	  and	  MDA-­‐MB-­‐231	  cells.	  However,	  
after	  DIZE	  treatment,	  HeLa	  cells	  did	  show	  a	  greater	  increase	  in	  the	  percentage	  of	  cells	  in	  the	  
G2/M	  phase	  of	  the	  cell	  cycle	  compared	  to	  the	  other	  cell	  lines.	  
	  
We	  monitored	   the	  expression	   levels	  of	   two	  proteins,	  phosphorylated	  Histone	  H3	   (pHisH3)	  
and	  Mcl-­‐1,	   that	   have	   been	   reported	   to	   correlate	   with	   the	   G2/M	   phase	   of	   the	   cell	   cycle	  
following	   ACE-­‐2	   activation	   with	   DIZE.	   Histone	   H3	   phosphorylation	   takes	   place	   during	  
chromosome	  condensation	  during	  mitosis,	  specifically	  during	  the	  G2	  phase	  of	  the	  cell	  cycle	  
and	  is	  completed	  and	  maintained	  during	  late	  prophase	  and	  metaphase.	  As	  cells	  exit	  mitosis	  
dephosphorylation	  of	  Histone	  H3	  occurs(Hans	  and	  Dimitrov,	  2001;	  Hendzel	  et	  al.,	  1997;	  Van	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Hooser	   et	   al.,	   1998).	  Mcl-­‐1	   is	   a	  member	   of	   the	   Bcl-­‐2	   family	   of	   proteins	   and	   is	   known	   to	  
regulate	  protein	  function	  by	  having	  a	  role	  in	  cancer	  cell	  survival	  as	  an	  apoptotic	  protein	  and	  
through	   its	   involvement	   in	   cell	   cycle	   progression.	  Mcl-­‐1	   degradation	   is	   typically	   observed	  
with	   the	   onset	   of	   apoptosis	   (Akgul,	   2009;	   Bednarek	   et	   al.,	   2007;	   Michels	   et	   al.,	   2005;	  
Perciavalle	  and	  Opferman,	  2013)	  
	  
Our	   results	   show	   that	  DIZE	   treatment	   caused	   an	   increase	   in	   pHisH3	   levels	   (Figure	   3.9	   A).	  
Mcl1	   levels	   conversely	   were	   progressively	   decreased	   over	   48	   hours	   in	   response	   to	   DIZE	  
treatment	   (Figure	  3.9	  B).	  These	   results	   support	   the	  notion	   that	  ACE-­‐2	  activation	   results	   in	  
cells	  being	  delayed	  in	  the	  G2/M	  phase	  of	  the	  cell	  cycle.	  	  
	   	  








Figure	   3.7:	   DIZE	   affects	   HeLa	   cell	   morphology	   by	   increasing	   the	   number	   of	   rounded	   cells	   as	  
determined	  by	  phase	  microscopy.	  A.	  HeLa	  cells	  were	  treated	  with	  the	  IC50	  concentration	  of	  DIZE	  for	  
48	  hours	  and	  images	  captured	  using	  the	  phase	  microscope.	  B:	  Image	  J	  quantitation	  of	  rounded	  cells	  
compared	   to	   healthy,	   adherent	   cells.	   	   Results	   shown	   are	   the	   mean	   +/-­‐	   SEM	   of	   experiments	  
performed	   in	   triplicate	   where	   rounded	   or	   normal,	   adherent	   cells	   were	   counted	   in	   >100	   cells	   per	  
condition	  (*p<0.05).	  Experiments	  were	  repeated	  at	  least	  two	  independent	  times.	   	  















Figure	  3.8:	  DIZE	  treatment	  induces	  a	  G2/M	  arrest	   in	  cancer	  cells	  using	  flow	  cytometry.	  HeLa	  (A.),	  
CaSki	  (B.)	  and	  MDA-­‐MB-­‐231	  (C.)	  cell	  cycle	  profiles	  showing	  the	  effects	  of	  IC50	  DIZE	  treatment	  for	  48	  
hours.	   Quantitation	   of	   cell	   cycle	   data	   showing	   significant	   changes	   in	   all	   phases	   of	   the	   cell	   cycle	  
(*p<0.05).	  Results	  shown	  are	  the	  mean	  +/-­‐	  SEM	  of	  experiments	  performed	  in	  triplicate	  and	  repeated	  
at	  least	  two	  independent	  times.	  	  
	  
	   	  





















Figure	   3.9:	   Expression	   of	   G2/M	   cell	   cycle	   proteins	   induced	   by	   DIZE	   treatment	   in	   HeLa	   cells.	  
Western	  blot	  analysis	  showing	  fluctuation	  of	   the	  expression	   levels	  of	   the	  G2/M	  cell	  cycle	  proteins.	  
(A.)	   pHistone	   H3	   protein	   expression	   is	   elevated	   after	   IC50	   DIZE	   treatment.	   (B.)	   Mcl-­‐1	   protein	  
degradation,	   indicative	   of	   G2/M	   arrest,	  was	   observed	   from	   4	   hours	   to	   48	   hour	   DIZE	   treatments.	  
Experiments	  shown	  were	  repeated	  two	  independent	  times.	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3.2.6	  Activation	  of	  ACE-­‐2	  by	  DIZE	  results	  in	  cell	  death	  via	  apoptosis	  
	  
As	   ACE-­‐2	   activation	   of	   cancer	   cells	   resulted	   in	   a	   significant	   increase	   in	   the	   subG1	   cell	  
population	  we	  next	   investigated	  whether	  this	  correlates	  with	  cell	  death	  via	  apoptosis.	  The	  
degree	  of	  cell	  damage	  and	  death	  caused	  by	  DIZE	  was	  determined	  using	  the	  Annexin	  V	  assay.	  
During	   apoptosis,	   the	   membrane	   phospholipid	   phosphatidylserine	   (PS)	   translocates	   from	  
the	   inner	   to	   the	   outer	   cell	   membrane	   while	   the	   plasma	   membrane	   remains	   intact.	  
Fluorochrome-­‐labelled	  Annexin	  V	  has	  a	  high	  affinity	  for	  PS	  thus	  binding	  would	  indicate	  the	  
onset	   of	   apoptosis.	   Propidium	   iodide	   (PI)	   is	   also	   used	   to	   distinguish	   viable	   cells	   from	  
damaged	  or	  dying	  cells	  as	  those	  with	  damaged	  membranes	  will	  readily	  take	  up	  PI	  whereas	  
healthy	  cells	  exclude	  it.	  Thus	  the	  combination	  of	  Annexin	  V	  and	  PI	  allows	  the	  differentiation	  
of	   healthy	   cell	   populations	   from	   those	   undergoing	   early	   apoptosis,	   late	   apoptosis	   or	  
necrosis(Riccardi	  and	  Nicoletti,	  2006;	  van	  Engeland	  et	  al.,	  1996;	  Vermes	  et	  al.,	  1995)	  
	  
Our	  results	  show	  that	  DIZE	  treatment	  at	  its	  IC50	  concentration	  in	  HeLa,	  CaSki	  and	  MDA-­‐MB-­‐
231	  cells,	  resulted	  in	  a	  significant	  reduction	  in	  the	  percentage	  of	  live	  cells	  and	  a	  significant	  
increase	  in	  the	  percentage	  of	  late	  apoptotic	  and	  necrotic	  cells	  (Figure	  3.10	  A,	  B	  and	  C).	  	  
	  
We	   independently	   confirmed	   that	   DIZE	   treatment	   resulted	   in	   cell	   death	   via	   apoptosis	   by	  
monitoring	   the	   PARP	   cleavage.	   PARP	   functions	   to	   repair	   DNA	   damage	   and	   when	   cells	  
undergo	   apoptosis,	   PARP	   is	   cleaved	   by	   caspase-­‐3	   preventing	   DNA	   repair	   and	   ultimately	  
leading	   to	  cell	  death(Boulares	  et	  al.,	  1999;	  Duriez	  and	  Shah,	  1997;	  Kaufmann	  et	  al.,	  1993;	  
Soldani	  et	  al.,	  2001)Western	  blot	  analysis	  of	  PARP	  identified	  PARP	  cleavage	  in	  DIZE-­‐treated	  
HeLa	  cell	  lysates	  confirming	  cell	  death	  was	  mediated	  by	  apoptosis	  (Figure	  3.11	  A).	  We	  also	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observed	   an	   increase	   in	   p53	   expression	   after	   treatment	   (Figure	   3.11	   B).	   The	   p53	   tumor	  
suppressor	   protein	   regulates	   cell	   death	   through	   the	  detection	  of	   stress	   signals.	   Apoptosis	  
can	  be	  initiated	  by	  p53	  via	  the	  activation	  of	  pro-­‐apoptotic	  proteins	  such	  as	  Bax,	  Puma	  and	  
Noxa,	  or	  the	  repression	  of	  anti-­‐apoptotic	  proteins	  such	  as	  Bcl-­‐2	  and	  Bcl-­‐XL	  and	  Mcl-­‐1	  (Amaral	  
et	  al.,	  2010;	  Elmore,	  2007;	  Vaux	  and	  Strasser,	  1996)	  
	  
Together,	   our	   results	   suggest	   that	   activation	   of	   ACE-­‐2	   by	   small	   molecules	   such	   as	   DIZE	  
associates	  with	  G2/M	  cell	  cycle	  arrest	  and	  accompanying	  cancer	  cell	  death	  via	  apoptosis	  and	  
necrosis.	  	  
	  
	   	  







Figure	  3.10:	  Effect	  of	  DIZE	  on	  cancer	  cell	  death	  using	  the	  Annexin	  V	  assay.	  HeLa,	  CaSki	  and	  MDA-­‐
MB-­‐231	  cells	  were	  treated	  with	  the	  IC50	  concentration	  of	  DIZE	  for	  48	  hours	  and	  effects	  on	  cell	  death	  
investigated	  using	  the	  Annexin	  V	  assay.	  Annexin	  V	  profiles	  of	  HeLa	  (A.),	  CaSki	  (B.)	  and	  MDA-­‐MB-­‐231	  
(C.)	   cells	   showing	   cells	   falling	   into	   four	   quadrants	   indicative	   of	   live	   cells,	   early	   apoptotic,	   late	  
apoptotic	  and	  necrotic	  cells.	  Quantitation	  of	  Annexin	  V	  profiles	  showing	  a	  significant	  reduction	  in	  the	  
percentage	   of	   live	   and	   early	   apoptotic	   cells	   and	   a	   significant	   increase	   in	   the	   percentage	   of	   late	  
apoptotic	   and	   necrotic	   cells	   (*p<0.05).	   Results	   shown	   are	   the	   mean	   +/-­‐	   SEM	   of	   experiments	  
performed	  in	  triplicate	  and	  repeated	  two	  independent	  times.	  
	   	  





Figure	  3.11:	  Effects	  of	  DIZE	  on	  PARP	  cleavage	  and	  p53	  expression	   in	  HeLa	  cells	   (A.)	  Western	  blot	  
analysis	   of	   PARP	   cleavage	   and	   (B.)	   p53	   expression	   after	   IC50	   DIZE	   treatment	   for	   48	   hours.	   PARP	  
cleavage	  and	  p53	  were	  used	  to	  confirm	  the	  induction	  of	  apoptosis	  in	  HeLa	  cells.	  GAPDH	  was	  used	  as	  
a	  loading	  control.	  Experiments	  were	  repeated	  three	  independent	  times.	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3.2.7	  ACE-­‐2	  activation	  by	  Ang-­‐(1-­‐7)	  associates	  with	  cell	  death	  via	  apoptosis	  
	  
We	   investigated	   the	  effects	  of	  Ang-­‐(1-­‐7)	   treatment	  on	   cell	   cycle	  progression	   in	  HeLa	   cells	  
revealed	  no	  change	  in	  the	  percentage	  of	  cells	  in	  the	  G1,	  G2/M	  and	  S	  phases	  of	  the	  cell	  cycle.	  
However,	   a	   7-­‐fold	   increase	   in	   cells	   in	   the	   subG1	   population	   was	   observed	   (Figure	   3.12).	  
Annexin	  V	  staining	  was	  performed	  to	  monitor	  the	  modes	  of	  cell	  death	  associated	  with	  Ang-­‐
(1-­‐7)	  treatment.	  In	  HeLa	  (Figure	  3.13	  A),	  CaSki	  (Figure	  3.13	  B)	  and	  MDA-­‐MB-­‐231	  cells	  (Figure	  
3.13	   C)	   Ang-­‐(1-­‐7)	   treatment	   caused	   an	   increase	   in	   cell	   death	   via	   both	   apoptosis	   and	  
necrosis.	  
	  
	   	  






Figure	   3.12:	   Effect	   of	   Ang-­‐(1-­‐7)	   on	   HeLa	   cell	   cycle	   profile	   using	   flow	   cytometric	   analysis.	   (A)	  
Representative	  picture	  of	  HeLa	  cell	  cycle	  profile	  showing	  the	  effects	  of	  Ang-­‐(1-­‐7)	  on	  cancer	  cell	  cycle	  
profile	  after	  1	  μM	  Ang-­‐(1-­‐7)	  treatment	  for	  48	  hours.	  (B).	   	  Quantitation	  of	  cell	  cycle	  data	  showing	  a	  
significant	   increase	   in	   the	   subG1	   population	   (*p<0.05).	   Results	   shown	   are	   the	   mean	   +/-­‐SEM	   of	  
experiments	  performed	  in	  triplicate	  and	  repeated	  twice.	  	   	  







Figure	  3.13:	  Effect	  of	  Ang-­‐(1-­‐7)	  on	  cancer	  cell	  death.	  	  
HeLa,	  CaSki	  and	  MDA-­‐MB-­‐231	  cells	  were	  treated	  with	  1	  μM	  Ang-­‐(1-­‐7)	  for	  48	  hours	  and	  effects	  on	  cell	  
death	  investigated	  using	  the	  Annexin	  V	  assay.	  Annexin	  V	  profiles	  of	  HeLa	  (A.),	  CaSki	  (B.)	  and	  MDA-­‐
MB-­‐231	   cells	   (C.)	  with	   cells	   falling	   into	   four	  quadrants	   indicative	  of	   live	   cells,	   early	   apoptotic,	   late	  
apoptotic	   and	   necrotic	   cells	   as	   shown.	   Quantitation	   of	   Annexin	   V	   profiles	   shows	   a	   significant	  
reduction	  in	  the	  percentage	  of	  live	  cells	  and	  early	  apoptotic	  cells	  as	  well	  as	  a	  significant	  increase	  in	  
the	  percentage	  of	  late	  apoptotic	  and	  necrotic	  cells	  (*p<0.05).	  Results	  shown	  are	  the	  mean	  +/-­‐SEM	  of	  
experiments	  performed	  in	  triplicate	  and	  repeated	  twice.	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3.3	  DISCUSSION	  
	  
There	  are	  numerous	  reports	  describing	  the	  involvement	  of	  the	  ACE-­‐1	  axis	  in	  diseases	  such	  as	  
hypertension	  and	  cardiovascular	  disease.	  Our	  earlier	   results	   suggest	   that	   the	  ACE-­‐1	  axis	   is	  
functional	  in	  certain	  cancer	  cell	  lines.	  There	  is	  a	  large	  body	  of	  evidence	  supporting	  the	  role	  
of	   ACE-­‐2	   axis	   in	   disease	   and	   cancer(Ager	   et	   al.,	   2008;	   Babacan	   et	   al.,	   2015;	   Cutler,	   1999;	  
Dinh	  et	  al.,	   2001;	   Fazeli	   et	   al.,	   2012;	   Ino	  et	  al.,	   2011;	  Kuniyasu,	  2012;	  Mizuiri	   and	  Ohashi,	  
2015;	  Verma	  et	  al.,	  2012).	  Thus,	  the	  role	  of	  the	  ACE-­‐2	  axis	  and	  the	  effect	  of	  ACE-­‐2	  activation	  
on	  specific	  cancer	  cell	  lines	  were	  investigated.	  
	  
The	  hypothesis	  that	  the	  ACE-­‐2	  axis	  may	  be	  able	  to	  counter	  ACE-­‐1	  effects	  in	  cancer	  cells	  was	  
tested	  using	  Ang-­‐(1-­‐7),	  the	  ACE-­‐2	  cleavage	  product.	  Treatment	  using	  Ang-­‐(1-­‐7)	  significantly	  
reduced	   cervical	   and	   breast	   cancer	   cell	   proliferation	   and	   induced	   cancer	   cell	   death	   via	  
apoptosis	  (Figure	  3.13).	  These	  findings	  support	  the	  notion	  that	  Ang-­‐(1-­‐7)	  confers	  protection	  
against	   ACE-­‐1	   cancer-­‐promoting	   effects,	   and	   inhibits	   the	  migration	   and	   invasion	   of	   A549	  
human	   lung	  adenocarcinoma	  cells(Ni	  et	  al.,	  2012)	  The	  anti-­‐cancer	  activity	  of	  Ang-­‐(1-­‐7)	  has	  
also	  been	  described	  using	  in	  vitro	  and	  in	  vivo	  model	  systems(Feng	  et	  al.,	  2010b;	  Gallagher	  et	  
al.,	  2014;	  Ni	  et	  al.,	  2012;	  Simoes	  E	  Silva	  and	  Teixeira,	  2016)	  
	  	  
Our	  study	  suggests	  that	  endogenous	  ACE-­‐2	  levels	  and	  enzyme	  activity	  is	  low	  in	  cancer	  cells	  
and	  that	  DIZE	  treatment	  significantly	  enhances	  ACE-­‐2	  activity	   in	  cervical	  and	  breast	  cancer	  
cell	  lines.	  We	  further	  showed	  that	  cancer	  cell	  proliferation	  was	  significantly	  inhibited	  by	  the	  
ACE-­‐2	  activators	  DIZE	  and	  Ang-­‐(1-­‐7).	  This	  suggests	  that	  the	  ACE-­‐2	  even	  though	  expressed	  at	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low	  levels	  in	  cancer	  cells,	  can	  be	  activated	  using	  small	  molecules	  such	  as	  DIZE	  and	  Ang-­‐(1-­‐7)	  
leading	  to	  cancer	  cell	  death.	  	  
	  
Since	  the	  discovery	  of	  RAS	  components	  in	  cancer	  it	  has	  been	  suggested	  in	  vitro	  as	  well	  as	  in	  
animal	  models	  that	  ACE-­‐1	  via	  Ang-­‐II	  and	  AT1R	  activation	  promotes	  tumour	  growth	  through	  
cell	   proliferation,	   vascularization	   and	   metastatic	   progression	   (Du	   et	   al.,	   2012;	   Duenas-­‐
Gonzalez	  et	  al.,	  2008b;	  Kuniyasu,	  2012;	  Miyajima	  et	  al.,	  2015;	  Stevens	  et	  al.,	  2015).	  The	  well-­‐
documented	  approach	   in	  cell	   lines,	  animal	  models	  and	  patient	  studies,	  has	  been	  to	  target	  
AT1R	   activation,	   and	   this	   has	   been	   effective	   in	   cancer	   of	   the	   prostate,	   breast	   and	   colon	  
(Alhusban	   et	   al.,	   2014;	   Babacan	   et	   al.,	   2015;	   Kuniyasu,	   2012;	   Namazi	   et	   al.,	   2015).	   An	  
alternate	   approach	   is	   aimed	   at	   exploiting	   ACE-­‐2/Ang-­‐(1-­‐7).	   A	   recent	   study	   by	   (Yu	   et	   al.,	  
2016)	   reported	   that	   down-­‐regulation	   of	   the	   ACE-­‐2	   axis	   promotes	   breast	   cancer	   cell	  
metastasis	   via	   increased	   calcium	   signaling.	   For	   the	   first	   time,	  we	   have	   shown	   that	   ACE-­‐2	  
activation	   in	   cervical	   and	   breast	   cancer	   cell	   lines	   using	   DIZE,	   resulted	   in	   decreased	   cell	  
proliferation	  that	  associated	  with	  a	  G2/M	  arrest	  and	  cancer	  cell	  death	  via	  apoptosis.	  	  
	  
There	   is	   great	   interest	   in	   repurposing	   compounds	   or	   investigating	   further	   potential	  
applications	   for	  drugs	  currently	  on	  the	  market.	  For	   this	   reason,	  more	  studies	   investigating	  
the	  anti-­‐cancer	  effects	  and	  downstream	  signaling	  of	  DIZE	   is	  required.	  Despite	  potential	  off	  
target	   effects	   our	   data	   suggests	   that	   DIZE	   has	   promise	   as	   an	   anti-­‐cancer	   agent.	   No	  
pharmacokinetic	   studies	   have	   yet	   been	   reported	   for	   DIZE	   thus	   more	   investigation	   is	  
required	  into	  DIZE	  and	  structurally	  similar	  compounds.	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Taken	  together,	  the	  data	  presented	  in	  this	  chapter	  suggest	  that	  activators	  of	  the	  ACE-­‐2	  axis	  
might	   have	   therapeutic	   potential	   against	   cervical	   and	   breast	   cancer	   as	   new	   agents	   or	   in	  
combination	   treatments	  with	   current	   chemotherapeutics.	  Moreover	   ACE-­‐2	   axis	   activation	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CHAPTER	  4	  




Considerable	   efforts	   have	   been	   made	   in	   pre-­‐clinical	   laboratory	   research	   methodology	   to	  
identify	  efficacious	  treatment	  options	  for	  cancer	  patients.	  Drug	  combination	  therapies,	  new	  
drug	   delivery	   techniques,	   and	   novel	   approaches	   are	   aimed	   at	   making	   cancer	   treatments	  
more	  effective	  by	  decreasing	  side	  effects	  and	  drug	  resistance	  (Nastiuk	  and	  Krolewski,	  2016).	  
While	  solid	  tumour	  malignancies	  can	  be	  effectively	  treated	  with	  surgery	  and	  radiotherapy,	  
the	  need	   for	   effective	   treatment	  of	  metastatic	   cancers	  makes	   researching	   chemotherapy,	  
and	  in	  particular	  novel	  combination	  treatments,	  crucial	  for	  emerging	  therapeutic	  options.	  	  
	  
Cisplatin	  (CDDP)	  and	  Doxorubicin	  (DOX)	  are	  effective	  anticancer	  drugs	  and	  are	  used	  against	  
a	   wide	   variety	   of	   human	   cancers	   including	   oesophageal,	   lung,	   bladder,	   ovarian,	   cervical,	  
testicular,	   prostate,	   and	   breast	   cancer	   (Dasari	   and	   Tchounwou,	   2014;	   Dhar	   et	   al.,	   2011;	  
Goodsell,	   2006;	   Khan	   et	   al.,	   1982;	  Morris	   et	   al.,	   1992;	   Patel	   and	   Kaufmann,	   2012).	   CDDP	  
destabilizes	   DNA	   through	   intercalation	   (Dasari	   and	   Tchounwou,	   2014)	  while	   DOX	   induces	  
DNA	  damage	  through	  topoisomerase	  II	  inhibition	  and	  by	  the	  formation	  of	  free	  radicals	  (Eom	  
et	  al.,	  2005).	  While	  these	  drugs	  are	  known	  to	  induce	  apoptosis	  in	  cancer	  cells,	  drug	  resistant	  
tumours	  and	  severe	  side	  effects	  are	  common	  (Akiyama	  et	  al.,	  1999;	  Dasari	  and	  Tchounwou,	  
2014;	  Keizer	  et	  al.,	  1990;	  Patel	  and	  Kaufmann,	  2012;	  Rajeswaran	  et	  al.,	  2008).	  Due	   to	   the	  
cytotoxic	   nature	   of	   such	   drugs	   they	   are	   often	   administered	   as	   a	   combination	   treatment,	  
where	  the	  combination	  of	  different	  drugs	  can	  achieve	  a	  synergistic	  therapeutic	  effect.	  This	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allows	  for	  the	  dose	  to	  be	  lowered,	  and	  therefore	  toxicity	  minimized	  (Akiyama	  et	  al.,	  1999;	  
Apostolou	  et	  al.,	  2013;	  Ardizzoni	  et	  al.,	  1991;	  Crino	  et	  al.,	  1997;	  Judson	  et	  al.,	  2014b;	  Lee	  et	  
al.,	  2014).	  	  	  
	  
Although	  CDDP	  is	  a	  compelling	  chemotherapeutic	  drug,	   it	  has	  been	  reported	  that	  patients	  
treated	  with	   this	  drug	  may	  develop	   resistance	  or	  may	  experience	   relapse	   (Akiyama	  et	  al.,	  
1999;	   Dancey	   and	   Chen,	   2006).	   In	   order	   to	   overcome	   CDDP	   resistance	   other	   platinum	  
compounds,	  such	  as	  carboplatin,	  have	  been	  developed,	  showing	  strong	  chemotherapeutic	  
properties	  (Dasari	  and	  Tchounwou,	  2014;	  Natarajan	  et	  al.,	  1999).	  Furthermore,	  combination	  
therapies	  have	  previously	  been	  shown	  to	  be	  effective	  against	  drug	  resistance	  while	  reducing	  
the	   harmful	   side	   effects	   associated	   with	   CDDP	   (Dasari	   and	   Tchounwou,	   2014;	   Lee	   et	   al.,	  
2014;	  Morris	  et	  al.,	  1992).	  
	  
As	   with	   CDPP,	   the	   use	   of	   the	   chemotherapeutic	   agent	   DOX	   is	   limited	   by	   drug	   resistance	  
(Housman	  et	  al.,	  2014).	  When	  DOX	   is	  used	   in	  conjunction	  with	  other	  drugs,	  such	  as	  CDDP	  
and	  the	  Hsp90	  inhibitor,	  Gamitrinib,	  enhanced	  anticancer	  effects	  have	  been	  demonstrated.	  
Gamitrinib,	   together	   with	   DOX,	   reduced	   the	   growth	   of	   tumours	   in	   breast	   and	   prostate	  
cancer	   xenograft	   models	   without	   worsening	   the	   cardiotoxic	   side	   effects	   of	   DOX	  
(Dombernowsky	  et	   al.,	   1996;	  Park	  et	   al.,	   2014).	  Combined	   treatment	  of	  DOX	  with	  natural	  
compounds	  such	  as	  grape	  seed	  extract	  and	  curcumin	  analogs	  have	  been	  successful	   in	   the	  
treatment	   of	   breast	   cancer	   (Dayton	   et	   al.,	   2011;	  Notarbartolo	   et	   al.,	   2005;	   Sharma	  et	   al.,	  
2004).	   Paclitaxel,	   a	   mitotic	   inhibitor	   isolated	   from	   the	   bark	   of	   Taxus	   brevifolia,	   (the	  
northwest	  Pacific	  Yew	   tree)	  has	   successfully	  been	  used	  with	  both	  DOX	  and	  CDDP	   to	   treat	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breast,	  oesophageal	  and	  cervical	  cancer	  (Cragg,	  1998;	  Dombernowsky	  et	  al.,	  1996;	  Lee	  et	  al.,	  
2014;	  Li	  et	  al.,	  2015).	  
	  
In	   addition	   to	   standard	   chemotherapeutic	   agents,	   repurposed	   drugs	   such	   as	   ACE-­‐1	  
inhibitors,	  are	  proving	  to	  have	  potential	  valuable	  in	  combatting	  cancer.	  It	  has	  been	  reported	  
that	   ACE-­‐1	   inhibition	   results	   in	   the	   reduction	   of	   side	   effects	   caused	   by	   chronic	   DOX	   and	  
CDDP	  treatment	  in	  rats.	  One	  such	  study	  by	  (Hiona	  et	  al.,	  2011)	  showed	  that	  pre-­‐treatment	  
of	  the	  ACE-­‐1	  inhibitor,	  Enalapril,	  reduced	  DOX-­‐induced	  cardiomyopathy	  in	  rats	  through	  the	  
prevention	  of	   free	  radical	   formation	  and	  preservation	  of	  mitochondrial	   function.	  Research	  
published	   by	   Sacco	   et	   al.	   (2001;	   2009)	   showed	   that	   the	   ACE-­‐1	   inhibitor,	   Zofenopril	  
prevented	  cardiac	  injury	  without	  interfering	  with	  the	  anti-­‐tumour	  activity	  of	  DOX.	  Combined	  
treatments	   of	   ACE-­‐1	   inhibitors	   with	   CDDP	   have	   also	   been	   reported	   to	   be	   beneficial.	  
Moreover,	   a	   xenograft	   study	   by	   (El-­‐Sayed	   et	   al.,	   2008)	   demonstrated	   how	   the	   ACE-­‐1	  
inhibitor,	   Captopril,	   provided	   a	   protective	   role	   against	   CDDP-­‐induced-­‐kidney	   damage	  
through	  antioxidant	  effects	  provided	  by	  the	  drug’s	  sulfhydryl	  group.	  
	  
Earlier	  data	  in	  our	  study	  has	  shown	  that	  inhibition	  of	  the	  ACE-­‐1	  axis	  of	  the	  Renin	  Angiotensin	  
System	  (RAS)	  as	  well	  as	  activation	  of	  the	  ACE-­‐2	  axis	  results	  in	  promising	  anticancer	  effects.	  
The	   effect	   of	   combination	   treatments	   using	   CDDP	  or	  DOX	   together	  with	   inhibitors	   of	   the	  
ACE-­‐1	   axis,	   Captopril	   or	   Lisinopril,	   or	   activators	   of	   the	   ACE-­‐2	   axis,	   such	   as	   Diminazene	  
aceturate	  (DIZE)	  are	   investigated	   in	  this	  chapter	   for	  potential	  anticancer	  effects	   in	  cervical	  
and	  breast	  cancer	  cells.	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4.2	  RESULTS	  
	  
4.2.1	  Effect	  of	  combination	  treatments	  of	  DOX	  and	  ACE-­‐1	  inhibitors	  on	  cancer	  cells	  
DOX	   was	   used	   in	   combination	   with	   the	   ACE-­‐1	   inhibitors,	   Captopril	   and	   Lisinopril,	   to	  
investigate	  the	  combined	  effect	  of	  these	  drugs.	  HeLa	  and	  MDA-­‐MB-­‐231	  cells	  were	  treated	  
with	   the	   half	   maximal	   inhibitory	   concentration	   (IC50)	   of	   either	   of	   the	   ACE-­‐1	   inhibitors,	  
Captopril	   or	   Lisinopril,	   together	  with	   a	   range	   of	   concentrations	   of	  DOX	   to	   investigate	   the	  
effect	  of	  such	  combinations	  on	  the	  IC50	  of	  DOX.	  Results	  showed	  that	  the	  addition	  of	  the	  IC50	  
concentration	   of	   Captopril,	   in	   HeLa	   or	   MDA-­‐MB-­‐231	   cells,	   did	   not	   result	   in	   a	   significant	  
change	  in	  the	  IC50	  of	  DOX	  (Figure	  4.1	  A).	  Similarly,	  in	  both	  cell	  lines,	  treatment	  with	  the	  IC50	  
concentration	  of	  Lisinopril	  together	  with	  a	  range	  of	  DOX,	  resulted	  in	  no	  significant	  change	  in	  
the	  IC50	  concentration	  of	  DOX	  (Figure	  4.1	  B).	  	  
	  
	   	  






Figure	   4.1:	   Effect	   of	   ACE-­‐1	   inhibitor	   treatment	   on	  DOX	   IC50	  concentration.	   (A.)	  HeLa	  and	  
MDA-­‐MB-­‐231	  cells	  were	  treated	  with	  either	  Captopril	  or	  Lisinopril	  (B.)	  and	  the	  effect	  of	  co-­‐
treatment	   on	  DOX	   IC50	   determined	  with	   the	  MTT	   assay.	  No	   significant	   change	   in	   IC50	  was	  
observed.	  Results	  shown	  are	  the	  mean	  +/-­‐	  SEM	  of	  experiments	  performed	  in	  triplicate	  and	  
repeated	  two	  independent	  times.	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4.2.2	  Effect	  of	  combination	  treatments	  of	  CDDP	  and	  ACE-­‐1	  inhibitors	  on	  cancer	  cells	  
CDDP	  was	  used	  with	  either	  of	  the	  ACE-­‐1	  inhibitors	  and	  the	  effect	  on	  HeLa,	  CaSki	  and	  MDA-­‐
MB-­‐231	  cell	  viability	  determined	  using	  the	  MTT	  assay	  (Figures	  4.2	  and	  4.3).	  Results	  showed	  
that	  co-­‐treatment	  with	  the	  IC50	  concentration	  of	  either	  of	  the	  ACE-­‐1	  inhibitors,	  Captopril	  or	  
Lisinopril	   reduced	   the	   cell	   killing	   effect	   of	   CDDP.	   The	   IC50	   concentration	   of	   CDDP	   was	  
significantly	  increased	  from	  19	  μM	  to	  37	  μM	  in	  HeLa	  cells	  and	  from	  24	  μM	  to	  32	  μM	  in	  MDA-­‐
MB-­‐231	  cells	  when	  combined	  with	  Captopril	  (Figure	  4.2	  A).	  A	  similar	  trend	  was	  observed	  in	  
Caski	   cells,	   even	   though	   the	   change	   in	   CDDP	   IC50	   concentration	  was	  marginal,	   increasing	  
from	  13	  μM	  to	  19	  μM	  (Figure	  4.2	  A).	  This	  data	  suggests	  that	  Captopril	  reduces	  the	  sensitivity	  
of	  cancer	  cells	  to	  CDDP.	  	  
	  
In	   all	   cell	   lines	   tested,	   Lisinopril	   significantly	   increased	   the	   IC50	   of	   CDDP.	   Combined	  
treatment	  of	  Lisinopril	  increased	  the	  IC50	  of	  CDDP	  from	  18	  μM	  to	  97	  μM	  in	  HeLa	  cells,	  13	  μM	  
to	  79	  μM	  in	  CaSki	  cells	  and	  26	  μM	  to	  214	  μM	  in	  MDA-­‐MB-­‐231	  cells	  (Figure	  4.2B).	  
	  
The	  Chou	  and	  Talalay	  method	  was	  then	  used	  to	  determine	  the	  potential	  association	  of	  the	  
ACE-­‐1	   inhibitors	  with	  CDDP	   (Chou	  and	  Talalay,	  1984;	  Chou,	  2006).	  This	  method	   involves	  a	  
combination	  treatment	  of	  the	  drugs	  in	  question,	  using	  a	  constant	  ratio	  of	  drug	  A	  with	  drug	  
B.	   Together	  with	   Compusyn’s	  mathematical	   analysis,	   the	   Chou-­‐Talalay	   combination	   index	  
(CI)	  method	  allows	  for	  the	  quantitative	  determination	  of	  synergism	  (where	  CI	  <	  1),	  additivity	  
(where	  CI	  =	  1),	  and	  antagonism	  (where	  CI	  >	  1)	  in	  drug	  combinations.	  Where	  the	  Log	  (CI)	   is	  
shown	  then	  Log	  (CI)	  <	  0	  indicates	  synergism,	  Log	  (CI)	  =	  0	  indicates	  additivity,	  and	  Log	  (CI)	  >	  0	  
indicates	   antagonism.	  Where	   Log	   CI	   profiles	   are	   shown	   this	   is	   indicative	   of	   the	   degree	   of	  
antagonism	   determined	   between	   the	   two	   drugs.	   Results	   show	   that	   when	   HeLa,	   CaSki	   or	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MDA-­‐MB-­‐231	  cells	  were	  treated	  with	  CDDP	  and	  Captopril	  in	  a	  1:1	  ratio,	  i.e.	  where	  the	  IC50	  of	  
CDDP	  was	  used	  with	  the	  IC50	  of	  Captopril	  in	  a	  constant	  ratio,	  a	  reduced	  cell	  killing	  effect	  was	  
observed	  in	  each	  of	  the	  cancer	  cell	  lines	  tested	  (Figure	  4.3	  A).	  Our	  results	  suggest	  that	  CDDP	  
is	  more	  effective	  as	  a	  single	  treatment.	  Determination	  of	  the	  CI	  of	  the	  combined	  treatment	  
of	  CDDP	  with	  Captopril	  showed	  that	  there	  was	  an	  antagonistic	  association,	  where	  the	  Log	  CI	  
of	   the	   two	  drugs	  was	  greater	   than	  0,	   thus	   reducing	   the	  cell	   killing	  effect	  of	   the	  combined	  
treatment.	  This	  trend	  was	  observed	  in	  each	  of	  the	  cell	  lines	  tested	  (Figures	  4.3	  B).	  	  
	  
A	  similar	  result	  was	  observed	  in	  these	  cell	   lines	  when	  a	  combined	  treatment	  of	  CDDP	  with	  
Lisinopril	   in	   a	   1:1	   ratio	   was	   applied	   (Figure	   4.4).	   The	   combined	   treatment	   of	   CDDP	   with	  
Lisinopril	  resulted	  in	  a	  marginal	  effect	  on	  cancer	  cell	  viability	  when	  compared	  to	  CDDP	  single	  
treatment	   (Figure	   4.4	   A).	   Determination	   of	   the	   CI	   values	   for	   the	   combined	   treatment	   in	  
HeLa,	   CaSki	   and	   MDA-­‐MB-­‐231	   cells	   all	   indicated	   antagonistic	   associations	   between	   the	  
drugs	  (Figure	  4.4	  B).	  	  	  
	  
	   	  





Figure	  4.2:	  ACE-­‐1	  inhibitors	  decrease	  sensitivity	  of	  cancer	  cells	  to	  CDDP	  treatment.	  HeLa,	  
CaSki	  and	  MDA-­‐MB-­‐231	  cancer	  cells	  were	  treated	  with	  varying	  concentrations	  of	  CDDP,	  with	  
or	  without	  the	  IC50	  of	  Captopril	  (A)	  or	  Lisinopril	  (B)	  for	  48	  hours.	  A	  significant	  increase	  in	  the	  
IC50	  of	  CDDP	  was	  observed	  In	  HeLa	  and	  MDA-­‐MB-­‐231	  cell	  lines	  (*p<0.05).	  Results	  shown	  are	  
the	   mean	   +/-­‐	   SEM	   of	   experiments	   performed	   in	   triplicate	   and	   repeated	   at	   least	   two	  
independent	  times.	  	  
	   	  





Figure	  4.3:	  CDDP	  and	  CAP	  combination	  treatment	  produces	  antagonistic	  effects	  in	  cancer	  
cells.	   (A.)	   HeLa,	   CaSki	   and	   MDA-­‐MB-­‐231	   cells	   were	   treated	   with	   a	   1:1	   ratio	   of	   the	   IC50	  
concentrations	  of	  CDDP	  and	  Captopril	  and	  cell	  viability	  measured	  after	  48	  hours	  using	  the	  
MTT	  assay.	  CDDP	  as	  a	  single	  treatment	  effectively	  kills	  HeLa,	  CaSki	  and	  MDA-­‐MB-­‐231	  cancer	  
cells	   whereas	   the	   1:1	   combined	   treatment	   of	   CDDP	   with	   Captopril	   results	   in	   a	   poorer	  
reduction	   in	   the	   cell	   viability	   of	   treated	   cells	   (B.)	   The	   CI	   for	   1CDDP:1Captopril	   was	  
determined	  and	  suggests	  an	  antagonistic	  effect	  (LogCI	  >0)	   in	  these	  cell	  lines.	  Results	  shown	  
are	   the	  mean	   +/-­‐	   SEM	   of	   experiments	   performed	   in	   triplicate	   and	   repeated	   at	   least	   two	  
independent	  times.	  
	   	  








Figure	   4.4:	  CDDP	   and	   Lisinopril	   combination	   treatment	   produces	   antagonistic	   effects	   in	  
cancer	  cells.	  (A.)	  HeLa,	  CaSki	  and	  MDA-­‐MB-­‐231	  cells	  were	  treated	  with	  a	  1:1	  ratio	  of	  the	  IC50	  
concentrations	  of	  CDDP	  and	  Lisinopril	  and	  cell	  viability	  measured	  after	  48	  hours	  using	   the	  
MTT	  assay.	  The	  1:1	  combined	  treatment	  results	  in	  a	  marginal	  reduction	  in	  cell	  viability	  when	  
compared	   to	   CDDP	   single	   treatment	   (B.)	   The	   CI	   for	   CDDP:Lisinopril	   was	   determined	   and	  
shows	  a	  predominantly	  antagonistic	  effect	   (CI>1)	   in	  these	  cell	   lines.	  Results	  shown	  are	  the	  
mean	   +/-­‐	   SEM	   of	   experiments	   performed	   in	   triplicate	   and	   repeated	   at	   least	   two	  
independent	  times.	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To	  support	  the	  findings	  that	  the	  combined	  treatments	  of	  CDDP	  with	  Captopril	  or	  Lisinopril	  
reduced	   sensitivity	   of	   cancer	   cells	   to	   CDDP,	   the	   effect	   of	   these	   combined	   treatments	   on	  
cancer	   cell	   death	   was	   investigated	   using	   the	   Annexin	   V	   assay.	   Annexin	   V	   profiles	   of	   a	  
representative	  experiment	  show	  that	  in	  HeLa	  cells	  the	  combination	  of	  CDDP	  together	  with	  
Captopril	   reduced	   the	   ability	   of	   CDDP	   to	   kill	   cancer	   cells,	   making	   the	   combination	   less	  
effective	  than	  a	  single	  treatment	  of	  CDDP	  alone	  (Figure	  A.2,	  Appendix	  I).	  The	  percentage	  live	  
cells	   increased	  from	  60.2%	  to	  97.9	  %	  when	  Captopril	  was	  combined	  with	  CDDP	  (Figure	  4.5	  
A).	  The	  Annexin	  V	  profile	  of	  Captopril	  single	  treatment	  (Figure	  A.2,	  Appendix	  I)	  showed	  that	  
there	  was	  a	  small,	  but	  significant	  effect	  on	  cancer	  cell	  death	  as	  12.8%	  of	  cells	  were	  either	  
apoptotic	  or	  necrotic	  after	  treatment	  (Figure	  A.2,	  Appendix	  I).	  
	  
Similarly	   in	   CaSki	   cells,	   Annexin	   V	   profiles	   of	   the	   single	   treatments	   of	   CDDP	   or	   Captopril,	  
compared	  to	  the	  combined	  treatment	  of	  the	  two	  drugs,	  show	  that	  a	  greater	  percentage	  of	  
cells	  were	  undergoing	  apoptosis	  or	  necrosis	  (Figure	  A.3,	  Appendix	  I).	  The	  percentage	  of	  live	  
cells	  after	  treatment	  with	  both	  drugs	  was	  observed	  as	  being	  98.3%	  whereas	  only	  76.2%	  live	  
cells	  remained	  after	  Captopril	  single	  treatment	  and	  58	  %	  after	  CDDP	  treatment	  (Figure	  4.5	  
B).	  A	  similar	  result	  can	  be	  seen	  in	  MDA-­‐MB-­‐231	  breast	  cancer	  cells	  (Figure	  A.4,	  Appendix	  I;	  
Figure	  4.5	  C).	  
	  
Similar	   results	   were	   observed	   after	   combined	   treatments	   of	   CDDP	   with	   Lisinopril	   in	   the	  
cancer	   cell	   lines.	   Annexin	   V	   profiles	   show	   that	   combined	   treatment	   in	   HeLa	   cells	   did	   not	  
result	   in	  a	  cell	  killing	  effect	  (Figure	  4.6	  A).	  The	  Annexin	  V	  profile	  of	  cells	  treated	  with	  both	  
CDDP	   and	   Lisinopril	   appear	   similar	   to	   that	   of	   the	   control	   cells,	   whereas	   profiles	   of	   cells	  
treated	  with	  either	  of	  the	  single	  agents	  show	  that	  there	  was	  an	  increase	  in	  the	  percentage	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of	  apoptotic	  and	  necrotic	  cells	  and	  thus	  a	  decrease	  in	  the	  percentage	  of	  live	  cells	  (Figure	  A.5,	  
Appendix	  I).	  	  
	  
In	  CaSki	  cells	  treatment	  of	  both	  CDDP	  and	  Lisinopril	  showed	  similar	  results	  to	  that	  of	  HeLa	  
cells	   and	  Annexin	   V	   profile	   of	   both	   drugs	   showed	   no	   significant	   difference	   to	   that	   of	   the	  
untreated	   sample	   (Figure	   A.6,	   Appendix	   I).	   Quantitation	   of	   each	   of	   the	   single	   treatments	  
however,	   showed	   a	   significant	   reduction	   in	   the	   percentage	   live	   cells	   and	   a	   significant	  
increase	   in	  cells	  undergoing	  cell	  death	  (Figure	  4.6	  B).	  A	  similar	  result	  can	  be	  seen	  in	  MDA-­‐
MB-­‐231	  breast	  cancer	  cells	  (Figure	  A.7,	  Appendix	  I;	  Figure	  4.6	  C).	  
	  
While	  the	  preliminary	  data	  presented	  here	  requires	  further	  validation,	  results	  suggest	  that	  
combination	  treatments	  of	  CDDP	  with	  the	  ACE-­‐1	  inhibitors,	  Captopril	  and	  Lisinopril,	  may	  not	  
have	  beneficial	  effects	  in	  the	  treatment	  of	  cancer.	  Such	  results	  may	  have	  future	  implications	  
for	   example,	   patients	   on	   ACE-­‐1	   inhibitors	   who	   develop	   cancer.	   Results	   presented	   in	   this	  
chapter	   suggest	   that	   it	  may	   not	   be	   a	   good	   approach	   to	   treat	   cancer	   patients	  with	   CDDP	  
while	  they	  are	  on	  ACE-­‐1	  inhibitors.	  	  	  	  
	  
	   	  





Figure	   4.5.	   The	   effect	   of	   CDDP	   and	   Captopril	   combined	   treatment	   on	   cancer	   cell	   death	  
using	  the	  Annexin	  V	  assay.	  HeLa	  (A.),	  CaSki	  (B.)	  and	  MDA-­‐MB-­‐231	  (C.)	  cells	  were	  treated	  with	  the	  
IC50	  concentrations	  of	  CDDP	  and	  Captopril	  for	  48	  hours	  and	  effects	  on	  cell	  death	  investigated	  using	  
the	  Annexin	   V	   assay.	  Quantitation	   of	   Annexin	   V	   profiles	   showing	   that	   the	   combination	   treatment	  
results	  in	  no	  significant	  effect	  on	  cancer	  cell	  death.	  CDDP	  and	  Captopril	  single	  treatments	  showed	  a	  
significant	   increase	   in	  the	  percentage	  of	   late	  apoptotic	  and	  necrotic	  cells	   (*p<0.05).	  Results	  shown	  
are	  the	  mean	  +/-­‐SEM	  of	  experiments	  performed	  in	  triplicate	  and	  repeated	  twice.	  	   	  






Figure	   4.6.	   The	   effect	   of	   CDDP	   and	   Lisinopril	   combined	   treatment	   on	   cancer	   cell	   death	  
using	  the	  Annexin	  V	  assay.	  HeLa	  (A.),	  CaSki	  (B.)	  and	  MDA-­‐MB-­‐231	  (C.)	  cells	  were	  treated	  with	  the	  
IC50	  concentrations	  of	  CDDP	  and	  Lisinopril	   for	  48	  hours	  and	  effects	  on	  cell	  death	  investigated	  using	  
the	  Annexin	  V	  assay.	  Quantitation	  of	  Annexin	  V	  profiles	  showing	  no	  significant	  effect	  on	  cancer	  cell	  
death.	   CDDP	   and	   Lisinopril	   single	   treatments	   showed	   a	   significant	   reduction	   in	   live	   cells	   and	   a	  
significant	   increase	   in	  the	  percentage	  of	   late	  apoptotic	  and	  necrotic	  cells	   (*p<0.05).	  Results	  shown	  
are	  the	  mean	  +/-­‐SEM	  of	  experiments	  performed	  in	  triplicate	  and	  repeated	  twice.	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4.2.3	   Combined	   treatments	   of	   chemotherapeutic	   drugs,	   CDDP	   and	   DOX,	   with	   ACE-­‐2	  
activator,	  DIZE	  
	  
4.2.3.1	  Investigating	  the	  effects	  of	  CDDP	  and	  DIZE	  combined	  treatment	  in	  cancer	  cells	  
	  
The	   previous	   chapter	   provided	   evidence	   showing	   that	   DIZE	   has	   anticancer	   properties,	  
significantly	  reducing	  cervical	  and	  breast	  cancer	  cell	  proliferation	  via	  a	  G2/M	  block	  in	  the	  cell	  
cycle.	  Here	  we	  investigate	  the	  effects	  of	  combination	  treatment	  of	  DIZE	  with	  CDDP	  and	  DOX	  
on	  cancer	  cells.	  
	  
HeLa,	  CaSki	  and	  MDA-­‐MB-­‐231	  cells	  were	  treated	  with	  CDDP	  and	  the	   IC50	  concentration	  of	  
DIZE	   for	  48	  hours	   in	  order	   to	  determine	   if	   the	  activation	  of	   the	  ACE-­‐2	  axis	   in	   conjunction	  
with	  a	  chemotherapeutic	  agent	  such	  as	  CDDP	  could	  produce	  an	  enhanced	  cell	  killing	  effect.	  
Activation	  of	   the	  ACE-­‐2	  axis	  with	  DIZE	   treatment	   in	   all	   three	   cell	   lines	  did	  not	   alter	  CDDP	  
cytotoxicity,	  as	  no	  significant	  change,	  positive	  or	  negative,	  in	  the	  IC50	  concentration	  of	  CDDP	  
was	  observed	  (Figure	  4.7).	  	  
	   	  











Figure	  4.7:	  Effect	  of	  DIZE	  treatment	  on	  CDDP	  IC50	  concentrations	   in	  cancer	  cell	   lines.	   (A.)	  
HeLa,	   CaSki	   and	   MDA-­‐MB-­‐231	   cancer	   cells	   were	   treated	   with	   varying	   concentrations	   of	  
CDDP,	  with	  or	  without	  the	  IC50	  concentration	  of	  DIZE,	  for	  48	  hours.	  The	  IC50	  concentration	  of	  
CDDP	  as	  a	  single	  treatment	  as	  well	  as	  with	  DIZE	  was	  determined	  using	  the	  MTT	  assay.	  No	  
change	   in	   the	   IC50	   concentration	   of	   CDDP	  was	   observed	   in	   any	   of	   the	   cell	   lines	   (*p<0.05).	  
Results	  shown	  are	  the	  mean	  +/-­‐	  SEM	  of	  experiments	  performed	  in	  triplicate	  and	  repeated	  
twice.	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4.2.3.2	  Investigating	  the	  effects	  of	  DOX	  and	  DIZE	  combined	  treatment	  in	  cancer	  cells	  
	  
The	  combined	  treatment	  of	  DOX	  with	  DIZE	  was	  next	  investigated	  in	  HeLa,	  CaSki	  and	  MDA-­‐
MB-­‐231	   cells.	   Results	   show	   that	   DIZE	   had	   a	   dramatic	   effect	   on	   the	   IC50	   concentration	   of	  
DOX,	  significantly	  reducing	  the	  required	  concentration	  of	  DOX	  to	  kill	  50	  %	  of	  cells,	  from	  the	  
micromolar	  to	  nanomolar	  range	  (Figure	  4.8).	  The	   IC50	  concentration	  of	  DOX	  changed	  from	  
1.8	  μM,	  2.6	  μM	  and	  2.7	  μM	  to	  24	  nM,	  39	  nM	  and	  44	  nM	  for	  HeLa,	  CaSki	  and	  MDA-­‐MB-­‐231	  
cells,	  respectively	  (Table	  4.1).	  This	  significant	  decrease	  in	  the	  IC50	  of	  DOX	  suggests	  that	  DOX	  
and	   DIZE	  may	   use	   similar	  mechanisms	   of	   action,	   or	   alternatively,	   synergistic	  mechanisms	  
resulting	  in	  enhanced	  cell	  death.	  	  
	   	  














Figure	  4.8:	  Effect	  of	  DIZE	  treatment	  on	  DOX	  IC50	  concentrations	  in	  cancer	  cell	   lines	  HeLa,	  
CaSki	  and	  MDA-­‐MB-­‐231	  cancer	  cells	  were	  treated	  with	  varying	  concentrations	  of	  DOX,	  with	  
or	  without	  the	  IC50	  concentration	  of	  DIZE,	  for	  48	  hours.	  The	  IC50	  concentration	  of	  DOX	  as	  a	  
single	   treatment	   as	  well	   as	  with	   DIZE	  was	   determined	   using	   the	  MTT	   assay.	   A	   significant	  
reduction	   in	   the	   IC50	   concentration	   of	   DOX	   was	   observed	   across	   all	   of	   the	   cell	   lines	  
(*p<0.05).	  Results	  shown	  are	  the	  mean	  +/-­‐	  SEM	  of	  experiments	  performed	  in	  triplicate	  and	  
repeated	  three	  independent	  times.	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Table	  4.1.	  IC50	  concentrations	  determined	  for	  DOX	  and	  the	  combined	  treatment	  of	  DOX	  







A	   strong	   reduction	   in	   DOX	   IC50	   concentration	   was	   observed	   in	   HeLa	   and	   CaSki,	   cervical	  
cancer	  cells	  and	  MDA-­‐MB-­‐231,	  breast	  cancer	  cells.	  Results	  shown	  are	  the	  mean	  +/-­‐	  SEM	  of	  
experiments	  performed	  in	  triplicate	  and	  repeated	  three	  independent	  times.	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To	  quantitatively	   analyse	   the	  dose-­‐effect	   relationships	  which	  may	   exist	  when	   cancer	   cells	  
are	   treated	   with	   DOX	   and	   DIZE	   in	   both	   the	   1DOX:1DIZE	   (Table	   A.1,	   Appendix	   II)	   and	  
1DOX:3DIZE	   (Table	   A.2,	   Appendix	   II)	   treatment	   ratios,	   the	   Chou-­‐Talalay	   constant	   ratio	  
method	  and	  Compusyn	   software	  were	  used.	   The	   Log	   combination	   index	   (LogCI)	   values	  of	  
the	   fractions	   of	   cells	   affected	   by	   DOX	   and	   DIZE	   treatment	   suggest	   whether	   potential	  
associations	  exist	  between	  the	  two	  drugs	  where	  (LogCI	  >0	  is	  indicative	  of	  antagonism,	  LogCI	  
<0	   of	   synergism,	   and	   LogCI=	   0	   an	   additive	   association	   between	   the	   drugs	   in	   question).	  
Results	  show	  that	  75%	  of	  HeLa	  cells,	  80%	  of	  MDA-­‐MB-­‐231	  cells	  and	  97%	  of	  CaSki	  cells	  were	  
affected	   through	   a	   synergistic	   association	   between	   DOX	   and	   DIZE	   when	   treated	   in	   a	  
1DOX:1DIZE	  ratio	  of	  the	  respective	  IC50	  concentrations	  (Figure	  4.9A).	  
	  
When	  cells	  were	  treated	  with	  a	  1DOX:3DIZE	  treatment	  results	  showed	  a	  more	  even	  spread	  
of	  data	  with	  a	   similar	   trend	  moving	   toward	   synergism.	  Results	   showed	   that	  65%	  of	  MDA-­‐
MB-­‐231	   cells,	   75%	   of	   CaSki	   cells	   and	   90%	   of	   HeLa	   cells	   were	   sensitive	   to	   the	   combined	  
treatment	  due	  to	  a	  synergistic	  association	  between	  the	  drugs	   (Figure	  4.9	  B).	  This	  suggests	  
that	  HeLa	  cells	  are	  more	  sensitive	  to	  a	  higher	  dose	  of	  both	  DOX	  and	  DIZE	  whereas	  slightly	  
lower	  concentrations	  of	  DIZE	  are	  required	  to	  have	  a	  more	  substantial	  overall	  effect	  on	  CaSki	  
and	  MDA-­‐MB-­‐231	  cells.	  	  
While	   DOX	   is	   a	   potent	   anticancer	   drug	   on	   its	   own,	   the	   combined	   use	   with	   the	   ACE-­‐2	  
activator	  DIZE	  provides	  a	  greater	  cell	  killing	  effect.	  Preliminary	  results	  presented	  here	  show	  
that	  further	  investigations	  into	  the	  overall	  effects	  on	  cancer	  cells,	  such	  as	  CaSki	  or	  MDA-­‐MB-­‐
231	  cells,	  require	  lower	  concentrations	  of	  DIZE	  to	  be	  used	  in	  co-­‐treatments	  with	  DOX.	  	   	  








Figure	   4.9:	   Combination	   index	   for	   combined	   treatments	   of	   DOX	   and	  DIZE	   in	   cancer	   cell	  
lines.	  HeLa,	  CaSki	  and	  MDA-­‐MB-­‐231	  cells	  were	  treated	  with	  a	  constant	  ratio	  of	  1DOX:1DIZE	  
or	   1DOX:3DIZE	   ratio	   for	   48	   hours.	   Thereafter	   combination	   indices	   were	   calculated	   using	  
Compusyn	   analysis.	   Results	   shown	   are	   the	   mean	   +/-­‐	   SEM	   of	   experiments	   performed	   in	  
triplicate	  and	  repeated	  two	  independent	  times.	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4.2.3.3	   Effect	   of	   combined	  DOX	  and	  DIZE	   treatment	  on	   cancer	   cell	  morphology	   and	   cell	  
cycle	  progression	  
	  
Whist	  monitoring	   the	  DOX	  with	  DIZE	  co-­‐treatments	  using	  phase	  microscopy,	  we	  observed	  
changes	   in	   HeLa	   and	   CaSki	   cell	  morphology.	   Cells	   treated	  with	   the	   DOX	   single	   treatment	  
were	   adherent	   and	   appeared	   to	   be	   flatter	   and	   larger	   in	   size	   compared	   to	   control	   cells	  
(Figure	  4.10	  A).	  Many	  of	  the	  DIZE	  treated	  cells	  were	  still	  adherent,	  and	  those	  which	  were,	  
appeared	  rounded	  and	  smaller	  in	  size	  compared	  to	  control	  cells.	  In	  addition,	  many	  floating	  
clumps	   of	   cells	   could	   be	   seen	   suggestive	   of	   cell	   death.	  Observations	   of	   cells	   treated	  with	  
DOX	  and	  DIZE	  combined	  treatment	  showed	  very	  few	  adherent	  cells	  and	  clumps	  of	  rounded	  
cells	  and	  floating	  cells	  were	  observed	  (Figure	  4.10	  A).	  Similar	  results	  could	  be	  seen	  for	  CaSki	  
cells	  (Figure	  4.10	  B).	  Cells,	  which	  lose	  their	  ability	  to	  be	  adherent	  are	  often	  cells	  undergoing	  
cell	   death	  processes	   and	  while	   those	   that	  have	  a	  more	   rounded	  or	   flattened	  morphology	  
suggests	  changes	  in	  cell	  cycle	  progression.	  	  
	  
Possible	  explanations	  for	  rounded	  cells	  are	  that	  cells	  are	  entering	  G2/M	  arrest	  or	  becoming	  
apoptotic,	  while	  a	   flattened	  cytoplasm	  with	  a	   large	  nucleus	  usually	  appearing	   like	  a	  “fried	  
egg”	   could	  be	   indicative	  of	   senescence	  or	   a	  G1/S	   arrest.	   These	  observations	  of	   change	   in	  
morphology	   support	   our	   earlier	   evidence	   that	   DIZE	   treatment	   results	   in	   a	   G2/M	   block	   in	  
cancer	  cells	  as	  well	  as	  causes	  death.	  Furthermore,	  it	  is	  well	  known	  that	  treatments	  using	  low	  
concentrations	   of	   DOX	   result	   in	   the	   induction	   of	   senescence	   in	   cells	   (Altieri	   et	   al.,	   2012;	  
Chang	  et	  al.,	  1999;	  Eom	  et	  al.,	  2005;	  Ewald	  et	  al.,	  2010;	  Roninson,	  2003).	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These	  observations	  suggest	  that	  both	  HeLa	  and	  CaSki	  cells	  exposed	  to	  combined	  treatment	  
of	  IC50	  concentrations	  of	  DOX	  and	  DIZE	  become	  increasingly	  sensitive	  to	  DOX	  treatment	  as	  
fewer	   cells	  were	   adherent	   and	   showed	   signs	  of	   healthy	  morphology.	   Increased	   cell	   death	  
was	  observed	  with	  both	  cell	  lines.	  	  	  
	   	  




Figure	   4.10:	  Morphology	   of	   cancer	   cells	   is	   affected	   by	   combined	   treatment	   of	  DOX	   and	  
DIZE.	   (A.)	   Combined	   DOX	   with	   DIZE	   treatment	   in	   HeLa	   and	   (B)	   CaSki	   cells	   affects	   cell	  
morphology.	  An	  increase	  in	  rounded	  and	  apoptotic	  cells	  as	  well	  as	  senescent	  appearing	  cells	  
were	   observed	   after	   48	   hour	   co-­‐treatment.	   Results	   shown	   are	   representative	   of	  
experiments	  performed	  in	  triplicate	  and	  repeated	  two	  independent	  times.	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Since	   the	   combination	   treatment	   was	   observed	   to	   significantly	   inhibit	   cancer	   cell	  
proliferation	  and	  affect	  morphology,	  the	  effect	  of	  the	  co-­‐treatment	  on	  cell	  cycle	  progression	  
as	   well	   as	   the	   ability	   of	   HeLa,	   CaSki	   and	   MDA-­‐MB-­‐231	   cancer	   cells	   to	   form	   clonogenic	  
colonies	  were	  evaluated	  next.	  	  
	  
For	   cell	   cycle	   analysis,	   HeLa	   and	   CaSki	   cells	   were	   treated	   with	   the	   IC50	   of	   DIZE	   and	   the	  
reduced	  dose	  of	  DOX,	  which	  showed	  efficacy	  in	  combination	  (Figure	  4.11).	  The	  DOX	  dose	  in	  
HeLa	  and	  CaSki	  cells	  was	  24nM	  and	  39nM,	  respectively.	  Cells	  were	  co-­‐treated	  for	  48	  hours	  
and	  cell	  cycle	  analysis	  performed	  on	  the	  BD	  Accuri	  C6	   flow	  cytometer.	  DIZE	  single	  treated	  
HeLa	  cells	  had	  an	  increase	  in	  the	  G2/M	  phase	  of	  the	  cell	  cycle	  (Figure	  4.11	  A),	  supporting	  the	  
rounded	   morphology	   observed	   under	   the	   microscope.	   In	   DOX	   single	   treated	   cells,	   an	  
increase	   in	  the	  subG1	  and	  G1	  phases	  of	  the	  cell	  cycle	  were	  observed	  compared	  to	  control	  
cells.	   Results	   using	   the	   combination	   treatment	   conditions	   show	   an	   increase	   in	   the	   subG1	  
and	  G1	  phases	  of	  the	  cell	  cycle.	  	  
	  
In	  CaSki	  cells	  a	  similar	  trend	  was	  seen	  after	  the	  treatments.	  Compared	  to	  control	  cells	  DOX	  
treated	  cells	  showed	  an	  increase	  in	  subG1	  and	  G1	  phases	  of	  the	  cell	  cycle	  while	  DIZE	  treated	  
cells	  showed	  an	  increase	  in	  G2/M	  and	  subG1	  cell	  cycle	  phases	  (Figure	  4.11	  B).	  Cells	  treated	  
with	  the	  combined	  treatment	  of	  DOX	  and	  DIZE	  showed	  an	  increase	  in	  subG1	  and	  G1	  phases.	  
Taken	   together	   these	   results	   show	   that	   the	   combined	   treatment	   of	   DOX	   and	   DIZE	   alter	  
cancer	  cell	  morphology,	  which	  associates	  with	  a	  delay	  in	  G1/S	  transtion.	   	  






Figure	  4.11:	  Cell	  cycle	  analysis	  of	  HeLa	  and	  CaSki	  cells	  after	  co-­‐treatment	  of	  DOX	  and	  DIZE.	  
(A.)	  HeLa	  cells	  were	  treated	   for	  48	  hours	  with	   IC50	  of	  DOX	  and	  24nM	  DIZE.	   (B.)	  CaSki	  cells	  
were	  treated	  with	  the	  IC50	  of	  DOX	  	  and	  39	  nM	  DIZE.	  Cell	  cycle	  analysis	  was	  performed	  the	  
following	   day.	   Co-­‐treatment	   of	  DOX	   and	  DIZE	   results	   in	   an	   increase	   in	   the	   subG1	   and	  G1	  
populations	  of	   cells	   in	  both	  HeLa	  and	  CaSki	   cells.	  Results	   shown	  are	   the	  mean	  +/-­‐	  SEM	  of	  
experiments	  performed	  in	  triplicate	  and	  repeated	  two	  independent	  times.	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4.2.3.4	  Effect	  of	  combined	  DOX	  and	  DIZE	  treatment	  on	  cancer	  cell	  clonogenic	  ability	  
	  
To	  determine	  the	  clonogenic	  ability	  of	  cancer	  cells	  after	  co-­‐treatment	  the	  clonogenic	  colony	  
forming	  assay	  was	  performed.	  Cells	  treated	  with	  the	  IC50	  concentration	  of	  DIZE	  were	  unable	  
to	  form	  colonies.	  Hence	  a	  lower	  concentration	  (½	  the	  IC50	  concentration)	  of	  DIZE	  was	  used	  
in	  this	  experiment.	  Cells	  were	  treated	  with	  either	  ½	  the	  IC50	  concentration	  of	  DIZE,	  the	  IC50	  
concentration	   of	   DOX,	   or	   a	   combination	   of	   both,	   and	   clonogenic	   colony	   formation	  
monitored	   for	   10	   days.	   Results	   showed	   that	   in	   all	   of	   the	   cell	   lines	   DOX	   and	   DIZE	   co-­‐
treatment	   reduced	   the	   number	   of	   clonogenic	   colonies	   able	   to	   survive	   by	   nearly	   100-­‐fold,	  
compared	   to	  either	   treatment	  alone	   for	  HeLa	   (Figure	  4.12),	  CaSki	   (Figure	  4.13)	  and	  MDA-­‐
MB-­‐231	  cells	  (Figure	  4.14).	  	  
	  
DOX	  and	  DIZE	  in	  combination	  (1/2	  IC50	  DIZE	  with	  DOX)	  was	  effective	  in	  reducing	  the	  number	  
of	   clonogenic	   HeLa	   (Figure	   4.12	   A	   and	   B),	   CaSki	   (Figure	   4.13	   A	   and	   B)	   or	   MDA-­‐MB-­‐231	  
(Figure	  4.14	  A	  and	  B)	  colonies	  able	  to	  survive	  after	  10	  days,	  even	  more	  so	  than	  the	  single	  
treatment	  of	  either	  drug.	  This	  data	  shows	  that	  DIZE	  enhances	  DOX	  cytotoxicity	  reducing	  the	  
ability	  of	  cancer	  cells	  to	  form	  clonogenic	  colonies.	  
	  	   	  














Figure	  4.12:	  DOX	  and	  DIZE	  co-­‐treatment	  reduces	  the	  clonogenic	  ability	  of	  HeLa	  cells.	  	  (A.)	  
HeLa	  cells	  were	   treated	  once	  off	  with	  ½	   IC50	  DIZE	  and	  clonogenic	  ability	  monitored	   for	  10	  
days.	   Thereafter	   colonies	   were	   stained	   with	   crystal	   violet	   and	   colonies	   quantified	   with	  
ImageJ	  (B.).	  The	  percentage	  survival	  fraction	  is	  indicated	  in	  the	  bar	  graphs	  for	  the	  treatment	  
conditions.	   Results	   shown	   are	   representative	   of	   experiments	   performed	   in	   triplicate	   and	  
repeated	  two	  independent	  times.	  	  	  
	   	  












Figure	  4.13:	  DOX	  and	  DIZE	  co-­‐treatment	  reduces	  the	  clonogenic	  ability	  of	  CaSki	  cells.	  (A.)	  
CaSki	  cells	  were	  treated	  once	  off	  with	  the	   IC50	  DOX	  and	  ½	   IC50	  DIZE	  and	  clonogenic	  ability	  
monitored	   for	   10	   days.	   Thereafter	   colonies	   were	   stained	  with	   crystal	   violet	   and	   colonies	  
quantified	  with	  ImageJ	  (B.)	  The	  percentage	  survival	  fraction	  is	  indicated	  in	  the	  bar	  graphs	  for	  
the	   treatment	   conditions.	   Results	   shown	   are	   representative	   of	   experiments	   performed	   in	  
triplicate	  and	  repeated	  two	  independent	  times.	  	  	  
	   	  






Figure	   4.14:	  DOX	  and	  DIZE	   co-­‐treatment	   reduces	   the	   clonogenic	   ability	   of	  MDA-­‐MB-­‐231	  
cells.	  	  (A.)	  MDA-­‐MB-­‐231	  cells	  were	  treated	  once	  off	  with	  the	  IC50	  of	  DOX	  and	  ½	  IC50	  of	  DIZE	  
and	  clonogenic	  ability	  monitored	  for	  10	  days.	  Thereafter	  colonies	  were	  stained	  with	  crystal	  
violet	  and	  colonies	  quantified	  with	   ImageJ	   (B.).	  Percentage	  survival	   fraction	   is	   indicated	   in	  
the	   bar	   graphs	   for	   the	   treatment	   conditions.	   Results	   shown	   are	   representative	   of	  
experiments	  performed	  in	  triplicate	  and	  repeated	  two	  independent	  times.	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4.2.3.5	   DOX	   and	  DIZE	   combined	   treatment	   results	   in	   increased	   cell	   death	   via	   apoptosis	  
and	  necrosis	  
	  
To	  investigate	  the	  effect	  of	  the	  combined	  treatment	  of	  DOX	  and	  DIZE	  on	  cancer	  cell	  death,	  
the	  Annexin	  V	  assay	  was	   then	  used.	  HeLa	   (Figure	  4.15	  A),	  CaSki	   (Figure	  4.15	  B)	  and	  MDA-­‐
MB-­‐231	   cells	   (Figure	   4.15	   C)	  were	   treated	  with	   either	   the	   IC50	   concentration	   of	  DIZE,	   the	  
lower,	  nanomolar	  concentration	  of	  DOX	  (being	  24	  nM,	  39	  nM	  and	  44nM	  for	  HeLa,	  CaSki	  and	  
MDA-­‐MB-­‐231	  cells,	  respectively),	  or	  the	  combination	  of	  DIZE	  and	  DOX.	  Annexin	  V	  results	  of	  
DIZE	  treated	  HeLa	  cells	  show	  that	  the	  percentage	  live	  cells	  decreased	  from	  88.8%	  in	  control	  
cells	  to	  61.5%,	  and	  to	  57.8	  %	  in	  combined	  DOX	  and	  DIZE	  treated	  cells	  (Figure	  4.15	  A).	  Since	  
the	  DOX	  concentration	  was	  now	  lower,	  the	  percentage	  live	  cells	  in	  the	  DOX	  treated	  sample,	  
was	   now	   comparable	   to	   that	   in	   the	   control.	   Quantifying	   the	   percentage	   cells	   in	   each	  
quadrant	  of	  the	  Annexin	  V	  profile	  results	  show	  after	  DIZE	  treatment	  there	  was	  a	  significant	  
decrease	  in	  percentage	  live	  cells,	  with	  a	  significant	  increase	  in	  the	  percentage	  necrotic	  cells.	  
No	   significant	   change	   in	   cells	   was	   seen	   using	   a	   DOX	   single	   treatment	   at	   the	   lowered	  
concentration.	  The	  Annexin	  V	  profiles	  of	  HeLa	   treated	  cells	   show	  a	  significant	  decrease	   in	  
the	   percentage	   live	   cells	   was	   observed	   in	   combination	   treatment	   of	   DOX	   and	   DIZE	  
accompanied	   by	   a	   significant	   increase	   in	   late	   apoptotic	   and	   necrotic	   cells	   (Figure	   4.15	   A,	  
Figure	  A.8,	  Appendix	  III).	  	  
	  
The	  Annexin	  V	  profiles	  of	  CaSki	  cells	  showed	  that	  DIZE	  treatment	  reduced	  the	  percentage	  of	  
live	   cells	   and	   a	   greater	   scatter	   of	   cells	   in	   the	   quadrants	   representative	   of	   apoptotic	   and	  
necrotic	   processes	   were	   observed	   (Figure	   4.15	   B,	   Figure	   A.9,	   Appendix	   III).	   Annexin	   V	  
profiles	   of	   DOX	   and	   DIZE	   treated	   cells	   showed	   fewer	   cells	   in	   the	   lower	   left	   quadrant	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representative	   of	   live	   cells	  with	   a	   significant	   increase	   in	   the	   percentage	   of	   apoptotic	   and	  
necrotic	  cells	  (Figure	  A.9,	  Appendix	  III).	  
	  
A	   similar	   observation	  was	   found	   in	  MDA-­‐MB-­‐231	   cells	  where	  DIZE	   treatment	   significantly	  
reduced	  the	  percentage	  live	  cells	  compared	  to	  the	  untreated	  (Figure	  4.15	  C).	  The	  Annexin	  V	  
profiles	   of	   DOX	   and	   DIZE	   treated	   cells	   showed	   fewer	   cells	   in	   the	   lower	   left	   quadrant	  
representative	  of	  live	  cells	  with	  a	  significant	  increase	  in	  the	  percentage	  of	  late	  apoptotic	  and	  
necrotic	  cells	  (Figure	  A.10,	  Appendix	  III).	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Figure	  4.15:	  The	  effect	  of	  DOX	  and	  DIZE	  combined	  treatment	  on	  cancer	  cell	  death	  using	  
the	  Annexin	  V	  assay.	  HeLa	  (A.),	  CaSki	  (B.)	  and	  MDA-­‐MB-­‐231	  (C.)	  cells	  were	  treated	  with	  the	  IC50	  
concentrations	  of	  DOX	  and	  DIZE	  for	  48	  hours	  and	  effects	  on	  cell	  death	  investigated	  using	  the	  
Annexin	   V	   assay.	   Quantitation	   of	   the	   respective	   Annexin	   V	   profiles	   shows	   a	   significant	  
reduction	   in	   the	   percentage	   of	   live	   cells	   and	   a	   significant	   increase	   in	   late	   apoptotic	   and	  
necrotic	  cells	  compared	  to	  untreated	  cells	  (*p<0.05).	  Results	  shown	  are	  the	  mean	  +/-­‐	  SEM	  
of	  experiments	  performed	  in	  triplicate	  and	  repeated	  twice.	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To	  further	  investigate	  the	  effect	  of	  DIZE	  and	  DOX	  combined	  treatment	  on	  HeLa	  cell	  death,	  
western	   blot	   analysis	   was	   performed	   to	   determine	   PARP	   cleavage	   as	   an	   indicator	   of	   cell	  
death	   via	   apoptosis.	   Results	   show	   an	   induction	   of	   PARP	   cleavage	   after	   the	   combination	  
treatment,	   which	   is	   more	   pronounced	   when	   compared	   to	   either	   DIZE	   or	   DOX	   single	  
treatments	  (Figure	  4.16).	  This	  confirms	  the	  elevated	  level	  of	  apoptosis	  after	  DIZE	  and	  DOX	  
combined	  treatment.	  	  
	  
Taken	  together,	  results	  from	  this	  chapter	  suggest	  that	  ACE-­‐1	  inhibitors	  reduce	  the	  sensitivity	  
of	   cancer	   cells	   to	   CDDP	  while	   having	   no	   significant	   effect	   on	  DOX	  potency.	  However,	   the	  
ACE-­‐2	  activator,	  DIZE	  significantly	  increases	  the	  sensitivity	  of	  cancer	  cells	  to	  DOX	  treatment	  
altering	  cancer	  cell	  morphology	  and	  inducing	  cell	  death	  via	  apoptosis	  and	  necrosis.	  The	  DOX	  
and	  DIZE	  combination	  is	  associated	  with	  an	  increase	  in	  cells	  delayed	  in	  the	  G1	  phase	  of	  the	  
cell	  cycle	  and	  cell	  death	  via	  apoptosis.	  	  	  
	   	  














Figure	  4.16:	  Effects	  of	  DOX	  and	  DIZE	  treatment	  on	  HeLa	  cell	  death.	  Western	  blot	  analysis	  
showing	   increased	  PARP	  cleavage	  after	  a	  combined	   treatment	  of	  24nM	  DOX	  with	   the	   IC50	  
concentration	  of	  DIZE	  in	  HeLa	  cells.	  Results	  shown	  were	  repeated	  two	  independent	  times.	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4.3	  DISCUSSION	  
	  
In	  this	  chapter	  we	  investigated	  possible	  effects	  in	  the	  combined	  use	  of	  ACE-­‐1	  inhibitors,	  as	  
well	   as	   the	  ACE-­‐2	  axis	   activator	  DIZE,	   and	   currently	  used	   chemotherapeutic	   agents,	   CDDP	  
and	   DOX,	   on	   cancer	   cell	   viability.	   Current	   chemotherapeutic	   agents,	   while	   being	   highly	  
effective	  in	  killing	  cancer	  cells,	  are	  known	  for	  their	  harsh	  side	  effects	  and	  it	   is	  hopeful	  that	  
investigations	   into	   the	   possible	   combined	   treatments	   will	   result	   in	   the	   improvement	   of	  
patient	  outcomes.	  Due	  to	  the	  cytotoxic	  nature	  of	  such	  drugs	  they	  are	  often	  administered	  as	  
a	   combined	   treatment	   (Budman	   et	   al.,	   2002;	   Esteban	   et	   al.,	   2006;	   Fernandez	   and	   Sessel,	  
2009).	  In	  light	  of	  this,	  it	  is	  important	  to	  note	  that	  not	  all	  combination	  treatments	  may	  show	  
a	   preferred	   outcome	   or	   provide	   evidence	   of	   tolerability	   in	   patients,	   as	   was	   observed	   by	  
Giacconne	   et	   al.,	   (2004)	   where	   the	   efficacy	   of	   a	   combined	   treatment	   of	   Gefitinib	   with	  
Gemcitabine	  and	  CDDP	  was	  compared	  to	  the	  single	  treatments	   in	  advanced	  non-­‐small	  cell	  
lung	   cancer	   (NSCLC)	   patients.	   For	   this	   reason	   it	   is	   important	   to	   investigate	   combination	  
treatments	   in	  model	  systems	  like	  cultured	  cells	  and	  animal	  studies	  before	  advancing	  them	  
to	  clinical	  trials.	  
	  
Since	   literature	   has	   shown	   that	   RAS	   inhibitors	   (i.e	   ACE-­‐1	   inhibitors)	   possess	  
chemoprevention	  and	  anticancer	  effects,	  which	  our	  earlier	  data	  supported,	  we	  investigated	  
whether	   the	   anticancer	   effects	   of	   DOX	   and	   CDDP	   could	   be	   enhanced	   through	   the	   use	   of	  
ACE-­‐1	   inhibitors,	  Captopril	   and	  Lisinopril,	   as	  well	   as	   the	  ACE-­‐2	  activator,	  DIZE.	   It	  has	  been	  
reported	   that	   ACE-­‐1	   inhibitors	   may	   be	   used	   with	   DOX	   to	   act	   as	   cardioprotective	   agents	  
reducing	   the	   main	   side	   effect	   of	   DOX,	   cardiac	   damage.	   An	   in	   vivo	   study	   by(Sacco	   et	   al.,	  
2009)showed	   that	  ACE-­‐1	   inhibitors,	   Captopril,	   Lisinopril	   and	  Zofenopril	   provide	  protection	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against	  DOX-­‐induced	  cardiac	  damage.	  Furthermore,(Akolkar	  et	  al.,	  2015)reported	  from	  their	  
in	   vivo	   study	   that	   Captopril	   and	   Lisinopril	   prevent	   cardiotoxicity	   induced	   by	   combined	  
treatments	  of	  DOX	  with	  Trastuzumab,	  a	  monoclonal	  antibody	  used	  to	  treat	  breast	  cancer.	  
Our	  findings	  however,	  indicate	  that	  ACE-­‐1	  inhibitors	  do	  not	  significantly	  affect	  DOX	  potency	  
in	  HeLa	  and	  MDA-­‐MB-­‐231	  cells,	  as	  the	  concentration	  of	  DOX	  required	  to	  kill	  50%	  cancer	  cells	  
remained	  unchanged.	  The	  data	  does	  not	   indicate	  whether	  the	  ACE-­‐1	   inhibitors	  used	  could	  
provide	  potential	  protective	  effects	  to	  a	  surrounding	  tumour	  microenvironment.	  Future	  co-­‐
culture	   experiments	   of	   cancer	  with	   healthy	   cells	   could	   perhaps	   provide	   insight	   on	   such	   a	  
matter.	  	  
	  
Our	   study	   shows	   that	   ACE-­‐1	   inhibitors	   negatively	   affect	   CDDP	   potency	   in	   an	   antagonistic	  
manner.	  CompuSyn	  analysis	   identified	   that	  a	  1:1	   ratio	  of	   the	   IC50	   concentrations	  of	  either	  
Captopril	  or	  Lisinopril	  was	  antagonistic	  if	  used	  in	  combination	  with	  CDDP.	  Our	  results,	  using	  
cells	  in	  culture,	  suggest	  that	  a	  combined	  use	  of	  CDDP	  with	  Captopril	  or	  Lisinopril	  may	  not	  be	  
beneficial.	  Literature	  reports	  however,	  support	  the	  use	  of	  cardioprotective	  drugs	  like	  ACE-­‐1	  
inhibitors	   in	   patients	   undergoing	   chemotherapy	   to	   prevent	   chemotherapy-­‐induced	  
cardiotoxicity	   (Cardinale	   et	   al.,	   2006).	   While	   this	   might	   be	   the	   case	   for	   some	  
chemotherapies,	   further	   research	   is	   warranted	   to	   investigate	   the	   potential	   benefits	   and	  
adverse	  effects	  of	   these	   combinations	   as	   the	  mechanisms	  behind	  ACE-­‐1	   inhibitor-­‐induced	  
prevention	  of	  cardiotoxicity	  is	  unclear.	  	  
	  
The	   cause	   for	   the	   observed	   antagonism	   could	   perhaps	   be	   due	   to	   the	   structure	   of	   ACE-­‐1	  
inhibitors	  and	  thus	  conflicting	  mechanisms	  of	  action.	  In	  a	  study	  conducted	  by	  (Lesan	  et	  al.,	  
2014)	   the	   anti-­‐diabetic	   drug,	  Metformin,	  was	   shown	   to	   antagonize	   CDDP	   function.	   It	  was	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proposed	  that	  this	  could	  be	  due	  to	  the	  reduction	  of	  oxidative	  stress	  caused	  by	  Metformin.	  
As	   Captopril	   contains	   a	   sulfhydryl	   group,	   which	   is	   a	   known	   scavenger	   of	   reactive	   oxygen	  
species	   (ROS)	   (Chopra	   et	   al.,	   1989;	   Napoli	   et	   al.,	   2004),	   the	   antioxidant	   capabilities	   of	  
Captopril,	  may	  similarly	  to	  Metformin,	  be	  a	  possible	  reason	  why	  Captopril	  antagonizes	  CDDP	  
function	  in	  our	  study.	  	  Further	  investigation	  into	  the	  reasons	  behind	  the	  antagonistic	  effect	  
Lisinopril	  has	  with	  CDDP	  need	  to	  be	  conducted.	  
	  
The	  data	  presented	  here	  suggest	  that	  ACE-­‐1	  inhibitors	  induce	  cancer	  cell	  death	  on	  their	  own	  
and	   this	   supports	   literature	   findings	   describing	   ACE-­‐1	   inhibition	   as	   potential	   anticancer	  
drugs	   (Araujo	  et	  al.,	  2015;	  Babacan	  et	  al.,	  2015;	  Kowalski	  and	  Herman,	  1996;	  Wang	  et	  al.,	  
2008).	   In	  combination	  however,	  the	  cell	  killing	  effect	  of	  the	  ACE-­‐1	  inhibitors	  together	  with	  
CDDP	   was	   reduced.	   This	   could	   possibly	   be	   as	   a	   result	   of	   the	   promotion	   of	   the	   c-­‐Jun	   N	  
terminal	   kinase	   (JNK)	   survival	   pathway	   that	   ACE-­‐1	   inhibitors	   are	   known	   to	   activate	   in	  
endothelial	   cells	   (Kohlstedt	   et	   al.,	   2006;	  Ryan	   and	   Sigmund,	   2004).	  Depending	  on	   the	   cell	  
type	  as	  well	  as	  the	  nature	  and	  duration	  of	  death	  stimuli,	  the	  JNK	  pathway	  can	  either	  be	  seen	  
as	  pro-­‐	  or	  anti-­‐apoptotic	  (Liu	  and	  Lin,	  2005).	  	  
	  
Since	   the	   CDDP	   combination	   treatment	   with	   the	   ACE-­‐1	   inhibitors	   Captopril	   or	   Lisinopril	  
proved	   to	   be	   antagonistic	   we	   investigated	   the	   effect	   of	   the	   ACE-­‐2	   axis	   activator	   DIZE	   on	  
CDDP	  outcome,	  based	  on	  the	  natural	  counteractive	  role	  that	  the	  ACE-­‐2	  axis	  plays.	  Our	  data	  
show	  that	  DIZE	  did	  not	  enhance	  the	  cytotoxicity	  of	  CDDP.	  In	  a	  study	  using	  MCF-­‐7	  and	  MDA-­‐
MB-­‐231	   breast	   cancer	   cells,	   Bielawski	   et	   al.	   (2008)	   showed	   that	   platinum-­‐containing	  DIZE	  
derivatives,	  possessed	  strong	  DNA-­‐binding	  activity.	  A	  possible	  reason	  for	  the	   lack	  of	  effect	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on	  CDDP	  outcome	  on	   cancer	   cells	   in	   our	   study	   could	  perhaps	  be	   that	  DIZE	  out	   competes	  
CDDP	  in	  binding	  DNA.	  	  
	  
We	   did	   however	   find	   that	   combination	   treatments	   of	   DIZE	   with	   DOX	   allowed	   the	   IC50	  
concentration	  of	  DOX	   to	  be	   reduced	   substantially	   from	   the	  micromolar	   to	   the	  nanomolar	  
range.	   In	   addition	   both	   a	   1:1	   and	   1:3	   DOX	   and	   DIZE	   combination	   treatment	   showed	  
synergistic	   associations	   at	   the	   higher	   spectrum	   of	   the	   combined	   treatments.	   There	   are	  
reports	  in	  the	  literature	  of	  DOX	  combination	  treatments	  that	  show,	  in	  addition	  to	  cytotoxic	  
effects,	  synergistic	  effects,	  such	  as	  the	  combined	  treatment	  of	  curcumin	  with	  DOX	  (Judson	  
et	  al.,	  2014b;	  Notarbartolo	  et	  al.,	  2005;	  Park	  et	  al.,	  2014)	  showed	  that	  the	  addition	  of	  the	  
Hsp90	   inhibitor,	   Gamitrinib,	   to	   DOX	   therapy	   in	   breast	   and	   prostate	   xenograft	   models,	  
sensitized	  tumour	  growth	  in	  a	  synergistic	  manner.	  
	  
The	   chemical	   structure	   of	   DIZE	   contains	   phenylhydrazine,	   a	   potent	   DNA	   damaging	   agent	  
(Ferrali	  et	  al.,	  1997;	  Yamamoto	  and	  Kawanishi,	  1992).	  A	  possible	  reason	  for	  the	  synergistic	  
associations	   between	   the	   ACE-­‐2	   activator,	   DIZE	   and	   DOX	   may	   simply	   be	   due	   to	   the	  
enhanced	  DNA	  damage	  capabilities	  of	  the	  combined	  treatment.	  As	  the	  mechanism	  of	  action	  
of	  DOX	  is	  topoisomerase	  II	  inhibition	  (Eom	  et	  al.,	  2005;	  Lenglet	  and	  David-­‐Cordonnier,	  2010;	  
Patel	  and	  Kaufmann,	  2012),	  the	  added	  stress	   induced	  by	  DIZE	  could	  be	  a	  factor	   leading	  to	  
the	  potential	  drug	  synergism	  observed	  in	  this	  study.	  The	  observation	  of	  a	  partly	  antagonistic	  
association	  between	  DOX	  and	  DIZE	  correlating	  with	   lower	  concentrations	  of	  the	  combined	  
treatment	  may	  be	  of	  value	  as	  Fernandez	  et	  al.,	  (2009)	  provide	  evidence	  of	  their	  hypothesis	  
that	  antagonism	  between	  drug	  A,	   (referred	   to	  by	   the	  authors	  as	   the	  “editor”)	  and	  drug	  B	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(the	   primary	   drug),	   could	   play	   an	   effective	   therapeutic	   role	   if	   drug	   A	   suppresses	   the	  
downstream	  signaling	  responsible	  for	  side	  effects	  induced	  by	  drug	  B.	  	  
	  
We	  also	  show	  morphological	  evidence	  and	  results	  from	  the	  Annexin	  V	  assay	  which	  suggest	  
that	  DOX	  and	  DIZE	  co-­‐treatment	  results	  in	  an	  increase	  in	  apoptotic,	  necrotic	  and	  senescent	  
cells	  which	  is	  supported	  by	  data	  showing	  an	  increase	  in	  cells	  in	  the	  G1	  and	  subG1	  population	  
of	   the	   cell	   cycle	   after	   treatment.	   This	   suggests	   that	   DOX	   and	   DIZE	   co-­‐treatment	   induces	  
apoptosis,	   necrosis	   and	   possibly	   senescence	   or	   quiescence.	   The	   β–galactosidase	   assay	  
together	   with	   western	   blot	   evidence	   of	   senescence	   protein	   markers	   such	   as	   the	   cyclin-­‐
dependent	   kinase	   inhibitors,	  p16	  and	  p21,	   could	  provide	   further	   support	   for	  our	   findings.	  
P16	  and	  p21	  regulate	  cell	  cycle	  at	  the	  G1	  to	  S	  phase	  transition	  and	  are	  up-­‐regulated	  during	  
cellular	   senescence.	   	   Alternatively	   the	   combined	   treatment	   of	   DOX	   and	   DIZE	   could	   be	  
increasing	   the	   subG1	   population	   of	   cells	   by	   mediating	   quiescence.	   (Yumoto	   et	   al.,	   2014)	  
suggest	  cells	  are	  pushed	  to	  dormancy	  through	  high	  levels	  of	  high	  levels	  of	  TGFβ1	  as	  well	  as	  
disruptions	  in	  the	  ERK	  MAPK	  and	  p38	  MAPK	  pathways.	  Future	  investigations	  into	  the	  effect	  
of	  DOX	  and	  DIZE	  treatment	  on	  markers	  such	  as	  these	  could	  provide	  further	  insight	  into	  this	  
drug	  combination.	  	  	  
	  
While	  current	  chemotherapies	  are	  effective	  at	  killing	  cancer	  cells	  they	  are	  toxic	  to	  healthy	  
cells	  in	  patients.	  Our	  results	  have	  shown	  that	  not	  all	  combination	  treatments	  with	  currently	  
available	  chemotherapeutic	  agents	  will	  be	  synergistic	  and	  have	  an	  improved	  end	  result.	  The	  
association	   analysis	   of	   the	   drugs	   from	   combined	   DOX	   and	   DIZE	   treatment	   suggests	   that	  
small	  molecules	  with	  the	  potential	  to	  activate	  the	  ACE-­‐2	  enzyme	  may	  have	  further	  positive	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effects	  on	  other	  chemotherapeutic	  agents	  and	  such	  combinations	  may	  be	  promising	  in	  the	  
future.	  	  
	   	  





While	   there	  are	   studies	   indicating	   the	  existence	  of	   the	  RAS	  not	  only	   systemically	  but	  also	  
within	  several	  organs	  at	  tissue	  level,	  there	  is	  contention	  over	  the	  impact	  that	  the	  RAS	  and/or	  
inhibitors	  thereof	  impact	  cancer.	  Recent	  evidence	  suggests	  that	  RAS	  components	  influence	  
carcinogenesis	  with	  examples	  including	  AT1R	  expression	  being	  differentially	  up-­‐regulated	  in	  
cancers	  such	  as	  breast,	  ovarian	  and	  colorectal	  (Ager	  et	  al.,	  2011;	  Chen	  et	  al.,	  2013;	  Ino	  et	  al.,	  
2006).	  Ang-­‐II,	  the	  ligand	  for	  AT1R,	  has	  also	  been	  shown	  to	  be	  associated	  with	  an	  increase	  in	  
proliferation	   of	   various	   cancer	   cell	   types	   including	   ovarian	   and	   breast;	   the	   activation	   of	  
invasiveness	   of	   cervical	   cancer	   cells,	   as	   well	   as	   angiogenesis	   and	   metastasis	   of	   other	  
gynecologic	  cancers	  such	  as	  endometrial,	  ovarian	  and	  gestational	  choriocarcinoma	  (Chen	  et	  
al.,	   2013;	   Du	   et	   al.,	   2012;	   Ino	   et	   al.,	   2011;	   Kikkawa	   et	   al.,	   2004;	   Puddefoot	   et	   al.,	   2006;	  
Suganuma	  et	  al.,	  2005;	  Uemura	  et	  al.,	  2003).	  
	  
This	  study	  provides	  evidence	  showing	  high	  ACE-­‐1	  as	  well	  as	  AT1R	  expression	  in	  cancer	  cell	  
lines.	  Ang-­‐II	  treatment	  resulted	  in	  a	  significant	  increase	  of	  cervical	  cancer	  cell	  proliferation.	  
Our	  data	  also	  shows	  that	  ACE-­‐1	  protein	  expression	  associates	  with	  increased	  ACE-­‐1	  enzyme	  
activity	   in	   breast	   and	   cervical	   cancer	   cell	   lines.	   These	   findings	   are	   in	   agreement	   with	  
previous	  studies	  reporting	  differential	  expression	  of	  RAS	  components,	  e.g.	  AT1R,	  observed	  
in	   brain,	   lung,	   pancreatic,	   prostate,	   ovarian	   and	  breast	   cancer	  when	   compared	   to	   normal	  
tissue	  counterparts	  (Ager	  et	  al.,	  2008;	  Deshayes	  and	  Nahmias,	  2005;	  Suganuma	  et	  al.,	  2005).	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We	   hypothesized	   that	   increased	   RAS	   components	   may	   have	   significance	   to	   cancer	   cell	  
biology.	   To	  explore	   this,	   the	   effects	   of	   RAS	   inhibitors,	   specifically	  ACE-­‐1	   axis	   inhibitors,	   as	  
well	  as	  activators	  of	  ACE-­‐2	   function	  were	   investigated.	  Our	   initial	  experiments	   focused	  on	  
the	   ACE-­‐1	   axis	   of	   the	   RAS	   and	   we	   observed	   that	   exposure	   of	   cancer	   cells	   to	   Captopril,	  
Lisinopril	  or	  Candesartan	  treatment	  inhibited	  cancer	  cell	  proliferation.	  Using	  the	  Annexin	  V	  
assay	   it	   was	   determined	   that	   the	   mode	   of	   cell	   death	   was	   via	   apoptosis.	   Further	  
investigations	   into	  the	  effects	  of	  ACE-­‐1	   inhibition	   in	  cancer	  are	  required	  as	  existing	  data	   is	  
conflicting.	   As	   our	   results	   were	   obtained	   from	   in	   vitro	   studies,	   they	   may	   be	   considered	  
preliminary,	  however,	  do	  support	  existing	  bodies	  of	  work	  such	  as	  that	  of	  (Miao	  et	  al.,	  2016;	  
Wilop	   et	   al.,	   2009),	   which	   showed	   that	   ACE-­‐1	   inhibition	   together	   with	   chemotherapy,	  
resulted	   in	   a	  positive	   impact	  on	  progression-­‐free	   survival,	   regardless	  of	  whether	   the	  non-­‐
small	  cell	  lung	  cancer	  patients	  were	  in	  early	  or	  advanced	  stages	  of	  disease	  progression.	  	  
	  
Our	  data	  also	  shows	  that	  Ang-­‐II	   treatment	  of	  cancer	  cells	   results	   in	  the	  release	  of	  calcium	  
from	   intracellular	   stores	   and	   the	   activation	   of	   calcium	   signaling	   pathways	   via	  
phosphorylation	  of	  CAMKII	  and	  the	  transcription	  factor,	  NFAT.	  Inhibiting	  the	  Ang-­‐II	  receptor,	  
AT1R,	   blocked	   these	   effects.	   Typically	   in	   healthy	   cells,	   growth	   factors	   set	   off	   spikes	   of	  
calcium	  release	  to	  act	  as	  signals	  carefully	  regulating	  cell	  cycle	  progression	  (Berridge,	  1995;	  
Berridge	  et	  al.,	  2000;	  Santella,	  1998).	  Calcium	  release	  signals	  at	  the	  various	  phases	  activate	  
cell	  cycle	  events	  including:	  early	  genes	  responsible	  for	  inducing	  resting	  cells	  to	  re-­‐enter	  the	  
cell	   cycle,	   DNA	   synthesis	   at	   the	   G1/S	   transition	   phase	   and	   mitotic	   events.	   It	   has	   been	  
reported	   that	   in	   cancer	   cells,	   the	   increasing	   rate	   of	   continuous	   calcium	   signals	   associates	  
with	   increased	  cell	  proliferation(Berridge,	  1995;	  Berridge	  et	  al.,	   2000;	  Capiod	  et	  al.,	   2007;	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Roderick	  and	  Cook,	  2008).	   In	  our	  study	  we	  showed	  that	   inhibition	  of	  AT1R	  function,	  using	  
Candesartan,	  significantly	  reduced	  these	  effects.	  
	  
This	  study	  also	  reports	  that	  activation	  of	  the	  ACE-­‐2	  axis,	  through	  natural	  or	  synthetic	  small	  
molecules,	  reduced	  cancer	  cell	  proliferation,	  with	  DIZE	  in	  particular	  inducing	  a	  G2/M	  arrest	  
in	  cancer	  cells,	  suggesting	  a	  mechanism	  of	  action	  different	  to	  that	  of	  Ang-­‐(1-­‐7).	  It	  has	  been	  
documented	  that	  in	  the	  cardiovascular	  context,	  the	  ACE-­‐2	  axis	  serves	  to	  counter	  ACE-­‐1	  axis	  
effects	   and	   restore	   balance	   where	   AT1R	   activation	   has	   led	   to	   deleterious	   consequences	  
(Ferrario,	  1990a;	  Ferrario,	  1990c).	   Similar	  observations	  of	  hyper-­‐activated	  ACE-­‐1	  axis	  have	  
also	   been	   reported	   in	   other	   diseases	   including	   atherosclerosis,	   dementia	   and	   metabolic	  
syndrome,	  which	   could	   lead	   to	   cardiovascular	   disease,	   a	   stroke	   or	   diabetes	   (Engeli	   et	   al.,	  
2000;	   Engeli	   and	   Sharma,	   2002;	   Engeli,	   2006;	  Mogi	   and	  Horiuchi,	   2009;	   Sata	   and	   Fukuda,	  
2010).	   This	   leads	   us	   to	   believe	   that	   the	   natural,	   or	   synthetic	   activation	   of	   the	   ACE-­‐2	   axis	  
using	  treatments	  with	  Ang-­‐(1-­‐7),	  or	   the	  small	  molecule	  DIZE,	   in	  cervical	  and	  breast	  cancer	  
serves	   to	   protect	   against	   harmful	   ACE-­‐1	   axis	   effects.	   We	   found	   that	   both	   treatments	  
significantly	  reduced	  the	  clonogenic	  ability	  of	  single	  cancer	  cells,	  with	  DIZE	  effective	  at	  half	  
the	  IC50	  concentration	  and	  through	  the	  Annexin	  V	  assay,	  we	  found	  that	  both	  Ang-­‐(1-­‐7)	  and	  
DIZE	  induced	  cell	  death	  via	  apoptosis	  or	  necrosis.	  
	  
The	  use	  of	  RAS	  inhibitors	  and	  ACE-­‐2	  axis	  activation	  in	  combination	  drug	  treatment	  to	  fight	  
cancer	   is	   another	   promising	   route,	  which	   could	   be	   explored	   in	   xenograft	  models.	   Further	  
studies	  using	  xenograft	  mouse	  models	  as	  opposed	   to	   transgenic	  mice,	   could	  offer	  a	  more	  
feasible	  solution	  as	  research	  could	  be	  implemented	  sooner	  and	  at	  lower	  cost.	  	  Our	   in	  vitro	  
study	   found	   that	   combination	   treatments	   using	   ACE-­‐1	   axis	   inhibitors	   and	   CDDP	   were	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antagonistic	   to	   the	   effects	   of	   CDDP	   only.	   On	   the	   other	   hand	  we	   found	   that	   combination	  
treatments	  of	  DOX	  and	  the	  ACE-­‐2	  activator,	  DIZE,	  were	  synergistic	  allowing	  for	  a	  significant	  
lowering	  of	  the	  DOX	  concentration	  associated	  with	  cancer	  killing	  effects.	  Whether	  this	  will	  
correlate	   with	   a	   reduction	   in	   side	   effects	   associated	   with	   DOX	   treatments	   will	   require	  
further	  investigation	  using	  in	  vivo	  models.	  	  
	  
While	  there	  are	  no	  reports	  of	  direct	  combination	  treatments	  using	  Captopril	  or	  Lisinopril	  in	  
conjunction	  with	  CDDP	  to	  treat	  cancers,	  there	  is	  evidence	  for	  the	  impact	  of	  ACE-­‐1	  inhibitors	  
and	  AT1R	  blockers	  (note	  the	  names	  of	  these	  drugs	  were	  not	   included	  in	  the	  study)	  on	  the	  
survival	   of	   non-­‐small-­‐cell	   lung	   cancer	   patients	   receiving	   platinum-­‐based	   chemotherapy.	  
Patients	   who	   had	   received	   long	   term	   (minimum	   of	   three	   months)	   treatments	   of	  
antihypertensive	   agents	   showed	   improved	   survival	   than	   patients	   who	   had	   not	   received	  
antihypertensive	   treatment	   before	   chemotherapy	   (Wilop	   et	   al.,	   2009).	   Our	   method	   of	  
combination	   treatment	   using	   Captopril	   or	   Lisinopril	   with	   CDDP	   did	   not	   involve	   a	   pre-­‐
treatment,	  so	  an	  improved	  outcome	  may	  possibly	  result	  if	  this	  method	  were	  to	  be	  used	  in	  
future	   investigations.	   Combination	   treatments	   using	   CDDP	   have	   had	   mixed	   outcomes	  
showing	  both	  antagonistic	  as	  well	  as	  synergistic	  effects.	  The	  combination	  treatment	  of	  the	  
EGFR	  antagonist,	  Gefitinib,	  together	  with	  CDDP	  has	  been	  reported	  to	  have	  an	  antagonistic	  
response	   in	  a	  number	  of	  non-­‐small-­‐cell	   lung	  cancer	  cell	   lines	   (Tsai	  et	  al.,	  2011).	   In	  cervical	  
cancer	  however,	  CDDP	  combination	  treatments	  with	  naturally	  derived	  compounds	  such	  as	  
cinnamon	   essential	   oil,	  myricetin	   and	  methyl	   eugenol,	   showed	   synergistic	   effects	   in	  HeLa	  
cells	   inhibiting	   proliferation	   via	   apoptosis	   (Larasati	   et	   al.,	   2014;	   Yi	   et	   al.,	   2015).	   The	  
synergistic	  effects	  induced	  through	  these	  combination	  treatments	  could	  possibly	  be	  due	  to	  
the	  antioxidant	  properties	  associated	  with	  the	  natural	  compounds	  and	  knowledge	  of	  these	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possible	  associations	  could	  empower	   the	  growing	  body	  of	  evidence	  supporting	   the	  use	  of	  
combined	  treatments.	  	  	  
	  
Similarly	   to	  CDDP	  combined	   treatments,	   those	   involving	  DOX	  and	  antihypertensive	  agents	  
suggest	   that	  pre-­‐treatment	  of	  ACE-­‐1	   inhibitors	  offer	  protection	  against	   the	   side	  effects	  of	  
DOX	  (Hiona	  et	  al.,	  2011;	  Sacco	  et	  al.,	  2009).	  Our	  study	  shows	  that	  ACE-­‐2	  activation	  with	  DIZE	  
reduces	  the	  effective	  concentration	  of	  DOX	  needed	  to	  kill	  50%	  of	  the	  cells	  treated.	  Such	  a	  
dose	   reduction	   could	  be	   further	   investigated	   to	  determine	  whether	  protective	  effects	   are	  
indeed	   possible	  with	   the	   use	   of	   DIZE.	   There	   are	   numerous	   reports	   stating	   the	   synergistic	  
effects	   of	   combined	   treatments	   using	   DOX	   (Alberts	   et	   al.,	   1981;	   Ardizzoni	   et	   al.,	   1991;	  
Judson	  et	  al.,	  2014b;	  Lee	  et	  al.,	  2014;	  Morris	  et	  al.,	  1992;	  Park	  et	  al.,	  2014;	  Wu	  et	  al.,	  2013).	  
Our	  data	  is	  novel	  in	  that,	  to	  our	  knowledge,	  this	  is	  the	  first	  study	  to	  report	  synergistic	  effects	  
as	  a	  combined	  treatment	  consisting	  of	  an	  ACE-­‐2	  axis	  activator	  and	  DOX.	  Such	  combinations	  
using	   small	   molecules	   capable	   of	   activating	   the	   ACE-­‐2	   axis	   in	   cancer	   warrant	   further	  
investigations.	  Our	  study	  provides	  insight	  into	  future	  possible	  therapeutic	  strategies	  to	  treat	  
cervical	   cancer.	   Moreover,	   our	   results	   suggest	   further	   investigation	   into	   the	   treatment	  
regimens	   for	   cervical	   cancer	   patients	   receiving	   ACE-­‐1	   inhibitors	   as	   our	   preliminary	   data	  
shows	  that	  antihypertensive	  treatment	  reduces	  the	  effect	  of	  the	  potent	  chemotherapeutic	  
drug,	  CDDP.	  	  	  
	  
Future	   work	   could	   investigate	   the	   role	   of	   the	   RAS	   in	   the	   cervical	   cancer	   context	   within	  
animal	   models	   to	   get	   a	   clearer	   understanding	   of	   the	   functioning	   of	   RAS	   actions	   using	   a	  
model,	  which	  better	  mimics	  the	  cancer	  environment.	  Further	  study	  of	  this	  complex	  system	  
is	  required	  to	  better	  understand	  the	  roles	  played	  by	  the	  various	  components	  in	  the	  cervical	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and	  breast	  cancer	  environment.	  In	  addition,	  possible	  experiments	  into	  alternative	  combined	  
treatments	   using	   ACE-­‐1	   inhibitors	   or	   ACE-­‐2	   activators	   should	   be	   performed,	   as	   well	   as	  
investigations	  into	  the	  transcriptional	  regulation	  of	  poorly	  expressed	  ACE-­‐2	  protein	  in	  cancer	  
cells.	  While	  we	  were	  not	  without	  limitations	  in	  our	  study	  our	  results	  provide	  a	  more	  holistic	  
view	  of	  the	  role	  played	  by	  integral	  RAS	  components	  in	  cervical	  and	  breast	  cancer.	  	  
	  
The	  key	  findings	  from	  our	  study	  can	  be	  summarized	  as	  follows:	  We	  observed	  elevated	  ACE-­‐1	  
expression	  and	  enzyme	  activity	   in	  vitro,	  with	  Ang-­‐II	  promoting	  cancer	  cell	  proliferation,	  via	  
the	  AT1R,	  in	  a	  dose	  dependent	  manner.	  AT1R	  function	  activates	  calcium	  signaling	  pathways	  
resulting	   in	   increased	  cancer	  cell	  proliferation,	  which	  ACE-­‐1	   inhibition	  can	  reduce,	  through	  
the	  induction	  of	  apoptosis	  or	  necrosis.	  We	  observed	  lower	  ACE-­‐2	  expression	  and	  activity	  in	  
cancer	  cells,	  which	  DIZE	  treatment	  could	  rescue.	  Treatment	  with	  DIZE	  or	  Ang-­‐(1-­‐7)	  reduced	  
cancer	  cell	  proliferation,	  with	  DIZE	   inducing	  a	  G2/M	  arrest	  and	  cell	  death	  via	  apoptosis	  or	  
necrosis.	  Both	  treatments	  prevented	  the	  clonogenic	  ability	  of	  single	  cancer	  cells	  with	  DIZE	  
being	   effective	   at	   half	   IC50	   concentration.	   We	   found	   while	   ACE-­‐1	   inhibitors	   induced	   cell	  
death	  on	  their	  own,	  they	  reduced	  the	  sensitivity	  of	  cancer	  cells	  to	  chemotherapeutic	  drugs,	  
DOX	  and	  CDDP,	  with	  associations	  between	  ACE-­‐1	  inhibitors	  and	  CDDP	  showing	  antagonistic	  
effects.	   We	   show	   that	   DIZE	   does	   not	   affect	   the	   potency	   of	   CDDP	   whereas	   combined	  
treatment	  with	  DOX,	  results	  in	  the	  reduced	  ability	  of	  cells	  to	  produce	  clonogenic	  colonies	  as	  
well	  as	  an	  enhanced	  cell	  killing	  effect.	  The	  data	  suggests	  that	  inhibitors	  of	  the	  ACE-­‐1	  axis,	  or	  
activators	   of	   ACE-­‐2	   function,	   could	   serve	   as	   potential	   anti-­‐cancer	   agents	   with	   improved	  
effects	  if	  used	  in	  conjunction	  with	  currently	  used	  chemotherapies	  such	  as	  DOX.	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CHAPTER	  6	  
	  
MATERIALS	  AND	  METHODS	  
	  
6.1	  MATERIALS	  
6.1.1	  Cell	  lines	  	  
The	   following	   cell	   lines	  were	   obtained	   from	   the	   American	   Type	   Culture	   Collection	   (ATCC)	  
(Rockville,	  MD,	  USA):	  	  
• cervical	   cancer	   cell	   lines	   C33A	   (HPV-­‐negative),	   CaSki,	   HeLa	   and	   SiHa	   (all	   HPV-­‐
positive),	  and	  breast	  cancer	  cell	  line,	  MDA-­‐MB-­‐231	  
• Non-­‐cancer,	   lung	   	   fibroblast	   cell	   line,	   WI38	   and	   the	   SV40	   transformed	   lung	  
fibroblasts	  (SVWI38)	  	  
FG0	  skin	  fibroblasts	  were	  a	  gift	   from	  Dr.	  A.D	  Marais	  (Groote	  Schuur	  Hospital,	  Cape	  Town).	  	  
HepG2,	  liver	  carcinoma	  cells	  were	  obtained	  from	  the	  UCT	  Heart	  Foundation	  
	  
6.1.2	  Cell	  culture	  media	  
Most	  cell	  lines	  were	  cultured	  under	  adherent	  conditions	  in	  complete	  medium	  consisting	  of	  
Dulbecco’s	   Modified	   Eagle’s	   Medium	   (DMEM),	   supplemented	   with	   10%	   heat	   inactivated	  
fetal	   calf	   serum	   (FCS)	   (Gibco,	   Life	   Technologies,	   Carlsbad,	   CA,	   USA)	   with	   an	   antibiotic	  
cocktail	  of	  100	  U/ml	  Penicillin	  and	  100	  μg/ml	  Streptomycin.	  Alternatively,	  HepG2	  cells	  were	  
cultured	   adherently	   in	   antibiotic	   free,	   DMEM	  and	   10%	   (v/v)	   non-­‐heat-­‐inactivated	   FCS.	   All	  
cell	   lines	   were	   maintained	   in	   a	   humidified	   incubator	   at	   37ᵒC	   and	   5%	   CO2	   and	   routinely	  
passaged	  every	  2-­‐3	  days.	  Cells	  were	  grown	  to	  60-­‐80%	  confluency	  before	  being	  trypsinized	  
with	  0.05%	  trypsin	  and	  EDTA.	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When	   freezing	   stocks	   of	   cells,	   cells	   were	   resuspended	   in	   cell	   freezing	   media	   (100U/ml	  
penicillin	  and	  100	  μg/ml	  Streptomycin,	  20%	  FCS	  and	  10%	  DMSO)	  and	  1	  ml	  was	  aliquoted	  per	  
cryotube.	  Cells	  were	  placed	  at	  -­‐80	  °C	  for	  up	  to	  a	  week	  before	  being	  placed	  in	  liquid	  nitrogen	  
for	  long	  term	  storage.	  Sensitive	  cell	  lines	  such	  as	  WI38	  and	  HepG2	  were	  thawed	  into	  media	  
containing	   20%	   FCS	   for	   the	   first	   24	   hours	  while	   less	   sensitive	   cell	   lines	  were	   thawed	   into	  
their	  normal	  growth	  media.	  	  
	  
6.1.3	  Transfections	  with	  siRNA	  
Transient	  knockdown	  of	  ACE-­‐1	  protein	  expression	  was	  achieved	  using	  short-­‐interfering	  RNA	  
(siRNA)	   technology.	   ACE-­‐1	   siRNA	   (sc-­‐270350,	   Santa	   Cruz	   Biotechnology,	   Dallas,	   TX,	   USA)	  
mediated	   knockdown	  was	   performed	   using	   20	   nM	   siRNA	  with	   a	   3:1	   ratio	   of	   transfection	  
reagent	   (HiPerfect,	   Qiagen,	   MD,	   USA)	   to	   siRNA.	   The	   transfection	   mix	   was	   added	   to	   the	  
medium	  and	  left	  for	  5	  minutes	  after	  which	  either	  control	  or	  ACE-­‐1	  specific	  siRNA	  (Santa	  Cruz	  
Biotechnology)	  was	  added.	  The	  mixture	  was	  left	  for	  15	  minutes	  and	  added	  dropwise	  to	  the	  
cells,	   which	   thereafter	   were	   left	   in	   the	   incubator	   for	   6	   hours.	   This	   medium	   was	   then	  
replaced	  with	  normal	  complete	  medium	  (DMEM,	  10%	  FCS	  with	  Penicillin	  and	  Streptomycin	  
antibiotics).	  Control	  siRNA	  (sc-­‐37007,	  Santa	  Cruz	  Biotechnology)	  was	  used	  to	  control	  for	  the	  
effect	   of	   DNA	   transfection.	   siRNAs	   were	   acquired	   as	   lyophilized	   powders	   and	   were	  
suspended	  in	  RNAse-­‐free	  water	  to	  give	  a	  stock	  concentration	  of	  10	  μM.	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6.1.4	  Small	  molecules	  and	  inhibitors	  
Captopril	   and	   Lisinopril	   were	   a	   gift	   from	   Prof.	   E.D	   Sturrock	   at	   the	   Zinc	   Metalloprotease	  
group,	   IBMS,	   UCT	   and	   were	   resuspended	   in	   sterile	   water	   before	   being	   stored	   at	   4°C.	  
Candesartan	  cilexitil	  (Sigma,	  Aldrich,	  Germany)	  was	  resuspended	  in	  sterile	  water	  and	  stored	  
at	   4°C.	   The	   AT2R	   antagonist,	   PD123319	   (Sigma,	   Aldrich,	   Germany)	   was	   resuspended	   in	  
sterile	  water	  and	  stored	  at	  4°C.	  Ang-­‐II	  and	  Ang-­‐(1-­‐7)	  were	  purchased	  from	  Sigma	  and	  stored	  
at	   -­‐20	   °C.	   Diminazene	   aceturate	   (Sigma)	   was	   dissolved	   in	   water	   and	   stored	   at	   room	  
temperature.	  Doxorubicin	  and	  Cisplatin	  were	  resuspended	  in	  sterile	  water	  and	  and	  stored	  at	  
-­‐80°C.	  12-­‐o-­‐tetradecanoylphorbol-­‐13-­‐	  acetate	  (TPA),	  was	  purchased	  from	  Sigma	  Aldrich®	  Co	  




6.2.1	  Transfections	  with	  siRNA	  
HeLa	  cells	  were	  plated	   in	  60	  mm	  dishes	  at	  a	   concentration	  of	  400	  000	  cells	  per	  dish.	  The	  
following	   day	   the	   transfection	   mix	   was	   prepared	   using	   DMEM	   (Gibco)	   media	   free	   of	  
antibiotics	  and	  fetal	  calf	  serum	  (FCS),	  HiPerfect	  lipid	  reagent	  ACE-­‐1	  siRNA	  (sc-­‐270350,	  Santa	  
Cruz	   Biotechnology,	   Dallas,	   TX,	   USA)	   mediated	   knockdown	   was	   performed	   using	   20	   nM	  
siRNA	  with	  a	  3:1	  ratio	  of	  transfection	  reagent	  (HiPerfect)	  to	  siRNA.	  The	  transfection	  mix	  was	  
added	   to	   the	  medium	   and	   left	   for	   5	  minutes	   after	  which	   either	   control	   or	   ACE-­‐1	   specific	  
siRNA	   (Santa	   Cruz	   Biotechnology)	   was	   added.	   The	   mixture	   was	   left	   for	   15	   minutes	   and	  
added	  dropwise	   to	   the	  cells,	  which	   thereafter	  were	   left	   in	   the	   incubator	   for	  6	  hours.	  This	  
medium	  was	  then	  replaced	  with	  normal	  complete	  medium	  (DMEM,	  10%	  FCS	  with	  Penicillin	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and	  Streptomycin	  antibiotics).	  Control	  siRNA	  (sc-­‐37007,	  Santa	  Cruz	  Biotechnology)	  was	  used	  
to	  control	  for	  the	  effect	  of	  DNA	  transfection.	  siRNAs	  were	  acquired	  as	  lyophilized	  powders	  
and	  were	  suspended	  in	  RNAse-­‐free	  water	  to	  give	  a	  stock	  concentration	  of	  10	  μM.	  
	  
6.2.2	  Western	  blot	  analysis	  
Protein	   lysates	   from	   cells	  were	   extracted	  using	   protein	   lysis	   buffer	   containing	  RIPA	   and	   a	  
fresh	   mixture	   of	   sodium	   orthovanadate	   (Na3VO4)	   and	   protease	   inhibitors.	   Protein	  
concentrations	  were	  determined	  using	  a	  bicinchoninic	  acid	  (BCA)	  protein	  assay	  kit	   (Pierce,	  
Thermo	   Scientific,	   Rockford,	   IL,	   USA).	   Equal	   amounts	   of	   protein	   were	   loaded	   into	   SDS	  
Polyacrylamide	  gel	  and	  ran	  at	  150V	  for	  approximately	  1	  hour	  30	  minutes	  or	  until	  proteins	  
were	  sufficiently	   separated	  according	   to	   the	  molecular	   size	  of	   the	  protein	  of	   interest.	  The	  
protein	  molecular	  weight	  marker,	   Spectra-­‐BR	   (Thermo	  Fisher	   Scientific	   Fermentas,	   Illinois,	  
USA)	  for	  the	  determination	  of	  protein	  size.	  20-­‐30	  μg	  of	  total	  protein	  was	   loaded	  onto	  SDS	  
Polyacrylamide	  gels	  prepared	  according	  to	   (Table	  6.1)	  Proteins	  were	  then	  transferred	  to	  a	  
Hybond-­‐ECL	  nitrocellulose	  membrane	  (ACE-­‐Amersham,	  Buckinghamshire,	  UK)	  for	  1	  hour	  at	  
100	   V.	   Membranes	   were	   blocked	   for	   an	   hour	   at	   room	   temperature	   in	   5%	   milk	   and	  
thereafter	   the	  appropriate	  dilution	  of	  primary	  antibody	  specific	   for	   the	  protein	  of	   interest	  
(Table	  6.2)	  was	  added	  and	  incubated	  overnight	  at	  4°C.	  β-­‐tubulin	  or	  GAPDH	  were	  used	  as	  the	  
loading	  controls	   in	   these	  experiments.	  Chemiluminescence,	  was	  used	  to	  detect	  bands	  and	  
depending	  on	   the	   strength	  of	   the	   signal	  either	   Lumiglo	  or	   Lumiglo	  Reserve	   (KPL	  112,	   Inc.,	  
Gaithersburg,	  MD,	   USA),	   were	   used.	   	  When	   different	   antibodies	   were	   used	   on	   the	   same	  
blot,	   the	  membranes	  were	  stripped	   in	  1	  M	  Glycine,	  pH	  2.5	   for	  5	  minutes	  then	  neutralised	  
with	  1/10	  volume	  1	  M	  Tris-­‐Cl,	  pH	  7.5.	  The	  membranes	  were	  then	  washed	  four	  times	  with	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TBST	   after	   which	   blocking	   and	   re-­‐probing	   with	   the	   primary	   antibody	   of	   interest	   could	  
proceed.	  
	  
Table	  6.1	  Preparation	  of	  resolving	  and	  stacking	  gels	  for	  thickness	  and	  pore	  sizes	  (%)	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Table	  6.2	  Antibody	  concentrations	  and	  incubation	  conditions	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6.2.3	  IC50	  Determination	  and	  Cell	  Proliferation	  (MTT)	  assay	  
3000	  cells	   in	  90	  µL	  complete	  medium	  per	  well	  were	  seeded	   in	  triplicate	   in	  a	  96	  well	  plate	  
and	  allowed	  to	  settle	  overnight	  in	  a	  conditioned	  incubator.	  The	  next	  day	  cells	  were	  treated	  
with	  a	  dose	  range	  of	  Captopril,	  Lisinopril	  or	  Candesartan.	   In	  order	  to	  factor	   in	  background	  
absorbance	  readings,	  media	  blanks	  were	  treated	  with	  the	  same	  dose	  range	  of	  drugs.	  Cells	  
were	   incubated	   for	  48	  hours	  with	   the	   respective	  drugs	  when	  10	  µL	  MTT	   reagent,	   (3-­‐[4,5-­‐
dimethylthiazol-­‐2-­‐yl]-­‐2,5-­‐diphenyltetrazolium	   bromide,	   Sigma)	   was	   added	   to	   assess	  
metabolically	  active	  cells.	  Four	  hours	  later	  100	  µL	  SDS	  containing	  solubilisation	  reagent	  was	  
added	  and	  the	  absorbance	  read	  the	  following	  morning	  at	  595	  nm	  using	  a	  Biotek	  microplate	  
spectrophotometer	  (Winooski,VT,USA).	  
	  
6.2.4	  Transfections	  with	  ACE-­‐1	  siRNA	  
250	  000	  cells	  were	  plated	  in	  35	  mm	  dishes	  and	  allowed	  to	  settle	  overnight	  in	  a	  humidified	  
chamber	   at	   37°C	   and	   5%	   CO2.	   The	   following	   day	   a	   transfection	  mixture	  was	   prepared	   in	  
DMEM	  (Gibco)	  medium	  free	  of	  fetal	  calf	  serum	  (FCS)	  and	  antibiotics.	  A	  transfection	  reagent	  
(HiPerfect,	  Qiagen,	  MD,	  USA)	  was	  added	  to	  the	  medium	  and	  left	  for	  5	  minutes	  after	  which	  
either	  control	  or	  ACE-­‐1	  specific	   siRNA	   (Santa	  Cruz	  Biotechnology)	  was	  added.	  The	  mixture	  
was	   left	   for	  15	  minutes	  and	  added	  dropwise	  to	  the	  cells	  which	  were	  thereafter	   left	   in	   the	  
incubator	   for	   6	   hours.	   This	   medium	   was	   then	   replaced	   with	   normal	   complete	   medium	  
(DMEM,	   10%	   FCS	   with	   Penicillin	   and	   Streptomycin	   antibiotics).	   The	   effect	   of	   ACE-­‐1	  
knockdown	  was	  investigated	  accordingly	  using	  western	  blot	  analysis.	  
	  
6.2.5	  Combination	  Treatments	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To	  test	  the	  effects	  of	  the	  combined	  treatments	  on	  cancer	  cells,	  i.e.	  whether	  ACE-­‐1	  inhibitors	  
Captopril	   and	   Lisinopril,	   had	   an	   effect	   on	   the	   efficacy	   of	   CDDP	   or	   DOX,	   or	   if	   DIZE	   could	  
enhance	   the	   effect	   of	   DOX	   in	   cancer	   cells,	   we	   investigated	   the	   effects	   of	   the	   combined	  
treatments	  using	  the	  fixed	  ratio	  method	  of	   (Chou	  and	  Talalay,	  1984)MTT	  assay.	  CDDP	  and	  
the	  ACE-­‐1	   inhibitors,	  Captopril	  and	  Lisinopril,	  were	   treated	   in	  a	  1:1	   ratio	  of	   the	   respective	  
IC50	  concentrations	  of	  each	  drug	  appropriate	  to	  the	  cell	  lines	  tested.	  	  Cells	  were	  treated	  with	  
DOX	  and	  DIZE	  in	  a	  fixed	  1:1	  or	  1:3	  ratio	  compared	  to	  single	  treatments	  (see	  Tables	  A2	  and	  
A3	   in	  Appendix	   II).	   5000	   cells/well	   in	   a	  96-­‐well	   plate	  were	   left	   to	   adhere	  overnight	  under	  
incubated	  conditions.	  Cells	  were	  treated	  with	  the	  drugs	  of	   interest	  for	  48	  hours	  giving	  the	  
total	  volume	  per	  well	  of	  100	  µL.	  The	  next	  day	  MTT	  reagent	  was	  added	  with	  the	  addition	  of	  
Solubilization	   solution	   four	   hours	   later.	   The	   absorbance	   was	   measured	   the	   following	  
morning	  at	  OD595nm	  using	  a	  Biotek	  microplate	  spectrophotometer.	  
	  
6.2.6	  ACE-­‐1	  functional	  assay	  	  
To	  determine	  the	  endogenous	  ACE-­‐1	  activity	   in	  normal	  and	  cancer	  cells,	  a	  modification	  of	  
the	   spectrofluorimetric	   ACE-­‐1	   enzyme	   assay	   was	   used	   where	   cleavage	   of	   the	   substrate	  
benzyloxycarbonyl-­‐Phe-­‐His-­‐Leu	  (ZFHL,	  Sigma,	  USA)	  is	  monitored.	  After	  a	  48	  hour	  treatment	  
with	  Captopril	  or	  Lisinopril,	  cell	  lysates	  were	  incubated	  for	  two	  hours	  (instead	  of	  30	  minutes)	  
at	  37°C	  with	  the	  ACE-­‐1	  specific	  substrate	  ZFHL.	  The	  reaction	  was	  stopped	  with	  0.28M	  NaOH	  
solution	   and	   the	   sensitive	   fluorescent	   agent,	   o-­‐phthalaldehyde	   (Sigma,	   USA)	   added	   to	  
derivatise	  the	  HL	  released	  from	  the	  substrate.	  This	   reaction	  was	  stopped	  with	  3N	  HCl	  and	  
after	   10	  minutes	   read	   in	   a	   Cary	   Eclipse	   fluorescent	   spectrophotometer	   (Varian	   Inc.,	   USA)	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with	  an	  excitation	  wavelength	  of	  360nm	  and	  an	  emission	  wavelength	  of	  485nM.	  A	  sample	  of	  
purified	  testes	  ACE-­‐1	  was	  used	  as	  the	  positive	  control.	  	  
	  
6.2.7	  ACE-­‐2	  functional	  assay	  
To	   determine	   endogenous	   ACE-­‐2	   enzyme	   activity	   in	   normal	   and	   cancer	   cells	   the	   ACE-­‐2	  
specific	   substrate,	   Mca-­‐Y-­‐V-­‐A-­‐D-­‐A-­‐P-­‐K(Dnp)-­‐OH	   (fluorogenic	   peptide	   substrate;	   R&D	  
Systems	  Inc,	  USA)	  was	  used.	  Cells	  were	  incubated	  with	  the	  substrate	  for	  1	  hour	  at	  37°C	  with	  
a	   total	   reaction	  volume	  of	  100	  uL.	   The	   reaction	  mixture	   contained	   final	   concentrations	  of	  
100mM	  Tris,	  pH	  7,	  and	  300	  mM	  NaCl.	  Reaction	  product	  was	  measured	  by	   the	   increase	   in	  
fluorescence	   detected	   at	   excitation	   and	   emission	   wavelengths	   of	   320nm	   and	   430	   nm	  
respectively	   using	   a	   Cary	   Eclipse	   fluorescence	   spectrophotometer.	   Fluorescent	   readings	  
were	  normalised	  to	  100	  μg	  protein.	  
	  
6.2.8	  Calcium	  release	  assay	  
Cells	  were	  trypsinized,	  washed,	  placed	  in	  eppendorf	  tubes	  at	  1	  x	  106	  cells/ml,	  and	  incubated	  
in	  the	  dark	  with	  1.5	  uM	  Fluo-­‐4	  AM	  (Molecular	  Probes,	  Eugene,	  OR,	  USA)	  in	  complete	  DMEM	  
at	   37°C	   for	   20	  minutes.	   Cells	  were	   then	  washed	   3	   times	  with	   Ca2+/Mg2+	   PBS	   buffer	   using	  
centrifugation	  (1	  min	  at	  1700rpm)	  and	  resuspended	  in	  Ca2+/Mg2+	  PBS.	  Propidium	  iodide	  was	  
added	   for	   5	  minutes	   to	   stain	  DNA	   content	   of	   live	   cells.	   Fluorescence	   data	  was	   thereafter	  
analysed	   on	   the	   C6	   Accuri	   flow	   cytometer.	   Baseline	   calcium	   levels	   were	  monitored	   for	   1	  
minute	  to	  ensure	  stable	  readings	  before	  400nm	  Ang-­‐II	  was	  added.	  Thereafter	  calcium	  levels	  
were	   monitored	   for	   a	   further	   11	   min.	   Fluorescence	   was	   measured	   before	   and	   after	  
treatment	   with	   Ang-­‐II.	   To	   determine	   whether	   the	   IC50	   of	   Candesartan	   could	   prevent	   the	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release	  of	   intracellular	  calcium,	  an	  overnight	  pretreatment	  was	  applied	  to	  cells	  before	  the	  
fluorescence	  data	  was	  collected.	  
	  
6.2.9	  NFAT	  Luciferase	  assay	  
To	   investigate	   if	   Ang-­‐II	   effects	   within	   cancer	   cells	   are	   a	   result	   of	   NFAT	   related-­‐Calcium	  
signalling	  the	  NFAT	  luciferase	  assay	  will	  be	  used.	  30	  000	  HeLa	  cells	  were	  seeded	  in	  a	  volume	  
of	  500	  µL	  per	  well	  in	  a	  24	  well	  plate	  and	  left	  to	  settle	  overnight	  in	  a	  humidified	  incubator	  at	  
37ᵒC	   and	   5%	   CO2.	   The	   next	   day	   cells	   were	   transfected	   with	   100	   ng	   GFP-­‐NFAT,	   NFAT-­‐
luciferase	   and	   the	   Renilla	   plasmid.	   To	   normalize	   for	   transfection	   efficiency	   cells	  were	   co-­‐
transfected	  with	   this	   serving	   as	   a	   control	   along	  with	   promoter	   constructs.	   After	   8	   hours,	  
medium	  is	  replaced	  with	  complete	  medium.	  The	  cells	  were	  treated	  with	  400	  nM	  Ang-­‐II	  or	  
190	  μM	  Candesartan	  for	  24	  hours.	  Control	  samples	  were	  stimulated	  with	  100	  nM	  TPA	  and	  
1.3	  µM	  Ionomycin	  to	  perforate	  the	  cell	  membrane	  allowing	  calcium	  influx	  thereby	  activating	  
NFAT.	   5	   hours	   after	   TPA	   and	   Ionomycin	   treatment	   the	   control	   sample	   were	   ready	   for	  
assaying.	  All	  samples	  were	  prepared	  using	  replacing	  media	  with	  2	  1xPBS	  washes	  and	  100	  µL	  
1xPassive	   Lysis	   Buffer	   (Promega).	   Firefly	   luciferase	   activity	  was	   determined	  with	   the	  Dual	  
Luciferase	  Kit	   (Promega)	  and	   luminescence	  measured	  using	   the	  Glomax	  96	  well	  microtitre	  
luminometer	  (Promega).	  
	  
6.2.10	  Cell	  cycle	  analysis	  	  
For	  analysis	  of	  the	  effects	  of	  the	  ACE-­‐1	  axis	  inhibitors,	  Ang-­‐(1-­‐7)	  and	  DIZE	  on	  the	  cell	  cycle,	  
150	  000	  cancer	  cells	  were	  plated	  in	  60	  mm	  dishes,	  treated	  with	  the	  appropriate	  drug,	  and	  
then	  harvested	  at	  the	  appropriate	  time	  point.	  Once	  floating	  cells	  were	  collected	  cells	  were	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harvested	  using	  trypsin	  and	  cells	  resuspended	  in	  2	  ml	  media	  and	  fixed	  in	  8	  ml	  ice-­‐cold	  100	  %	  
ethanol.	  Cells	  in	  ethanol	  were	  then	  incubated	  at	  -­‐20°C	  for	  up	  to	  two	  weeks.	  Prior	  to	  sample	  
analysis	  ethanol	  was	  subsequently	  removed	  by	  centrifugation	  and	  1	  x	  106	  cells	  transferred	  
to	  an	  eppendorf,	  where	  50	  μg/ml	  RNase	  was	  added	  to	  remove	  RNA.	  2	  μl	  from	  a	  100	  μg/ml	  
solution	   of	   Propidium	   iodide	   was	   then	   added	   to	   stain	   the	   DNA	   content	   of	   the	   cells	   and	  
allowed	  to	  incubate	  for	  20	  minutes	  in	  the	  dark	  at	  room	  temperature.	  Cell	  cycle	  profiles	  were	  
analysed	  using	  the	  BD	  Accuri	  C6	  Flow	  Cytometer	  (BD	  BioSciences,	  NJ,	  USA).	  The	  percentage	  




6.2.11	  Annexin	  V/Propidium	  Iodide	  Assay	  	  
The	   Annexin	   V/Propidium	   Iodide	   detection	   assay	   (Thermo	   Fisher	   Scientific,	   USA)	   was	  
performed	  to	  determine	  the	  mode	  of	  cell	  death	  of	  cancer	  cells	  after	  treatment	  with	  either	  
the	  ACE-­‐1	  axis	  inhibitors,	  ACE-­‐2	  axis	  activators	  or	  combination	  drug	  treatments	  used	  in	  this	  
study.	   Cells	   were	   harvested	   and	   washed	   twice	   with	   cold	   sterile	   1x	   PBS	   before	   being	  
resuspended	  in	  1ml	  of	  1	  x	  Annexin	  V	  solution	  containing	  1x	  Annexin	  binding	  buffer	  with	  1	  μl	  
PI	  and	  2	  μl	  FITC	  Annexin	  V	  (supplied	  in	  the	  kit).	  	  Samples	  were	  gently	  mixed	  and	  incubated	  at	  
room	   temperature	   in	   the	   dark	   for	   15	   minutes	   before	   anaylsis	   on	   the	   BD	   Accuri	   C6	   flow	  
cytometer.	  Fluorescence	  of	  the	  stained	  cells	  was	  measured	  using	  the	  FL1	  and	  FL3	  channels	  
and	  the	  distinction	  of	  cell	  populations	  undergoing	  apoptosis	  or	  necrosis	  observed.	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6.2.12	  Clonogenic	  Colony	  Formation	  Assay	  	  	  
This	   in	  vitro	  assay	  monitors	  the	  ability	  of	  a	  single	  cell	  to	  form	  colonies.	  Briefly,	  1000	  HeLa,	  
CaSki	  or	  MDA-­‐MB-­‐231	  cells	  were	  seeded	  into	  each	  well	  of	  a	  6	  well	  plate.	  Treatments	  were	  
plated	   in	   triplicate	   and	   cells	   were	   allowed	   to	   settle	   overnight.	   The	   next	   day	   cells	   were	  
treated	   for	   24	  hours	  with	  ½	   IC50	   or	   IC50	   of	  DIZE,	   or	   1μM	  Ang-­‐(1-­‐7).	   Fresh	  media	  was	   then	  
applied	  to	  the	  cells	  and	  colony	  formation	  was	  subsequently	  monitored	  over	  a	  10	  day	  period.	  
Visible	  colonies	  were	  then	  stained	  overnight	  with	  0.5%	  crystal	  violet	  staining	  solution	  (see	  
solutions),	  carefully	  rinsed	  with	  water	  and	  allowed	  to	  dry	  before	  being	  photographed	  with	  a	  
high	   definition	   (HD)	   resolution	   camera	   and	   colonies	   quantified	   using	   ImageJ	   software.	  
Plating	   efficiency	   (PE%)	   and	   survival	   fraction	   (SF%)	   was	   calculated	   using	   the	   following	  
equations:	  (PE%)=	  number	  of	  colonies/	  number	  of	  cells	  plated	  x	  100;	  (SF%)	  =	  PE	  of	  treated	  
sample/PE	   of	   control	   x	   100.	   Cell	   survival	   was	   calculated	   as	   the	   number	   of	   counted	  
colonies/[number	  of	  seeded	  cells	  x	  PE	  control/100].	  
	  
6.2.14	  Statistical	  Analyses	  
	  
Experiments	  were	  performed	  in	  triplicate	  and	  represented	  as	  the	  mean	  +/	  standard	  error	  of	  
the	   mean	   (SEM)	   and	   repeated	   at	   least	   twice.	   For	   comparisons,	   the	   Student’s	   two-­‐tailed	  
paired	  t-­‐test	  was	  used	  with	  a	  p	  value	  of	  	  <0.05	  considered	  statistically	  significant.	  	  
	   	  




6.3.1	  Tissue	  culture	  solutions	  
Cell-­‐freezing	  media	  
70	  %	  DMEM	  
20	  %	  FCS	  
10	  %	  DMSO	  
	  
10	  X	  PBS	  
40	  g	  NaCl	  	  
1	  g	  KCl	  	  
5.75	  g	  Na2HPO4.7H2O	  
	  
6.3.2	  MTT	  (5	  mg/ml)	  
100	  mg	  MTT	  
20	  ml	  1	  X	  PBS	  
Vortex	  and	  incubate	  at	  37°C	  for	  15	  min,	  filter	  through	  a	  0.2	  μm	  filter.	  Wrap	  in	  foil	  and	  store	  
at	  4°C	  for	  up	  to	  one	  month.	  
	  
Solubilisation	  Reagent	  
25	  g	  SLS	  	  
Make	  up	  to	  250	  ml	  with	  dH2O	  then	  adding	  76.6	  μl	  conc.	  HCl	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6.3.3	  Western	  Blot	  solutions	  
Resolving	  gel	  buffer	  
36.2	  g	  Tris,	  0.8	  g	  SLS	  
Dissolve	  in	  150	  ml	  dH2O,	  pH	  to	  8.9	  with	  1	  N	  HCL	  or	  1	  N	  NaOH	  and	  make	  up	  to	  200	  ml	  with	  
dH2O.	  Store	  at	  4°C.	  
	  
Stacking	  Gel	  Buffer	  
5.9	  g	  Tris,	  0.4	  g	  SLS	  
Dissolve	  in	  70	  ml	  dH2O,	  pH	  to	  6.8	  with	  1	  N	  HCL	  or	  1	  N	  NaOH	  and	  make	  up	  to	  100	  ml	  with	  
dH2O.	  Stored	  at	  4°C.	  
	  
10x	  Running	  buffer	  
30.2	  g	  Tris,	  144	  g	  Glycine,	  10	  g	  SDS	  
Make	  up	  to	  1	  L	  with	  dH2O	  
	  
1x	  Running	  buffer	  
100	  ml	  of	  10x	  running	  buffer	  900	  ml	  of	  dH2O	  
	  
10x	  Transfer	  Buffer	  
144	  g	  Glycine	  38	  g	  Tris,	  make	  up	  to	  1	  L	  with	  dH2O	  
	  
1x	  Transfer	  Buffer	  
100	  ml	  10x	  transfer	  buffer	  (in	  this	  order)	  700	  ml	  dH2O,	  200	  ml	  methanol/isopropanol	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10x	  Tris	  Buffered	  Saline	  (TBS)	  
60.5	  g	  Tris,	  87.6	  g	  NaCl	  	  




100	  ml	  10x	  TBS,	  900	  ml	  dH2O	  and	  1	  ml	  Tween	  20	  
	  
4	  X	  Laemmli	  Loading	  Dye	  




0.5	  g	  fat	  free	  milk	  powder	  (Elite)	  
10ml	  1	  x	  TBST	  
	  
RIPA	  Buffer	  
150	  mM	  Sodium	  Chloride,	  1	  %	  Triton	  X-­‐100,	  1	  %	  Sodium	  Deoxycholate,	  0.1	  %	  SDS	  and	  10	  
mM	  Tris-­‐Cl,	  pH	  7.4	  
	  
6.3.4	  ACE-­‐1	  functional	  assay	  solutions	  	  
0.28M	  NaOH	  	  
24	  mg/ml	  (in	  methanol)	  	  o-­‐phthaldialdehyde	  
3N	  HCl	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6.3.5	  ACE-­‐2	  functional	  assay	  solutions	  
100mM	  Tris,	  pH	  7	  
300	  mM	  NaCl	  
	  
6.3.6	  Calcium	  release	  solutions	  
Ca2+/Mg2+/PBS	  	  
0.1 mM	  CaCl2	  	  
0.1 mM	  MgCl2	  
1x	  PBS	  
	  
6.3.7	  Clonogenic	  colony	  formation	  solutions	  
0.5%	  crystal	  violet	  staining	  solution	  
0.5g	  crystal	  violet	  powder	  
80ml	  dH20	  
20ml	  methanol	  
Dissolve	   crystal	   violet	   powder	   in	   H20	   thereafter	   add	   methanol.	   Store	   solution	   at	   room	  
temperature	  in	  the	  dark	  and	  use	  within	  2	  months.	  	  
	  
	  	   	  










Figure	  A.1:	  Densitometric	  quantification	  of	  pCAMKII	  protein	  bands	  relative	  to	  total	  CAMKII	  in	  HeLa	  
and	  CaSki	  cells.	  Densitometry	  of	  HeLa	  (A)	  and	  CaSki	  (B)	  protein	  bands	  from	  western	  blots	  detecting	  
relative	   pCAMKII	   expression	   after	  minutes	   of	   Ang	   II	   treatment.	   Candesartan	   treatment	   prevented	  
phosphorylation	   in	   HeLa	   (C)	   and	   CaSki	   (D)	   cells.	   Relative	   phosphorylation	   of	   positive	   controls	   for	  
each	   cell	   line	   were	   shown.	   Representative	   experiments	   of	   two	   independent	   experiments	   were	  
shown.	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Annexin	   V	   profiles	   of	   the	   combined	   treatment	   of	   CDDP	   and	   Captopril	   in	   HeLa,	   cervical	  






Figure	   A.2:	   The	   effect	   of	   CDDP	   and	   Captopril	   combination	   treatment	   on	   HeLa	   cervical	  
cancer	   cell	   death	   using	   the	   Annexin	   V	   assay.	   HeLa	   cells	   were	   treated	   with	   the	   IC50	  
concentrations	  of	  CDDP	  and	  Captopril	  for	  48	  hours	  and	  effects	  on	  cell	  death	  investigated	  using	  the	  
Annexin	  V	  assay.	  Profiles	  of	  HeLa	  cells	  with	  cells	  falling	  into	  four	  quadrants	  as	  previously	  described	  
Combined	   treatment	   of	   CDDP	   with	   Captopril	   showed	   no	   significant	   effect	   on	   HeLa	   cell	   death,	  
however,	  CDDP	  and	  Captopril	  single	  treatments	  showed	  a	  significant	  decrease	  in	  the	  percentage	  of	  
live	  cells	  and	  a	  significant	  increase	  in	  the	  percentage	  of	   late	  apoptotic	  and	  necrotic	  cells	  (*p<0.05).	  
Experiments	  were	  performed	  in	  triplicate	  and	  repeated	  twice.	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Annexin	   V	   profiles	   of	   the	   combined	   treatment	   of	   CDDP	   and	   Captopril	   in	   CaSki,	   cervical	  








Figure	   A.3:	   The	   effect	   of	   CDDP	   and	   Captopril	   combination	   treatment	   on	   CaSki	   cervical	  
cancer	   cell	   death	   using	   the	   Annexin	   V	   assay.	   CaSki	   cells	   were	   treated	   with	   the	   IC50	  
concentrations	  of	  CDDP	  and	  Captopril	  for	  48	  hours	  and	  effects	  on	  cell	  death	  investigated	  using	  the	  
Annexin	  V	  assay.	  Profiles	  of	  CaSki	  cells	  with	  cells	  falling	  into	  four	  quadrants	  as	  previously	  described.	  
Combined	   treatment	   of	   CDDP	   with	   Captopril	   showed	   no	   significant	   effect	   on	   CaSki	   cell	   death,	  
however,	  CDDP	  and	  Captopril	  single	  treatments	  showed	  a	  significant	  decrease	  in	  the	  percentage	  of	  
live	  cells	  and	  a	  significant	  increase	  in	  the	  percentage	  of	   late	  apoptotic	  and	  necrotic	  cells	  (*p<0.05).	  
Experiments	  were	  performed	  in	  triplicate	  and	  repeated	  twice.	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Annexin	   V	   profiles	   of	   the	   combined	   treatment	   of	   CDDP	   and	   Captopril	   in	  MDA-­‐MB-­‐231,	  








Figure	   A.4:	   The	   effect	   of	   CDDP	   and	   Captopril	   combination	   treatment	   on	   MDA-­‐MB-­‐231	  
breast	  cancer	  cell	  death	  using	  the	  Annexin	  V	  assay.	  MDA-­‐MB-­‐231	  cells	  were	  treated	  with	  the	  
IC50	  concentrations	  of	  CDDP	  and	  Captopril	  for	  48	  hours	  and	  effects	  on	  cell	  death	  investigated	  using	  
the	  Annexin	  V	  assay.	  Profiles	  of	  MDA-­‐MB-­‐231	  cells	  with	  cells	  falling	  into	  four	  quadrants	  as	  previously	  
described.	  Combined	   treatment	  of	  CDDP	  with	  Captopril	   showed	  no	  significant	  effect	  on	  MDA-­‐MB-­‐
231	  cell	  death,	  however,	  CDDP	  and	  Captopril	  single	  treatments	  showed	  a	  significant	  decrease	  in	  the	  
percentage	  of	   live	   cells	   and	  a	   significant	   increase	   in	   the	  percentage	  of	   late	  apoptotic	  and	  necrotic	  
cells	  (*p<0.05).	  Experiments	  were	  performed	  in	  triplicate	  and	  repeated	  twice.	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Annexin	   V	   profiles	   of	   the	   combined	   treatment	   of	   CDDP	   and	   Lisinopril	   in	   HeLa	   cervical	  




Figure	   A.5:	   The	   effect	   of	   CDDP	   and	   Lisinopril	   combination	   treatment	   on	   HeLa	   cervical	  
cancer	   cell	   death	   using	   the	   Annexin	   V	   assay.	   HeLa	   cells	   were	   treated	   with	   the	   IC50	  
concentrations	  of	  CDDP	  and	  Lisinopril	   for	  48	  hours	  and	  effects	  on	  cell	  death	  investigated	  using	  the	  
Annexin	  V	  assay.	  Profiles	  of	  HeLa	  cells	  with	  cells	  falling	  into	  four	  quadrants	  as	  previously	  described	  
Annexin	  V	  profile	  of	  the	  combined	  treatment	  shows	  no	  significant	  effect	  on	  cell	  death.	  CDDP	  showed	  
a	  significant	  decrease	  in	  the	  percentage	  of	   live	  cells	  and	  a	  significant	   increase	  in	  the	  percentage	  of	  
late	  apoptotic	  and	  necrotic	  cells.	  The	  Lisinopril	  profile	  showed	  a	  significant	  decrease	   in	   live	  cells	  as	  
well	   as	   a	   significant	   increase	   in	   necrotic	   cells	   (*p<0.05).	   Experiments	  were	   performed	   in	   triplicate	  
and	  repeated	  twice.	   	  
	   176	  
Annexin	   V	   profiles	   of	   the	   combined	   treatment	   of	   CDDP	   and	   Lisinopril	   in	   CaSki	   cervical	  
cancer	  cell	  line.	  
	  
	  
Figure	   A.6:	   The	   effect	   of	   CDDP	   and	   Lisinopril	   combination	   treatment	   on	   CaSki	   cervical	  
cancer	   cell	   death	   using	   the	   Annexin	   V	   assay.	   CaSki	   cells	   were	   treated	   with	   the	   IC50	  
concentrations	  of	  CDDP	  and	  Lisinopril	   for	  48	  hours	  and	  effects	  on	  cell	  death	  investigated	  using	  the	  
Annexin	  V	  assay.	  Profiles	  of	  CaSki	  cells	  with	  cells	  falling	  into	  four	  quadrants	  as	  previously	  described.	  
Profile	   of	   the	   combined	   treatment	   shows	   no	   significant	   effect	   on	   cell	   death.	   CDDP	   showed	   a	  
significant	  decrease	  in	  the	  percentage	  of	  live	  cells	  and	  a	  significant	  increase	  in	  the	  percentage	  of	  late	  
apoptotic	  and	  necrotic	  cells.	  The	  profile	  of	  Lisinopril	  showed	  a	  significant	  decrease	  in	  live	  cells	  as	  well	  
as	   a	   significant	   increase	   in	   apoptotic	   and	  necrotic	   cells	   (*p<0.05).	   Experiments	  were	  performed	   in	  
triplicate	  and	  repeated	  twice.	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Annexin	   V	   profiles	   of	   the	   combined	   treatment	   of	   CDDP	   and	   Lisinopril	   in	  MDA-­‐MB-­‐231,	  







Figure	   A.7:	   The	   effect	   of	   CDDP	   and	   Lisinopril	   combination	   treatment	   on	   MDA-­‐MB-­‐21	  
breast	  cancer	  cell	  death	  using	  the	  Annexin	  V	  assay.	  MDA-­‐MB-­‐231	  cells	  were	  treated	  with	  the	  
IC50	  concentrations	  of	  CDDP	  and	  Lisinopril	   for	  48	  hours	  and	  effects	  on	  cell	  death	  investigated	  using	  
the	  Annexin	  V	  assay.	  Profiles	  of	  MDA-­‐MB-­‐231	  cells	  with	  cells	  falling	  into	  four	  quadrants	  as	  previously	  
described.	   Profile	   of	   the	   combined	   treatment	   shows	   no	   significant	   effect	   on	   cell	   death.	   CDDP	  
showed	   a	   significant	   decrease	   in	   the	   percentage	   of	   live	   cells	   and	   a	   significant	   increase	   in	   the	  
percentage	   of	   late	   apoptotic	   and	   necrotic	   cells.	   The	   profile	   of	   Lisinopril	   showed	   a	   significant	  
decrease	   in	   live	   cells	   as	   well	   as	   a	   significant	   increase	   in	   apoptotic	   and	   necrotic	   cells	   (*p<0.05).	  
Experiments	  were	  performed	  in	  triplicate	  and	  repeated	  twice.	   	  
	  
	  














Table	  A.1.	  DOX	  and	  DIZE	  concentrations	  used	  in	  determination	  of	  the	  association	  between	  
the	   drugs.	   	   Cells	   were	   treated	   with	   the	   combined	   DOX	   and	   DIZE	   treatment	   or	   single	  
treatments	  of	  each	  drug.	  In	  each	  experiment	  the	  combination	  treatment	  maintained	  a	  fixed	  
ratio	  of	  1:1.	   	  













Table	  A.2.	  DOX	  and	  DIZE	  concentrations	  used	  in	  determination	  of	  the	  association	  between	  
the	   drugs.	   	   Cells	   were	   treated	   with	   the	   combined	   DOX	   and	   DIZE	   treatment	   or	   single	  
treatments	  of	  each	  drug.	  In	  each	  experiment	  the	  combination	  treatment	  maintained	  a	  fixed	  
ratio	  of	  1:3.	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APPENDIX	  III	  







Figure	  A.8:	  The	  effect	  of	  DOX	  and	  DIZE	  combination	  treatment	  on	  HeLa	  cervical	  cancer	  cell	  
death	  using	   the	  Annexin	  V	  assay.	  HeLa	  cells	  were	  treated	  with	  the	   IC50	  concentrations	  of	  
DOX	  and	  DIZE	  for	  48	  hours	  and	  effects	  on	  cell	  death	  investigated	  using	  the	  Annexin	  V	  assay.	  
The	  above	   shows	  Annexin	  V	  profiles	  of	  HeLa	  cells	  with	  cells	   falling	   into	   four	  quadrants	  as	  
previously	  described.	  Experiments	  were	  performed	  in	  triplicate	  and	  repeated	  twice.	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Figure	  A.9:	  The	  effect	  of	  DOX	  and	  DIZE	  combination	  treatment	  on	  CaSki	  cervical	  cancer	  cell	  
death	  using	   the	  Annexin	  V	  assay.	  CaSki	  cells	  were	  treated	  with	  the	  IC50	  concentrations	  of	  
DOX	  and	  DIZE	  for	  48	  hours	  and	  effects	  on	  cell	  death	  investigated	  using	  the	  Annexin	  V	  assay.	  
The	  above	  shows	  Annexin	  V	  profiles	  of	  CaSki	  cells	  with	  cells	   falling	   into	   four	  quadrants	  as	  
previously	  described.	  Experiments	  were	  performed	  in	  triplicate	  and	  repeated	  twice.	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Annexin	  V	  profiles	  of	   the	  combined	  treatment	  of	  DOX	  and	  DIZE	   in	  MDA-­‐MB-­‐231,	  breast	  








Figure	  A.10:	  The	  effect	  of	  DOX	  and	  DIZE	  combination	  treatment	  on	  MDA-­‐MB-­‐231	  breast	  
cancer	  cell	  death	  using	  the	  Annexin	  V	  assay.	  MDA-­‐MB-­‐231	  cells	  were	  treated	  with	  the	  IC50	  
concentrations	  of	  DOX	  and	  DIZE	  for	  48	  hours	  and	  effects	  on	  cell	  death	  investigated	  using	  the	  
Annexin	  V	  assay.	  The	  above	  shows	  Annexin	  V	  profiles	  of	  MDA-­‐MB-­‐231	  cells	  with	  cells	  falling	  
into	   four	   quadrants	   as	   previously	   described.	   Experiments	   were	   performed	   in	   triplicate	   and	  
repeated	  twice.	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